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General introduction and outline of this thesis
Elucidation of genetic disorders is important for clinical practice and basic science. It reveals new 
insights of key mechanisms i.e. in development, metabolism and function. This thesis describes 
the molecular and functional genetics of the transcription factor p63 gene (alias Tumor pro­
tein p63, TP63 or Tumor protein p73-like, TP73L). Heterozygous mutations in the p63 gene can 
cause five different human ectodermal dysplasia syndromes and two non-syndromic conditions: 
Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome (EEC, OMIM 604292), Anky­
loblepharon-ectodermal defects-cleft lip/palate syndrome (AEC, OMIM 106260), Limb mammary 
syndrome (LMS, OMIM 603543), Acro-dermato-ungual-lacrimal-tooth syndrome (ADULT, OMIM 
103285), Rapp-Hodgkin syndrome (RHS, OMIM 129400), Split hand/foot malformation (SHFM4, 
OMIM 605289) and Non-syndromic cleft lip/palate (NSCL). Common characteristics of these 
p63-associated diseases are abnormalities in ectodermal derived structures, limb malformations 
and orofacial clefting. I will summarize the present knowledge about the development of these 
tissues and structures, and discuss disease conditions overlapping the p63-associated disorders. 
Finally, I will describe the p63 gene and its function, and provide an outline of the work present­
ed in this thesis.
1,1 Ectodermal development
Gastrulation is the stage in the early embryonal development when cells are organized into three 
different germ layers: endoderm, mesoderm and ectoderm. These three primary germ layers 
consist of progenitors of all cellular and tissue lineages of the body, except the germ cells (Fig.
1). Each germ layer will differentiate and give rise to different organs, following series of specific 
signaling programs. The most inner endoderm forms respiratory and digestive tubes. The middle 
mesoderm layer forms connective tissue (blood, cartilage and bone cells), skeletal and heart 
muscle, the uro-genital system and parts of the internal organs. The outer ectoderm layer gives 
rise to skin, its appendages and nervous system. The ectoderm will differentiate into ventral 
epidermis and dorsal neural zone following signaling induction of fibroblast growth factor (FGF), 
Bone morphogenetic protein (BMP) and BMP antagonist (1,2). The neural zone comprises the 
neural plate and at later stages the neural tube, which will separate from the overlying epidermal 
ectoderm and give rise to the brain and the spinal cord. The cells connecting the neural tube 
and ectoderm will become neural crest cells and will generate peripheral neurons, glia-cells, skin 
pigment cells and several other cell types (3). Finally, the epidermal ectoderm will differentiate 
into stratified skin and its derivatives, which will be discussed later in this chapter. The main focus 
of interest of this thesis is the morphogenesis and differentiation of epidermal ectoderm that is 
altered in human ectodermal dysplasias.
Molecular signaling during human embryonal development and differentiation is complex. Dissec­
tion of the individual signaling pathways and the interplay between them is a challenging task. In 
addition, most of the studies have to be conducted in model organisms that may have a different 
structure or development than the organ of interest in humans. Nevertheless, animal-based 
studies, especially transgenic and conditional knock-out mouse models have greatly impacted 
our knowledge of the basic mechanisms of embryonal development and the genes involved in it. 
These studies have shown that the signaling between the developing epithelium and underlying 
mesenchyme is crucial for the correct induction, morphogenesis and differentiation of epidermis 
and its appendages (4).
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Cleavage
^  -> Primordial germ cells - » Gametes 
Gastrulation
ECTODERM |
- » Lens of the eye
- » Auditory vesicle* -» Inner ear mechanism 
—> Outer epithelium of the body
—»Mammary glands. Sweat glands, Sebaceous glands, Nails, Hair 
—> Nasal and olfactory epithelium and olfactory nerve
->  Stomodeal epithelium —> Enamel of teeth, Oral epithelium, Anterior lobe of hypophysis 
—> Proctodeal epithelium —» Anal canal*
—> Neural tube
—»Motor spinal nerve roots, Spinal cord. Pars neuralis of hypophysis. Brain, Cranial motor nerves.
Optic vesicles -»  Retina* and optic nerve
—> Neural crest
—»Cranial sensory ganglia and nerves
- > Spinal dorsal root ganglia —> Sensory spinal nerve roots. Medulla of adrenal, Sympathetic ganglia 
—»Dentine of teeth
—»Skull and branchial cartilages, Cephalic connective tissue (together from head mesenchyme)
MESODERM
—> Notochord 
->  Dorsal mesoderm
- » Sclerotomes —» Axial skeleton
- » Myotomes - » Appendicular skeleton, Muscles of appendages
—»Skeletal muscles of trunk 
—> Dermatomes ->  Connective tissue layers of skin 
—> Intermediate mesoderm
—»Mesonephric ducts —» Epidymis, vas deferens 
- » Metanefric diverticulum. Ureters, Renal pelvis. Collecting tubules
—»Mesonephros, Efferent ducts 
—»Metanephros, Kidney tubules*
- » Mullerian ducts —»Vagina*, Oviducts*, Uterus*
—»Pronephros 
—> Lateral mesoderm
—» Somatic mesoderm -> Pleura, Pericardium, Peritoneum 
->  Splanchnic mesoderm:
—> Mesenchyme —> Stroma of gonads
—> Connective tissue and smooth muscle of viscera and blood vessels 
->  Hemangioblastic tissue —> Blood corpuscles, Endothelium of blood vessels, Endocardium 
—»Mesenteries, Visceral pleura and peritoneum, Epimyocardium, Epicardium, Myocardium (Heart)
—> Head mesenchyme
—> Outer layers of eye 
- » Muscles
ENDODERM
-» Primitive gut —> Trachea*, Bronchi, Lungs
—* Digestive tube* —> Pancreas*, Liver, Allantois* Urinary bladder*
—» Pharynx —> Thyroid
—» Pharyngeal pouches* Middle ear*, Tonsillar recesses*, Primitive thymus, Parathyroids*
* Origin of epithelial part of organ only, secondary supporting investments of mesodermal origin.
Figure 1. Gastrulation gives rise to the three prim ary germ layers: endoderm, mesoderm and ectoderm. These 
primary germ layers consist of progenitors of all cellular and tissue lineages in the body, except the germ cells. 
Primordial germ cells separate from the zygote after the cleavage just prior to the gastrulation.
Zygote
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Although the signaling cascades are not fully understood, a number of pathways such as Trans­
forming growth factor-P (TGFP) including Bone morphogenetic proteins (BMP), Fibroblast growth 
factor (FGF), Wingless-type (WNT), Sonic hedgehog homolog (SHH), Tumor necrosis factor (TNF) 
signaling and several transcription factors have crucial roles in epidermal development and dif­
ferentiation (5-7).
Epidermis
Embryonic epithelium is initially a single cell layer of multipotent epithelial cells that covers the hu­
man embryo. Due to an unknown initiation event, these cells start to proliferate and produce a 
temporary outer single-cell layer of simple squamous cell epithelium, called periderm. Cells in 
the inner layer become then slow-cycling basal stem cells (SC) with a high proliferative capacity 
(Fig. 2). Stratification of the epidermis begins by an asymmetric cell division, where one daughter 
cell retains the stem cell capacity and the other becomes a rapidly proliferating transit amplify­
ing cell. After a few cell divisions transit amplifying cells detach from the basal lamina, migrate 
upwards and start their differentiation program. The transit amplifying cells that detach the basal 
lamina become spinous cells and constitute the stratum spinosum, a layer of keratin filament 
network. When spinous cells differentiate the keratin accumulates in granules in granular cells 
that constitute the cornified envelope, stratum granulosum. Finally, these granular cells transit to 
the stratum corneum that is a dead upper layer where all transcriptional and metabolic activities 
have ceased. The underlying basal lamina and stem cell layer, stratum basale, form together with 
these three differentiation layers the epidermis, which protects the human body from physical 
and chemical stress and prevents it from dehydration and infections caused by micro-organisms.
The embryonic ectoderm not only produces a stratified epidermis, but also several ectodermal ap­
pendages, such as hair, teeth, nails and a number of glands (e.g. sweat, sebaceous and mammary 
glands). These derivatives originate upon reciprocal signaling between the ectodermal epithe­
lium and underlying mesenchyme (7). The interactive signaling that can originate either from 
the mesenchyme (hair and mammary gland) or neural crest (teeth and cranial hair) results in 
proliferation and clustering of epidermal keratinocytes causing ectodermal thickenings.
Stratum corneum 
Stratum granulosum
Stratum spinosum 
Stratum basale
Figure 2. Epidermis. Epidermis is the outer part o f human skin and lies on the dermis and basal lamina. Epi­
dermis consists of four layers stratum basale, stratum spinosum, stratum granulosum and stratum corneum.
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The resulting epidermal placode then signals back to underlying dermis, which causes an ag­
gregation of mesenchymal cells and give rise to a bud that invaginates into the dermis. The 
beginning of the dialogue between epidermis and dermis is highly similar in the development of 
the various ectodermal appendages; however, the subsequent signaling events are more specific 
for each individual structure.
Hair and sebaceous gland development
Hair is the first specialized structure that differentiates from the embryonic ectoderm. Hair follicle 
development immediately follows the skin stratification and may play an important role in initiat­
ing barrier formation (8). Mesenchymal WNT, FGF and BMP inhibitory factors start the signaling 
crosstalk and together with epidermal WNT signaling give rise to placode formation and bud 
invagination (4). The hair bud begins to proliferate and becomes a rod like hair peg, of which 
dermal tip broadens. Also dermal cells proliferate and, due to SHH signaling, they form a dermal 
papilla underneath the hair bulb (4). The hair bulb consists of highly proliferative matrix cells. 
Following a growth stimulus from the dermal papilla the matrix cells exit the cell cycle, move up­
ward and differentiate into the hair shaft or inner root sheath (Fig. 3). Alongside the hair sheath 
is a bulge, which contains a reservoir of quiescent stem cells. These bulge stem cells become 
active at the beginning of every new hair cycle and move downward to the hair bulb to produce 
matrix cells (9). Above the bulge in every hair shaft is a sebaceous gland, which produces and 
secretes lipid-rich sebum into the hair canal that empties it out to the skin surface. Only little is 
known about sebaceous gland formation. However, it has been shown that the sebaceous gland 
can originate both from multipotent bulge stem cells and from its own progenitors, which exist 
within the sebaceous gland itself (9-12). By today several signaling pathways such as WNT, FGF, 
Nuclear factor k B (NFk B), Notch and BMP have been linked to hair induction and differentiation 
(4,5).
Epiderm is
Sebaceous gland
Bulge 
Hair shaft 
Cortex 
Inner root sheath 
Outer root sheath 
Connective tissue sheath
Figure 3. Structure of the hair. Hair shaft is surrounded by cortex, inner and outer root sheath and connective 
tissue sheath. Underneath the sebaceous gland lies bulge stem cells that give rise to matrix cells, which prolife­
rate and differentiate to a hair shaft and cortex.
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Developing teeth
Tooth induction is very similar to hair induction, however the first signals are derived from the oral 
ectoderm instead of mesoderm (13). The expression of FGF8, BMP4 and PITX2 are reported to 
induce formation of a dental lamina (7,13). Dental lamina is a thickened U-shaped epithelial 
ridge in the upper and lower jaws where teeth will be formed. This signaling activates mesenchy­
mal transcription factors (MSX1/2, DLX1/2, GLI2/3) that initiate bud formation in teeth mor­
phogenesis. Then ectodermal response of LEF1, EDAR and four main teeth signaling pathways 
(BMP, FGF, SHH and WNT) initiate invagination of the bud into the mesenchyme. Mesenchymal 
factors MSX1, PAX9 and RUNX2, and BMP and FGF signaling cause mesenchymal cell condensa­
tion around the tooth bud and extensive growth of the bud, which is followed by enamel knot 
induction. Enamel knot is a signaling center that is situated at the tip of the epithelial bud. 
Furthermore, enamel knot is crucial for transition of the bud to a cap-stage, marking the onset 
of tooth crown development. Several signaling pathways and EDAR are involved in induction and 
formation of enamel knots and a dental papilla. Dental papilla will be formed under the tooth 
bud, where it migrates upwards into the dental lamina and constitutes the core of the develop­
ing tooth. Finally, terminal differentiation takes place. Mesenchymal cells along the dental papilla 
will differentiate into dentin producing odontoblasts and dental lamina will differentiate into 
enamel producing amyloblasts that cover and protect the teeth. BMP, FGF, SHH and WNT signal­
ing pathways and several transcription factors are crucial for teeth development, but in total 
more than 300 genes have been associated with teeth patterning, morphogenesis and differen­
tiation. (7,13,14)
Mammary gland development
Mammary gland is the third structure that is initiated by extensive epithelial-mesenchymal interac­
tions and that follows the tooth and hair follicle development. Response to the first mesenchy­
mal signals cause thickening of the epidermal cells and give rise to two mammary ridges in the 
ventral epidermis. Placodes develop at the site of developing mammary gland, while the rest of 
the mammary line disappears in human. Several factors, such as TBX3 transcription factor, FGF 
and WNT signaling are reported to be important regulators of placode development (15,16). 
W NT signaling and MSX1/2 are needed for placode invagination into the dermis and also for 
primary bud formation (15). Parathyroid hormone related protein (PTHrP) induces the forma­
tion of mammary mesenchyme, and together with its receptor PTH1R and BMP4 it regulates 
mammary bud branching upon contact with fat pad and formation of secondary bud-structures 
that lengthen and form lactiferous ducts (17). These ducts open into an epithelial mammary pit, 
which will later differentiate into a nipple. The main pathways known to be involved in embry­
onic mammary gland development are WNT and FGF signaling, but recently also Hedgehog 
homolog signaling (HH) and GATA3 have been implicated (17).
Development of other ectodermal structures
Besides the described ectodermal appendage development also numerous other embryonal organs 
and structures arise from the ectoderm. Formation of the placode, the local ectodermal thickening 
and the reciprocal interactions between mesenchyme and epiderm are common for the initiation 
and morphogenesis of all of these structures. The head and facial region contain several structures
17
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Table 1. Ectodermal dysplasia syndrome can be divided into four different categories: (1) cell-cell communication and signaling, (2) cell junctions and intermediate filaments, (3) 
transcription regulation and (4) chromosome stability.
Group 1. Cell-cell communication and signaling.
Disease OMIM Inheritance Gene Protein Function Pathway Specific symptoms Reference
EDA (EDI) 305100 XR EDA Ectodysplasin-A Ligand NFk B, TNFa, 
JNK/c-fos/c-jun
Hypohidrotic ED (25)
Hypodontia 300606 XR EDA Ectodysplasin-A Ligand NFk B, TNFa, 
JNK/c-fos/c-jun
Nonsyndromic hypodontia (29,30)
ED3 129490 AD EDAR EDAR EDA receptor NFk B Hypohidrotic ED (26)
HED 224900 AR EDAR EDAR EDA receptor NFk B Hypohidrotic ED (26)
HED 224900 AR EDARADD EDARADD Adapter NFk B Hypohidrotic ED (27)
ED3 129490 AD EDARADD EDARADD Adapter NFk B Hypohidrotic ED (28)
HED-ID 300291 XR NEMO IKKy Ik B phosphorylating 
kinase complex
NFk B Hypohidrotic ED, ID (33)
IP 308300 XD NEMO IKKy
Ik B phosphorylating 
kinase complex NFk B
Incontinentia pigmenti 
(familial male lethal type)
(34)
OL-EDA-ID 300301 XD NEMO IKKy
Ik B phosphorylating 
kinase complex NFk B
Hypohidrotic ED with osteopetrosis, 
lymphoedema, ID (35)
EDA-ID - AD IKBA NFKBIA NFk B inhibitor complex NFk B ED, T-cell ID (36,38)
SMMCI 147250 AD SHH Shh Signal molecule Shh Fused incisors, midline developmental defects, craniofacial anomalies (39,40)
LADD 149730 AD FGFR2 Fgfr2 Receptor Fgf ED, ear anomaly, hearing loss (134)
LADD 149730 AD FGFR3 Fgfr3 Receptor Fgf ED, ear anomaly, hearing loss (134)
LADD 149730 AD FGF 10 FgflO Ligand Fgf ED, ear anomaly, hearing loss (134)
ALSG 180920 AD FGF 10 FgflO Ligand Fgf Lacrimal and salivary gland malformation (135)
OODD 257980 AR WNT10A WNT10A WNT regulator WNT ED, smooth tongue, keratoderma, hyperhydrotic 
palms and soles
(136)
Focal dermal 
hypoplasia
305600 XD PORC Porcupine
Membrane bound ER 
protein
WNT
Dermal hypoplasia, papillomas, limb 
malformation, eye problems
(137)
Hypotrichosis 604379 AR LIPH LIPH Lipase H LPA pathway Nonsyndromic hypotrichosis (138)
Localized
hypotrichosis
611452 AR P2RY5 P2Y5 Orphan G-protein- 
coupled receptor LPA pathway Nonsyndromic isolated alopecia (139)
Group 2. Cell junctions and intermediate filaments.
Disease OMIM Inheritance Gene Protein Function Pathway Specific symptoms Reference
CLPD1 (ED4) 225060 AR PVRL Nectin-1 Cell-cell adhesion molecule
NAP cell 
adhesion
ED, CL/P, limb defects or non-syndromic 
orofacial clefting (140,141)
ED-skin
fragility
syndrome
604536 AR PKP1 Plakophilin-1 Desmosomal protein Armadillo
protein ED with severe skin fragility (44-46)
Naxos disease 601214 AR PKGB Plakoglobin Desmosomal protein Armadillo
protein
ARVC, palmoplantar keratoderma, woolly hair (47)
that are of ectodermal origin. The eye lens is induced by neuro-ectodermal contact with ectoderm, 
the cornea develops from the ectoderm that overlays the lens and finally the eyelids form as the 
lens detaches from the ectoderm (18). The cochlea is a sensory organ in the inner ear for balance 
and hearing, which originates from endo-mesodermal and ectodermal signaling (19). Also part 
of facial morphogenesis is initiated by local ectodermal thickenings that comprise later the nasal 
and oral cavities. Furthermore, many eccrine glands such as salivary, lacrimal and sweat glands are 
all derivatives of the ectoderm. Limb development relies on the apical ectodermal ridge (AER), a 
signaling center controlling limb development and outgrowth. Finally also nails are of ectodermal 
origin. (3)
1,2 Ectodermal dysplasia syndromes
Ectodermal dysplasias (ED) are a large and heterogenous group of diseases that are characterized 
by abnormal development or growth of tissues and structures that originate from the outer 
embryonal layer, the ectoderm. A condition is called ED, when two or more of the following 
structures are affected: skin, hair, teeth, nails or sweat glands. Also conditions that combine a 
defect in one of those structures with an anomaly of another ectodermal structure are referred 
to as ectodermal dysplasia. ED patients have often dry, fine and hypopigmented epidermis. There 
can be scaling at birth or patches of hyperkeratosis, eczema or dermatitis resembling atopic skin 
disease. Abnormalities in hair follicles can give rise to sparse, curly and blond hair. Hypotrichosis 
or increased hair fragility can lead to alopecia. The amount of body hair follicles can be dimin­
ished, and eyelashes and eyebrows may be malformed or even absent. Dental changes can be 
seen in malformed and absent teeth. In addition, enamel dysplasia and salivary gland malfunc­
tion predispose the teeth for caries. Therefore teeth are often replaced by prosthesis already at 
young age. Nails can be dystrophic, abnormally keratinized, thickened, discolored and frag­
mented. Several glands can be affected. Impaired sweat gland function causes absent or reduced 
sweating, which can lead to life-threatening hyperthermia. Mammary glands and nipples can 
be hypoplastic or absent. Lacrimal and meibomian glands of the eye can be malformed causing 
dry eyes and recurrent infections. Other eye-related symptoms can be corneal dysplasia and 
cataracts. The above described symptoms can be seen in various combinations in ectodermal 
dysplasias, but can also be linked to other congenital abnormalities, such as orofacial clefting, 
limb malformations, diminished immune defense, hearing impairment, renal abnormalities, or 
mental retardation, and are subsequently termed ectodermal dysplasia syndromes (20,21).
By now about 170 different ED conditions have been described. However, each individual condition 
is rare on its own since the estimated cumulative incidence is seven in 10 000 births (21). In the 
past years several clinicians and researchers have established ectodermal dysplasia classifica­
tions. The first classification was purely based on clinical manifestations (22), whereas subse­
quent classifications took the molecular function of the pathogenic gene into account as well 
(20,23). Since an increasing number of EDs has been linked to gene mutations, it has become fea­
sible to group these genes into five categories: genes that are involved in (1) cell-cell communica­
tion and signaling, (2) adhesion, (3) transcription regulation, (4) development and (5) others (24). 
This classification by Lamartine allows clustering of similar genes and starts to connect these into 
several common pathways and functional mechanisms. For example EDA, EDAR, EDARADD, IKKy 
and IkBA are all members of NFkB pathway (see below). However, it should be noted that the 
classification is ambiguous as several genes may fit into two categories at the same time.
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Table 1 (Group 2 continues)
Disease OMIM Inheritance Gene Protein Function Pathway Specific symptoms Reference
Localized
hypotrichosis
607903 AR DSG4 Desmoglein-4 Desmosomal protein Nonsyndromic hypotrichosis (48)
Hypotrichosis 
simplex, scalp
146520 AD CDSN Corneodesmosin Glycoprotein Desmosome
molecule
Nonsyndromic isolated alopecia (49)
EEM 225280 AR CDH3 P-cadherin Adherin junction ED, macular dystrophy, ectrodactyly (43)
HJMD 601553 AR CDH3 P-cadherin Adherin junction ED, macular degeneration, early blindness (81)
Vohwinkel
syndrome 604117 AR LOR Loricrin
Cross-linked cell 
envelope Mutilating keratoderma, ichtyosis (142)
Palmoplantar
keratoderma
148350 AD GJB2 Connexin 26 Gap-junction Palmoplantar keratoderma, deafness (50,51)
KID syndrome 148210 AD GJB2 Connexin 26 Gap-junction Keratitis, ichtyosis, deafness (52,54)
HID syndrome 602540 AD GJB2 Connexin 26 Gap-junction Ichtyosis, hystrix-like, deafness (53)
Vohwinkel
syndrome
124500 AD GJB2 Connexin 26 Gap-junction Keratopachydermia, constrictions of fingers and 
toes, cong. deafness (55)
ED2 129500 AD GJB6 Connexin 30 Gap-junction Hidrotic ED (normal teeth) (56)
ODDD 164200 AD GJA1 Connexin 43 Gap-junction Oculo-dento-digital (isolated syndactyly type III?) (57-59)
ED hair-nail 
type
602032 AD KRT85 Keratin 85 Type II keratin Hair keratin Complete absence of all hair, nail dystrophy all 
finger/toe nails
(143)
NFJS 161000 AD KRT14 Keratin 14 Type 1 keratin Pair of KRT5 ED, hyperpigmentation, absence of dermatoglyphics (144)
DPR 125595 AD KRT14 Keratin 14 Type 1 keratin Pair of KRT5
ED, lifelong hyperpigmentation, absence of 
dermatoglyphics (144)
Pachyonychia
congenita-1
167200 AD KRT6A Keratin 6A Type II keratin Pair of KRT16
Focal palmoplantar keratoderma, oral 
leukokeratosis
(145)
Pachyonychia
congenita-1
167200 AD KRT16 Keratin 16 Type 1 keratin Pair of KRT6A Focal palmoplantar keratoderma, oral 
leukokeratosis
(146)
Pachyonychia
congenita-2
167210 AD KRT6B Keratin 6B Type II keratin Pair of KRT17 Multiple sebaceous cysts (147)
Pachyonychia
congenita-2 167210 AD KRT17 Keratin 17 Type 1 keratin Pair of KRT6B Multiple sebaceous cysts (148)
Steatocystoma
multiplex
184500 AD KRT17 Keratin 17 Type 1 keratin Pair of KRT6B Multiple sebaceous cysts, no nail changes (149)
Especially genes that were known to be involved in development (e.g. MSX1 andSHH) were 
categorized into the development group, although the molecular function was either in tran­
scriptional activity (MSX1) or cell signaling (SHH), which both have their own groups. For these 
reasons, I present a modified and up-dated classification of the ED genes and syndromes. It is 
based only on the molecular function of the ED genes and it clusters the disease causing genes 
into four categories: (Group 1) cell-cell communication and signaling, (Group 2) cell junctions and 
intermediate filaments, (Group 3) transcription regulation and (Group 4) chromosome stability 
(Table 1).
EDs are caused mainly by mutations in four types of genes that encode proteins that are involved in 
cell-cell communication and signaling, cell junctions and intermediate filaments, transcription 
regulation and chromosome instability (Table 1). Proteins that belong to the cell-cell communi­
cation group are involved in several signaling pathways, such as TNF, NFkB, FGF, SHH, WNT and 
Lysophosphatidic acid (LPA) signaling. Three proteins, Ectodysplasin-A (EDA), its receptor EDAR 
and an adapter signaling molecule EDARADD, are members of TNFa signaling family and are 
known to cause identical hypohydrotic ED phenotypes (25-28). Furthermore mutations in EDA 
can cause non-syndromic hypodontia (29,30). Activation of EDA signaling often leads to NFkB 
activation. However activation of NFkB is preceded by phosphorylation of the NFkB inhibitor I kB 
by the IKK kinase complex (27,31,32). Interestingly also mutations in the IKK kinase and NFkB in­
hibitor complexes cause ED. Mutations in IKKy give rise to two different types of ED accompanied 
either with immunodeficiency or a pigmentation disorder (IP) (33-35). Another type of ED with 
T-cell immunodeficiency is caused by mutations in IkBA, a member of NFkB inhibitor complex 
(36-38). Furthermore, mutations in Sonic hedgehog homolog (SHH) gene, which is a downstream 
target of NFkB, are reported to cause "Solitary median maxillary central incisors syndrome" (SM- 
MCI) characterized by fused incisors and craniofacial anomalies (32,39-41). The defects in various 
players in one single pathway and its downstream target strengthen the importance of NFkB 
signaling in the ectodermal appendage development, and suggest that defects in factors in other 
known ED-associated pathways may also cause ED.
The second group of the EDs consists of genes that encode cell-cell junction and intermediate 
filament proteins. These types of proteins are important for tissue structure and cell-cell con­
nection and are often seen in mature epithelial cells (Fig. 4). Adherens and desmosomes are 
the two types of cell-cell anchoring junctions that can be found in epithelial cells. The first one 
anchors actin filaments and the latter one intermediate filaments in order to connect them 
with neighboring cells. Mutations in both types of anchoring junction coding genes (P-cadherin, 
Plakophilin-1, Plakoglobin, Desmoglein-4, Corneodesmosin) can cause ED or non-syndromic 
hair disease (42-49). Gap-junctions are channel-forming junctions in epithelium, which allow 
small water-soluble molecules to move from cell to cell. Connexins are the major gap-junction 
proteins, and dominant mutations in three different connexin genes (CX26, CX30, CX43) have 
been reported to lead to different types of ED (50-59). Intermediate filaments, such as keratins 
create an important group of structural filament system of the cytoskeleton protecting the 
tissue against physical stress. Keratins are expressed mainly in epithelial cells, however, some 
keratins can be hair specific. Mutations in six different keratin genes (KRT6A, KRT6B, KRT14, 
KRT16, KRT17, KRT85) are causative for different types of EDs. Interestingly, some of these 
keratins form pairs together creating a functional keratin filament, thus suggesting that both 
members of the pair are important, but also that these certain keratin filaments are crucial for 
the ectodermal development.
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Ta b le  1 (continues)
Group 3. Transcription regulation.
Disease OMIM Inheritance Gene Protein Function Pathway Specific symptoms Reference
EEC 604292 AD p63 TP63 Transcriptionfactor ED, limb anomalies, CL/P (74)
AEC 106260 AD p63 TP63 Transcription factor ED, ankyloblepharon, CL/P (75)
RHS 129400 AD p63 TP63 Transcription factor ED, CL/P (76)
LMS 603543 AD p63 TP63 Transcription factor ED , limb anomalies (77)
ADULT 103285 AD p63 TP63 Transcription factor ED, limb anomalies (78,79)
Ellis-v-Creveld
syndrome
225500 AR EVC EVC Nuclear receptor? Chondro-ED, polydactyly, heart defects (84)
Ellis-v-Creveld
syndrome 225500 AR EVC2 EVC2 Nuclear receptor? Chondro-ED, polydactyly, heart defects (85)
Weyers
193530acrofacial AD EVC EVC Nuclear receptor? Chondro-ED, hypotelorism, polydactyly (84)
dysostosis
Weyers
193530
acrofacial AD EVC2 EVC2 Nuclear receptor? Chondro-ED, hypotelorism, polydactyly (86)
dysostosis
T-Cell ID,
alopecia and 601705 AD FOXN1 FOXN1 Transcription factor ED, alopecia, T-cell ID (69)
nail dystrophy
Nail dystrophy - AR FOXN1 FOXN1 Transcription factor Nonsyndromic nail dystrophy (70)
Bamforth-
Lazarus
syndrome
241850 AR FOXE1 FOXE1 Transcription factor Forkhead/winge 
d helix family
Hypothyroidism, thyroidal, choanal atresia, spiky 
hair, CL/P (71)
Atrichia with 
popular lesions 209500 AR HR Hairless
Nuclear receptor 
repressor WNT Hair loss after birth, follicular keratinous cysts (81)
Alopecia
universalis
congenita
203655 AR HR Hairless Nuclear receptor 
repressor
WNT Nonsyndromic alopecia (82,83)
Tricho-dento- 
osseous (TDO)
190320 AD DLX3 Distal-less-3 Transcription factor Homeobox
gene
ED and bone anomalies (66,68)
AIHHT 104510 AD DLX3 Distal-less-3 Transcription factor Homeobox
gene
Amelogenesis imperfecta, taurodontism (67)
Selective tooth 
agenesis 604625 AD PAX9 Pax9 Transcription factor
Paired box 
family Nonsyndromic tooth agenesis (60-62)
Tooth agenesis 106600 AD MSX1 Msxl
Transcriptional
repressor
Homeobox
gene
Nonsyndromic tooth agenesis, sometimes with 
orofacial clefting (63,64)
Witkop
syndrome
189500 AD MSX1 Msxl
Transcriptional
repressor
Homeobox
gene
Tooth and nail syndrome (65)
Figure 4. Cell-cell junction and intermediate filam ent proteins in epidermis.
The third ED group consists of nine genes that regulate transcription. Generally, mutations in ED 
causing genes can often cause several allelic conditions, because the type of mutation dictates 
the inheritance pattern and phenotype, but also probably due to different genetic background.
In some conditions also the way of inheritance modifies the phenotype, e.g. homozygous muta­
tions in EVC gene gives rise to Ellis van Creveld syndrome (OMIM 225500), whereas heterozygous 
mutations lead to Weyers acrofacial dysostosis (OMIM 193530). ED causing defects have been 
reported in genes from paired box (PAX9), homeobox (MSX1, DLX3) and forkhead/winged helix 
domain gene families (FOXE1, FOXN1) (60-71). Interestingly, certain mouse models of other 
members of these gene families also show aberrations in ectodermal development suggesting 
their importance in development, but also as ED candidate genes (72,73). Dominant mutations 
in p63 transcription factor gene also lead to several ED syndromes (74-79). Not only defects in 
transcription factors, but also in nuclear receptor co-repressor gene Hairless and possible nuclear 
receptors EVC1/2 cause ED (80-86). The large amount of mutated transcription factors causing 
ED indicates the important role of transcription regulation in ectodermal development.
The fourth group of genes regulates the chromosome stability. Five different genes are known to 
cause Dyskeratosis congenita, which is characterized by nail dystrophy, abnormal skin pigmenta­
tion, leucoplakia, bone marrow failure and predisposition to cancer (87). Four mutated genes 
DKC1, TERC, TERT and NOLA1 are components of telomerase complex, and it is believed that 
telomerase deficiency leads to chromosome instability (87-92). The fifth Dyskeratosis congenita 
causing gene TINF2 is a member of telomere protecting complex, shelterin (93). This "chromo­
some stability" group differs clearly from the rest three ED classification clusters that are linked 
together in a way that junctions allow cells to create pathways for communication and signaling, 
which then regulate the gene expression.
1,3 Transcription factor p63
Yang et al discovered a new member for the p53 and p73 gene family in 1998 (94). The new member 
p63 (also known as TP63, KET, Tp73L, p40) turned out to be the ancestral member of this tran­
scription factor gene family (94,95). It is located on the long arm of the chromosome 3 (3q27-28) 
and consists in total of 16 exons. At least six different p63 isoforms can be produced, due to
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Table 1 (continues)
Group 4. Chromosome stability.
Disease OMIM Inheritance Gene Protein Function Pathway Specific symptoms Reference
Dyskeratosis
congenital 305000 XR DKC1 Dyskerin-1
Small nucleolar 
ribonucleoprotein
Component of
telomerase
complex
Bone marrow failure, leucoplakia, abnormal skin 
pigmentation, nail dystrophy, predisposition to 
cancer
(88,89)
Dyskeratosis
congenital 224230
AR NOLA3 NOLA3
Small nucleolar 
ribonucleoprotein
Component of
telomerase
complex
Bone marrow failure, leucoplakia, abnormal skin 
pigmentation, nail dystrophy, predisposition to 
cancer
(90)
Dyskeratosis
congenital 127550 AD TERT TERT
Ribonucleoprotei n 
polymerase
Component of
telomerase
complex
Bone marrow failure, leucoplakia, abnormal skin 
pigmentation, nail dystrophy, predisposition to 
cancer
(91)
Dyskeratosis
congenital 127550 AD TERC
snoRNA (Telomerase 
RNA)
Component of
telomerase
complex
Bone marrow failure, leucoplakia, abnormal skin 
pigmentation, nail dystrophy, predisposition to 
cancer
(92)
Dyskeratosis
congenital
Component of Bone marrow failure, leucoplakia, abnormal skin
127550 AD TINF2 TRF1 DNA binding protein shelterin
complex
pigmentation, nail dystrophy, predisposition to 
cancer
(93)
two different promoter sites and three different splicing routes. The amino-terminal ends are 
encoded either by exons 1-3 or exon 3' only, and are called TA and AN, respectively (Figure 5A). 
The carboxy-terminal ends denoted a, P and y are result of alternative splicing routes for exons 
10-15. Several functional domains have been identified in p63 protein. The canonical transactiva­
tion domain (TA) bears homology to the TA domain of p53 and is present only in the TA-isoforms. 
However, ANp63 isoforms which lack this TA domain exhibit nonetheless transactivation activity 
and it has been demonstrated that the amino terminus of AN contains a second TA domain (TA2) 
(Fig. 5B) (96,97). The DNA binding domain (DBD) is present in all isoforms and is crucial for the 
binding on to its target promoter. The isomerization domain is needed for dimerization of p63 
molecules and is present in all isoforms. The carboxy-terminal end has two additional domains: 
sterile alpha motif domain (SAM) and transactivation inhibitory domain (TI). The SAM domain 
is involved in protein-protein interactions and is present only in the longest a-isoform. The TI 
domain that is found in a- and P-isoforms, is able to bind to the amino-terminal TA domain intra­
molecularly and inhibit its function (98).
Role of p63 in development
At the time p63 was found, it was anticipated that it has tumor-suppressor properties, just as its fa­
m ous family member p53. However, several studies provided unequivocal evidence that p63 has 
a major role in embryonal development: p63 knock-out (KO) mouse models showed an extreme 
form of developmental abnormalities and dominant p63 mutations in human led to congenital 
ectodermal dysplasia syndrome (74,99,100).
A TAp63
Figure 5. Schematic overview of the p63 gene and two of its protein products. A . p63 has two different pro­
moter sites resulting in two different N-terminal ends called TA and AN. ANp63 lacks the exons 1-3, which are 
present in TAp63, however it contains an alternative exon 3'. P63 has three C-terminal splicing routes: a, p and 
Y, thus at least six different gene products can be transcribed. B. The domain structure of TA and ANp63 is simi­
lar, only N-terminal transactivation domain is different, called TA and TA2, respectively. Domain abbreviations: 
ISO (Isomerization domain), SAM (Sterile alpha motif domain) and TID (Transactivation inhibitory domain). 
Figure adapted from Chapter 6.
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By now, mutations in p63 gene in human can cause seven different diseases: Ectrodactyly, 
ectodermal dysplasia, and cleft lip/palate syndrome (EEC, OMIM 604292), Ankyloblepharon- 
ectodermal defects-cleft lip/palate syndrome (AEC, OMIM 106260), Limb mammary syndrome 
(LMS, OMIM 603543), Acro-dermato-ungual-lacrimal-tooth syndrome (ADULT, OMIM 103285), 
Rapp-Hodgkin syndrome (RHS, OMIM 129400), Split hand/foot malformation (SHFM4, OMIM 
605289) and Non-syndromic cleft lip/palate (NSCL) (74-79,101). There are three main hallmarks 
that characterize these disease phenotypes: ectodermal dysplasia, orofacial clefting and limb 
malformations (ectrodactyly and syndactyly). The p63-deficient mice phenotype is reminiscent of 
the human p63-mutant syndrome, though it is more severe. P63-KO mice were born with trun­
cated or absent limbs, severe craniofacial hypoplasia, absent hair follicles, teeth inducements 
and several eccrine glands. These mice basically lacked all stratified epithelia and the epidermis, 
which caused dehydration and early dead. The mutant mouse studies together with the human 
disease phenotypes proved that p63 is a crucial developmental gene especially in the ectodermal 
development including the limbs and craniofacial parts.
p63: Master molecule of stem cell identity, differentiation or both?
The p63-deficient mice were created and studied by two separate research groups, whose interpre­
tations of the defects in the mouse mutants were not consistent (99,100). One of the groups 
claimed that p63 is required for the commitment of the simple ectoderm to the epidermal 
lineage, because the group was unable to detect any sign of differentiation (100). In contrast, the 
other group observed some patchy epidermal differentiation and concluded from their findings 
that instead of block the induction of stratified epithelia, p63 has main role in stem cell prolifera­
tion and maintenance (99). A detailed characterization of the stratification defects in the 
p63-deficient mice revealed that dental lamina, an initiation step in teeth development was 
normal, although it did not proceed into the teeth placode, whereas the hair follicle develop­
ment was not even initiated (99,100,102). It is unclear whether strain-specific factors may have 
affected the phenotype, or whether only different interpretation of the very same phenotype 
created the discrepancy in the final conclusions. The crucial but controversial role of p63 in ecto­
dermal stem cells inspired several research groups around the world to study the role of p63 and 
started an interesting and extremely active research period on p63.
Several further studies have been performed in order to resolve the primary role of p63. P63 has 
been shown to be highly expressed in epithelial cells that are highly clonogenic and have high 
proliferative capacity, whereas cells lacking the p63 start losing their proliferative capacity (103). 
Furthermore, adding p63 to primary keratinocytes when inducing the Ca2+-dependent differen­
tiation prevents the keratinocyte differentiation (104,105). Ample evidence exists that p63 is the 
master molecule that determines the proliferative potential of stem cells in stratified epithelia. 
However, several groups have also shown that p63 is necessary for epidermal cell lineage com­
mitment. Adding p63 into embryonal stem cell (ES) derived ectodermal cells (potential precur­
sors of the epidermal cells) increased the cell proliferation and survival as well as differentiated 
these cells into keratinocytes (106). Another study showed that excess p63 was able to induce 
epidermal stratification markers in single layered lung epithelia, suggesting the role of p63 also in 
epidermal cell lineage commitment (105). Thus, evidence for both roles of p63 is available, which 
strongly indicates that p63 is not only important for the stem cell maintenance and proliferation 
but also for the epidermal stem cell commitment.
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p63 isoforms in developing epidermis
Although, independent results support the role of p63 in epidermal cell lineage commitment, the re­
sults are not consistent. There is a discrepancy between the expression of different p63 isoforms. 
It has been claimed that TAp63 isoforms can be detected before the commitment to epidermal 
stratification at embryonal day 7.5 (E7.5) (105). In the same study it was suggested that TAp63 
starts the stratification and inhibits the terminal differentiation and expression of ANp63 isoforms 
(expression at E9.5). The counterbalanced expression by ANp63 isoforms would thereby allow the 
epidermis to differentiate (105). In all other epithelial cell studies the ANp63 isoforms appear to 
be the isoform with highest expression (102,106-108). Its expression has been detected first at 
around E8, whereas in only one study very small amounts (0.8 percent) of TAp63 isoforms have 
been detected (E13) (102). In contrast to Koster's study (105), the TAp63 expression has been 
detected to increase and ANp63 decrease during the keratinocyte differentiation (109). Results 
of isoform specific complementation in p63-deficient mice revealed that mice complemented by 
ANp63a (lacking the TAp63a) showed some differentiated epidermal structure, whereas mice 
complemented by TAp63a (lacking the ANp63a) had only poorly differentiated keratinocyte 
patches (107). Yet, the epidermis of the mice lacking ANp63a is very similar to the complete p63 
KO-mice. Interestingly, TA-specific KO-mice had normal epithelial morphogenesis, but showed de­
fects in genomic surveillance in oogenesis (110). Altogether this data strongly demonstrates that 
ANp63a is the crucial p63-isoform that is first expressed in the epidermis.
p63 regulates several developmental genes
By now several interesting developmental p63 target genes have been discovered. ANp63a has been 
shown to bind to the GATA-3 promoter and activate the gene transcription (111). GATA3 is a 
transcription factor that is involved in skin and hair follicle cell fate decision (109,111,112). Inter­
estingly, GATA3 can then regulate IkB kinase-a (IKKa) that has been linked to epidermal differ­
entiation, proliferation and limb development (111,113,114). However, also direct regulation of 
IKKa has been reported by TA/ANp63 (111,115). Recently, TA/ANp63 has been demonstrated to 
directly regulate three members of Distal-less homeobox gene family (DLX3, DLX5 and DLX6) that 
are linked into the development of head and limb skeleton (116,117). P63 does not only regulate 
genes by activating or repressing their transactivation but also through protein-protein interac­
tions. The SAM domain of p63 can bind to Apobec1-binding protein 1 (ABBP1) that is a member 
of RNA processing machinery and known to regulate differential splicing of the Fibroblast growth 
factor receptor 2 (FGFR2) towards the epithelial specific form (118). Very likely p63 and SAM 
domain have other interacting proteins that have not been discovered yet.
The amount of p63 direct and indirect target genes increases rapidly. The difficulty is to discover 
their contribution to the development when some of these targets are not expressed in epi­
thelial or ectoderm-derived tissues. Furthermore, several novel targets have been shown to 
be activated only by TAp63a isoform that is not expressed in epithelial or ectodermal derived 
tissues or structures. Recently, several research groups have performed genome-wide p63 target 
gene studies (119-121). Their studies resulted in detection of certain enriched cellular processes 
that are likely to be regulated by ANp63a: development, morphogenesis, proliferation, tissue 
regeneration, cell adhesion, death and signaling pathways (119,120). Some validated develop­
mental and morphogenic target genes have already been described above, and next to that I will 
introduce the known adhesion-linked genes that are regulated by p63.
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p63 regulates epithelial adhesion
Recently, p63 has been linked to the regulation of epithelial adhesion and survival (108). Since the 
epithelium is confronted with a lot of mechanical stress, its structure has to be very compact and 
solid. Cells are bound together by direct cell-cell anchoring junctions (adherens and desmosomes) 
and cells in the basal layer are anchored to the underlying basal lamina by cell-matrix junctions 
(actin-linked adhesions or intermediate filament-linked hemidesmosomes) (122) (Fig. 4). The sig­
nal transmission is allowed through the actin or intermediate filaments that are anchored to these 
junctions. P-cadherin, an adherens junction protein can be transcribed and activated by various 
p63 isoforms (123). Also PERP protein, a stabilizer of desmosomal complexes within cell-cell junc­
tions, can be regulated and activated by various p63 isoforms in stratified epithelia (124). Further­
more, several cell-matrix adhesion proteins have been shown to be regulated by p63 (108,125). 
Epithelial matrix, the basal lamina consists mainly from laminin molecules, and interestingly a 
component of a laminin receptor Integrin-a3 has been shown to be a TAp63y target (125). Knock­
down of endogenous p63 led to cell detachment from the plate, down-regulation of cell adhe­
sion-associated genes and cell death in human epithelial breast cell line and keratinocytes (108). 
ANp63a was shown to be able to occupy several Integrin (a3, |34, a5 and a6) and Laminin-y2 
promoters and activate their transcription. Thus the detachment of the plate was probably caused 
by the down-regulation of these adhesion-related genes. It was also shown that the detachment 
was independent of apoptosis, and that ANp63a was important for cell survival. Finally, Dystonin 
(BPAG1) that anchors keratin containing filaments to hemidesmosomes and basal layer intermedi­
ate protein Keratin-14 can be regulated by TAp63y and ANp63a, respectively (107,126-128).
Epithelium also has a selective permeability barrier function, which is formed by tight junctions.
Tight junctions seal gaps between epithelial cells to prevent exchange of water, ions and macro­
molecules across epithelial sheets. Claudins are main transmembrane proteins for the tight junc­
tion formation and function. (122,129) The importance of Claudin-1 (CLDN1) has been shown by 
Cldn1-deficient mice that lack the tight junctions in the skin epithelia and consequently dye on 
dehydration (130). Recently, ANp63 has been reported to bind CLDN1 promoter and activate its 
transcription, indicating that CLDN1 is a direct target gene of the ANp63a (131). The regulation of 
cell junction and adhesion genes strongly indicate that p63 has a role in cellular adhesion, which 
can have effects for cell metabolism, proliferation, migration, differentiation, structural organiza­
tion and cell survival (122,132).
1,4 Aim and outline of this thesis
The work in this thesis was initiated in 2004, five years after the p63 mutant mice studies and the 
first human p63 mutations were published (74,99,100). In these five years, it was discovered that 
mutations in p63 gene can lead to six different diseases: EEC, AEC, LMS, ADULT, RHS and SHFM4 
(74-79,101). In addition, Non-syndromic cleft lip/palate (NSCL) has been associated to p63 
mutations (101). Although the features in these phenotypes are overlapping they are sufficiently 
different to be considered as unique disorders. Moreover a clear genotype-phenotype correla­
tion has tentatively been established (133). Nonetheless, the exact molecular disease mechanism 
of these diseases was still poorly explored. My research focused in delineation of p63 genotype- 
phenotype association and exploration of the role of p63 in ectodermal dysplasia syndromes. In 
this thesis I have tried to provide more insight into the p63-associated diseases, their molecular 
disease mechanism and the role of p63 and its downstream signaling in these diseases.
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Chapter 2. Spotlight on p63: p63-associated disorders.
This chapter gives an overview of the known five ectodermal dysplasia syndromes and the non- 
syndromic SHFM4. Also a novel non-syndromic orofacial clefting (NSCL) caused by p63 mutation 
will be presented. This study gives an update of known p63 pathogenic mutations. This chapter 
has been published as a part of p63 special issue in Cell Cycle in 2007 (Spotlight on p63: The 
emerging p53 family) in order to introduce the p63- associated disorders.
Chapter 3. Pattern of p63 mutations and their phenotypes -  update.
This chapter describes the clinical spectrum of 227 patients with p63 mutations, which confirms 
the previously presented genotype-phenotype association. However, this phenotype delineation 
also identifies a large degree of clinical variability in each of the p63-associated disorders. This 
chapter has been published in American Journal of Medical Genetics in 2006.
Chapter 4. Delineation of the ADULT syndrome phenotype due to arginine 298 
mutations of the p63 gene.
This chapter delineates the ADULT syndrome genotype-phenotype association. On basis of 16 
patients it describes the general phenotype caused by the ADULT syndrome hot spot mutation 
at arginine (p.R298). Moreover it discusses the relevance of oral squamous cell carcinoma in one 
patient carrying the heterozygous p.R298 mutation. This chapter has been published in European 
Journal of Human Genetics in 2006.
Chapter 5. Spectrum of p63 mutations in a selected patient cohort affected with 
Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome (AEC).
This chapter presents and confirms the AEC/RHS syndrome genotype-phenotype association.
This study introduces one known and ten novel pathogenic p63 mutations in an American 
patient cohort. Here we present for the first time that missense mutations occur also in the TI 
domain. This chapter has been published in American Journal o f Medical Genetics in 2009 as part 
of the results of the National Foundation of Ectodermal Dysplasia meeting in Houston, in 2007.
Chapter 6. A novel translation re-initiation mechanism for the p63 gene revealed 
by amino-terminal truncating mutations in Rapp-Hodgkin/Hay-Wells like syndromes. 
This chapter presents completely new insight of AEC/RHS disease model. Here we describe three 
mutations in the 5' end of the p63 gene, which lead to premature termination codon. Further­
more, we show that these mutations do not lead to nonsense mediated decay, but to translation 
re-initiation producing a novel p63 protein variant. This chapter has been published in Human 
Molecular Genetics in 2008.
Chapter 7. Genome-wide profiling of p63 binding sites identifies genes and 
regulatory elements for p63-related disorders: Elucidation of the genetic 
basis of Split hand/foot malformation type 1.
This chapter combines a genome-wide p63 binding data with functional gene expression data 
obtained from keratinocytes in order to discover direct p63 target genes affected in p63-associ- 
ated patients. Here we discuss p63 binding to regulatory elements, direct target genes that are 
affected in patients and are contributed to p63-associated phenotypic features. We also report 
an example of a p63 regulatory element that is found in the SHFM1 locus and controls limb 
development. This chapter is under preparation to be submitted.
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Abstract
Heterozygous mutations in the transcription factor gene p63 are causative for several syndromes 
with ectodermal dysplasia, orofacial clefting and limb malformations as the key characteristics. 
Different combinations of these features are seen in five different syndromes, of which Ectro- 
dactyly, ectodermal dysplasia and cleft lip/palate syndrome (EEC) is the most common one. 
Mutations in p63 can also cause non-syndromic single malformations, such as Split hand/foot 
malformation (SHFM4) and isolated cleft lip/palate (NSCL). In this article we will present an 
overview of diseases caused by mutations in the p63 gene and review the known pathogenic p63 
gene mutations.
Introduction
The transcription factor p63 is a key regulator of ectodermal, orofacial and limb development. This 
became apparent in 1999, by the generation of p63 knockout mice (1,2) and by the finding of 
dominant mutations in human disorders with ectodermal dysplasia, split hand/foot malfor­
mation and orofacial clefting (3-7). Mutations in the p63 gene can cause at least five differ­
ent syndromes: Ectrodactyly, ectodermal dysplasia and cleft lip/palate syndrome (EEC, OMIM 
604292), Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome (AEC, OMIM 106260), 
Limb mammary syndrome (LMS, OMIM 603543), Acro-dermato-ungual-lacrimal-tooth syndrome 
(ADULT, OMIM 103285) and Rapp-Hodgkin syndrome (RHS, OMIM 129400). Furthermore, two 
non-syndromic human disorders are caused by p63 mutations: isolated Split hand/foot malfor­
mation (SHFM4, OMIM 605289) and recently Non-syndromic cleft lip/palate (8). Here we present 
an overview of these seven p63-linked conditions, the genotype-phenotype associations and give 
an update of all known pathogenic p63 mutations.
p63 phenotype
Ectodermal dysplasia (ED) is one of the three main characteristics of the p63-associated syndromes 
(Fig. 1). Ectodermal dysplasia manifests as the abnormal development or growth of tissues and 
structures that are developed from the outer embryonal layer, ectoderm. In this condition skin, 
hair, teeth, nails and several exocrine glands, such as sweat and sebaceous glands are usually 
abnormally developed. The epidermis of p63 patients can be very dry, itchy and hypopigmented. 
In extreme cases widespread areas of the skin can be erosed often including the scalp. This is 
most common in the AEC syndrome, where patients present patches of life-threatening con­
genital skin erosion. However, the skin usually recovers after the first year. The amount of scalp 
and body hair is often diminished and hair can be wiry or curly. Alopecia is sometimes reported. 
Occasionally the eyelashes and eyebrows are also absent. The number of teeth is often less than 
in healthy individuals, indicating that there is a reduced number of teeth placodes. Teeth can 
also be malformed by a conical shape and poor enamel formation, causing subsequent tooth 
decay. Nails can be dystrophic, thickened and discoloured. The absence or reduced amount of 
sweat glands is also reported among p63 patients and leads to diminished perspiration, which 
can be life-threatening. Mammary gland and nipple hypoplasia are other manifestations of the 
ectodermal dysplasia spectrum observed in p63 patients. Also the development and function of 
sebaceous and salivary glands are frequently abnormal. Lacrimal duct defects and obstruction of 
the lacrimal ducts impose a risk for conjunctivitis and corneal damage.
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Figure 1. Various combinations of ectodermal dysplasia, orofacial clefting and limb m alformations are the 
hallm ark of p63-associated syndromes. EEC syndrome is the prototype of these syndromes and together with 
LMS shows all three hallmarks. ADULT syndrome patients never show orofacial clefting, whereas AEC and RHS 
never show limb defects. Non-syndromic limb defect condition (SHFM4) and Non-syndromic cleft lip/palate 
(NSCL) are also caused by mutations in the p63 gene.
Characteristics of ED described here varies between the p63 syndromes and even within a one 
single syndrome, as will be discussed below in this article.
Split hand/foot malformation (SHFM) constitutes the second part of the p63 syndrome phenotype 
(Fig. 1). Hands and feet are often malformed and have a severe median cleft in the palm and/or 
in the sole. These clefts usually occur in conjunction with a lack of one or more central (2-3-4) 
digits, which is called ectrodactyly. Fusion of fingers or toes, which is called syndactyly, can be 
seen in conjunction with ectrodactyly. In most cases SHFM is part of a syndrome, but it can also 
be present in isolation, without other symptoms.
The third hallmark of p63 syndrome phenotype is orofacial clefting (Fig. 1). It is mainly seen in the 
form of cleft lip (CL) and/or cleft palate (CP). This symptom is usually observed as part of a com­
plex syndrome, where other organs are also affected, however, recently Leoyklang et al (8) have 
described mutations in p63 gene causing orofacial clefting as the only abnormality.
Most of the above developmental defects are also observed in p63 knockout mice, which have par­
ticular severe defects of ectodermal structures and the limbs (1,2). Heterozygous p63+/" mouse 
have no significant developmental abnormalities, suggesting that loss-of-function of one allele 
is not disease-causing. Recently, it has been reported that a high proportion of p63+/- aging mice 
develop tumours indicating a role of p63 in tumour suppression (9). However, this observation 
could not be confirmed in an independent study (10). There is no indication that individuals with 
heterozygous p63 mutation are prone to develop tumours.
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Allelic p63 conditions
EEC syndrome
The prototype of the p63 syndrome family is the EEC syndrome (Fig. 1). EEC syndrome patients are 
invariably characterized by one or more features of ectodermal dysplasia, which can present as 
defects of hair, skin, nails, teeth and glands. The severity and type of the ectodermal features is 
highly variable, and to some extent dependent on the exact nature of the mutation (see below). 
Only few patients show defects in all of the described ectodermal structures above. EEC patients 
occasionally also have mammary gland/nipple hypoplasia (14%) and hypohidrosis (11%). About 
two-thirds of these patients have ectrodactyly, and syndactyly is also frequent (43%). Cleft lip/ 
palate is present in about 40% of the EEC patients, mostly as CL with or without CP (11).
EEC syndrome is mainly caused by point mutations in the DNA binding domain (DBD) of the p63 gene 
(Table 1). Altogether 34 different mutations have been reported, and 20 different amino acids are 
involved. Only two mutations are outside the DNA binding domain: one insertion (c.1572insA) 
and one point mutation (p.L563P) in the Sterile alpha motif domain (SAM) (4,11). In earlier stud­
ies we found five frequently mutated amino acids: p.R204, p.R227, p.R279, p.R280 and p.R304 in 
the EEC population, all located in CpG islands (Fig. 2). These five mutations explain almost 90% 
of the EEC syndrome patients (11,12). The five p63 arginine hotspot mutations and probably 
also other DNA binding domain mutations that are found in EEC syndrome appear to impair the 
p63 protein binding to DNA (4). The autosomal dominant inheritance of EEC syndrome suggests 
that the EEC mutations have a dominant negative effect. However, recent genotype-phenotype 
analyses for the five hotspot mutations revealed significant differences between the correspond­
ing phenotypes. For instance cleft lip/palate is present in the p.R304 mutation population (80%), 
whereas p.R227 patients seldom have cleft lip/palate. Syndactyly is completely absent in p.R227 
population, while 30-60% of the other hotspot mutation population have syndactyly. Genito­
urinary defects are frequently observed in p.R227 mutation population (40%), while significantly 
less in other populations (11). It thus seems that these hotspot mutations exert specific effects. 
Such specificity might be brought about by different effects of these mutations on promoters 
for p63 transcriptional target genes. Alternatively, these hotspot mutations may exhibit gain-of- 
function effects, similar as for the p53 hotspot mutations (13).
Limb mammary syndrome (LMS)
The LMS phenotype resembles the EEC syndrome phenotype, but the ectodermal manifestations are 
milder (Fig. 1) (3). A consistent feature of LMS is the mammary gland and/or nipple hypoplasia 
(100%). Lacrimal duct obstruction and dystrophic nails are frequently observed (59 and 46% 
respectively), hypohydrosis and teeth defects are detected in about 30%, but other ectodermal 
defects such as hair and skin defects are rarely detected if at all. About 70% of LMS patients have 
similar limb malformations as in EEC syndrome, and about 30% orofacial clefting, notably always 
in form of cleft palate (11).
Mutations in LMS are located in the N- and C-terminus of the p63 gene (Table 1). A large LMS family 
(29 affected members) has a point mutation in exon 4, causing a p.G76W substitution in the AN- 
specific putative second transactivation domain (TA2) (3,12,14,15).
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Table 1. Pathogenic p63  mutations in seven allelic diseaseas.
Mutation Exon Domain Isoform Syndrome Reference
P.N6H 3' TA2 AN a. 6. y ADULT (23)
P.R58C 3 TA TA a. B. y SHFM (42)
P.G76W 4 AN. TA a. B. y LMS (12)
P.S90W 4 AN. TA a. B. y LMS *
3'ss intron 4 i4/e5 AN. TA a. B. y SHFM (6)
P.G134D 4 AN. TA a. B. y LMS *
P.G134D 4 AN. TA a. B. y ADULT (26)
P.L162P 5 AN. TA a. B. y EEC (11)
P.Y163C 5 AN. TA a. B. y EEC (12)
P.Y192C/D 5 DBD AN. TA a. B. y EEC *
P.K193E 5 DBD AN. TA a. B. y SHFM (6)
P.K194E 5 DBD AN. TA a. B. y SHFM (5)
P.V202M 5 DBD AN. TA a. B. y EEC (12.59)
P.R204L/Q/W 6 DBD AN. TA a. B. y EEC (4.6.11.12.60.61)
P.H208Y 6 DBD AN. TA a. B. y EEC (11)
P.R227Q 6 DBD AN. TA a. B. y EEC (11.12)
P.C269Y 7 DBD AN. TA a. B. y EEC (6)
P.S272N 7 DBD AN. TA a. B. y EEC (4)
P.C273Y 7 DBD AN. TA a. B. y EEC (6)
P.R279C/H/Q 7 DBD AN. TA a. B. y EEC (4.5.12.31.60-63)
P.R279H 7 DBD AN. TA a. B. y RHS (30)
P.R280C/H/S 7 DBD AN. TA a. B. y EEC (6.12.29.51)
P.R280C/H 7 DBD AN. TA a. B. y SHFM (5)
P.R298G/Q 8 DBD AN. TA a. B. y ADULT (20.22.24.25)
P.R304P/Q/W 8 DBD AN. TA a. B. y EEC (4-6.31.61.64.65)
P.C306Y/R 8 DBD AN. TA a. B. y EEC (4.66)
P.C308S/Y 8 DBD AN. TA a. B. y EEC (6)
P.P309S 8 DBD AN. TA a. B. y EEC (6)
P.D312G/H/N 8 DBD AN. TA a. B. y EEC (6.67)
P.R313G 8 DBD AN. TA a. B. y EEC *
P.R313G 8 DBD AN. TA a. B. y NSCL (8)
P.A315E 8 DBD AN. TA a. B. y EEC *
3'ss intron 10 i10/e11 AN. TA a. B. y AEC (29)
P.I510T 13 SA M AN. TA a RHS (27)
P.I510T 13 SA M AN. TA a AEC (27.38)
P.L514F/S/V 13 SA M AN. TA a AEC (7.35)
P.G518V 13 SA M AN. TA a AEC *
P.C522G/W 13 SA M AN. TA a AEC (7)
c.1572insA 13 SA M AN. TA a EEC (4)
c.1576delTT 13 SA M AN. TA a LMS (12)
P.G530V 13 SA M AN. TA a AEC (7)
P.T533P 13 SA M AN. TA a AEC (7)
P.534insPhe 13 SA M AN. TA a AEC (33)
P.Q536L 13 SA M AN. TA a AEC (7)
P.I537T 13 SA M AN. TA a AEC (7.12)
P.S541F 13 SA M AN. TA a AEC *
P.S541P/Y 13 SA M AN. TA a RHS (32.36)
P.R555P 14 SA M AN. TA a. B AEC (35)
P.I558T 14 SA M AN. TA a. B AEC *
P.L563P 14 SA M AN. TA a. B EEC (11)
c.1709delA 14 TI AN. TA a. B RHS (30)
c.1721delC 14 TI AN. TA a. B RHS (11.37)
c.1742delC 14 TI AN. TA a. B AEC (12)
c.1743delAA 14 TI AN. TA a. B LMS (6)
c.1787delG 14 TI AN. TA a. B RHS (25)
c.1859delA 14 TI AN. TA a. B RHS (31)
c.1859delA 14 TI AN. TA a. B AEC *
P.K632X 14 TI AN. TA a. B LMS (11)
P.Q634X 14 TI AN. TA a. B SHFM (6)
P.E639X 14 TI AN. TA a. B SHFM (12)
* Authors' unpublished data
46
One other point mutation (p.S90W) is also located between the TA domain and DBD. Other LMS 
mutations are reported in the C-terminus: a TT deletion in the exon 13 and an AA deletion in 
exon 14 (6,12). These will affect only the p63a protein isoforms, where they are predicted to 
cause a frame shift and a premature stop codon. Also a stop mutation in the transcription factor 
inhibitory domain (TI) (p.K632X) has been identified in a sporadic LMS patient (11). The latter 
mutation is predicted to impair the suppressive effect of the TI domain towards the TA domain, 
thus increasing the transactivation activity (16).
ADULT syndrome
ADULT syndrome phenotype is most similar to LMS syndrome, although clear differences can be seen 
when observing larger families or patient populations. The main difference is the absence of 
orofacial clefting and the presence of hair and skin defects in the ADULT syndrome (Fig. 1). Teeth, 
skin and nail defects are constantly present in ADULT syndrome (100, 93 and 100%, respectively), 
but only rarely in LMS. Hair (53%) and lacrimal duct defects (67%) are observed in ADULT pa­
tients more frequently than in LMS. Freckling has been reported, but cannot be considered to be 
a differentiating feature of this syndrome (20).
By today, four ADULT syndrome families and three sporadic cases have been reported (20-26). All the 
families and one of the sporadic cases have a point mutation in exon 8, changing p.R298 in the 
DNA binding domain into either a glutamine or a glycine (Table 1). While EEC syndrome muta­
tions in the DNA binding domain impair the binding of p63 protein to DNA (4), arginine p.298 
is not located close to the DNA-binding interface, and mutation of this arginine does not affect 
DNA binding (24). Instead, earlier studies have shown a gain-of-function effect for the mu­
tated ANp63y isoform, which usually does not have a transactivation activity in assays using an 
optimized p53-responsive element (20,24). Two other mutations are located in the N-terminus: 
p.N6H mutation affects only the AN-isoforms and in another isolated patient a missense muta­
tion p.G134D (In the article incorrect amino acid annotation, erratum pending Ref. Slavotinek et 
al. 2005(26)(19)) is located just front of the DBD in exon 4 (23,26).
AEC syndrome
The AEC syndrome phenotype differs from the other conditions mainly by the severity of the skin 
phenotype, the occurrence of an eyelid fusion at birth and the absence of limb malformations 
(Fig. 1). Approximately 80% of the patients have severe skin erosion at birth, which usually will 
recover in the first years of the life. The eyelid fusion, also called ankyloblepharon, is present 
in about 45% of AEC patients, but only rarely in other p63-associated conditions. The other ED 
symptoms, such as nail and teeth defects are present in more than 80% of patients, and hair 
defects and/or alopecia are almost constant features (94%). Lacrimal duct obstruction is seen in 
50% of patients, whereas mammary gland hypoplasia and hypohydrosis occur occasionally (both 
13%). Interestingly, almost 40% of patients have hearing impairment and genito-urinary defects. 
Cleft lip is present in 44% and cleft palate in about 80%. Limb malformations are almost absent. 
Ectrodactyly has never been reported, but 25% of patients has only mild syndactyly (11).
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Figure 2. Pathogenic p63 mutations cause at least five different syndromes and two non-syndromic condi­
tions. Mutations causing different diseases are illustrated in different colours. Only mutations that are discussed 
in the text are indicated, an overview of all mutations is given in Table 1. EEC hotspot mutations are clustered 
in DNA binding domain, and RHS and AEC syndrome mutations in SAM and TI domains. Several mutations, such 
as p.R280, p.R313, p.I510, p.S541 and c.1850delA, can have a variable clinical outcome, probably due to genetic 
background effects. The black asterisks illustrate sites needed for upiquitination (p.K193, p.K194 and PY) and 
the white asterisk represents a sumoylation site (fKXD/E) (17-19).
Rapp-Hodgkin syndrome (RHS)
RHS mimics AEC very much (Fig. 1). The differences discussed earlier in several papers are the ab­
sence of ankyloblepharon in RHS and the more severe skin phenotype in AEC (11,27). Other ED 
symptoms, such as orofacial clefting and the near absence of limb malformations are similar to 
AEC. These two conditions could be considered as a single entity, since the ankyloblepharon is 
present only in about 45% of AEC syndrome patients, and therefore is not a discriminating factor. 
Although, the severity of the skin phenotype is obvious and more severe in AEC patients than in 
RHS patients, the strong overlap between AEC and RHS suggest, that they are variable manifesta­
tions of the same clinical entity (11,27).
AEC and Rapp Hodgkin syndrome mutations are located in the C-terminus of the p63 protein (Fig. 2). 
They are either point mutations in the SAM domain or deletions in the SAM or TI domains (Table 
1) (7,11,12,27-38). The SAM domain is known to be involved in protein-protein interactions and 
therefore mutations in this domain are most probably hampering the binding to interacting 
proteins. One known interactor of p63 SAM domain is the Apobec1-binding protein 1 (ABBP1),
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which is a member of RNA processing machinery and known to regulate the alternative splic­
ing of the Fibroblast growth factor receptor 2 (FGFR2) towards the epithelial specific isoform.
AEC mutations in the SAM domain abolish the binding to ABBP1, which most probably leads 
to changes in FGFR2 RNA splicing (39). Interestingly, gain-of-function mutation in FGFR2 gene 
have been reported in a number of craniosynostosis syndromes, which are also characterized by 
distal limb malformations (40). Recently, loss-of-function mutations in FGFR2 have been found 
in Lacrimo-auricolo-dento-digital syndrome (LADD), an ED syndrome characterized by dominant 
inheritance of limb defects in association with abnormal lacrima, ear cups and teeth (41). Inter­
estingly, LADD shows marked overlap with EEC syndrome, and was earlier also presumed to be 
caused by mutations in the p63 gene.
Non-syndromic p63 conditions
Split hand/foot malformation type 4 (SHFM4) is a "pure" limb malformation (ectrodactyly and syn­
dactyly) condition, thus without orofacial clefting or ectodermal dysplasia. The non-syndromic 
SHFM4 is caused by several mutations, which are dispersed throughout the p63 gene: a point 
mutation in the Transactivation domain (TA) (p.R58C), a splice-site mutation in front of exon 4 
(3'ss intron 4), four missense mutations in the DNA binding domain (p.K193E, p.K194E, p.R280C, 
p.R280H), and two nonsense mutations in the Tl-domain (p.Q634X, p.E639X) (Table 1) (5,6,42). It 
is still unclear how these widely dispersed mutations cause the limb defect. Interestingly, several 
SHFM4 mutations are reported to cause alteration in the p63 protein activation and stability: 
p.Q634X and p.E639X are known to disrupt the sumoylation site, and therefore increase the sta­
bility and transcriptional activity of the p63a isoform (19,43). Furthermore, amino acids p.K193 
and p.K194 are required for ubiquitin conjugation by E3 ubiquitin ligase (Itch) and naturally 
occurring mutations in those amino acids cause more stable p63 protein (17). Possibly, SHFM is 
caused by altered protein degradation, even though different degradation routes are involved. 
Another divergent phenomenon is the p.R280C/H mutations, which are not only causative for 
SHFM4, but also for the syndromic EEC phenotype in other families. In such families, the phe­
notype is always consistent, either EEC or SHFM4. In SHFM4 families decreased penetrance is 
reported, for the p.R280 mutation, suggesting an effect of a nearby genetic modifier.
Recently, a non-syndromic orofacial clefting type was also linked to p63 gene (8). The amino acid 
change p.R313G is the first mutation causing the Non-syndromic cleft lip (NSCL) phenotype in the 
p63 gene (8). This mutation was also observed in a sporadic EEC syndrome phenotype (authors' 
unpublished data). Mutations and/or polymorphisms in 3 other genes, IRF6, MSX1 and PVRL, 
are also associated with a syndromic and non-syndromic forms of orofacial clefting (44-50). In 
the study of Leoyklang et al (8) also other changes in the p63 gene were found (p.N87N, p.S90L, 
p.L248L, p.H406H, p.D564H), but because the mutations did not change the amino acid se­
quence or were also found in one of the healthy parents or in the control population, they were 
not considered to be pathogenic changes. Nevertheless, since orofacial clefts are considered to 
have a multifactorial origin it is quite possible that these changes in the p63 gene impose a risk 
factor for facial clefting type, similar as was reported for the IRF6 gene.
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Discussior
The mutation patterns in the p63 gene that are associated with different p63 clinical conditions 
display a clear genotype-phenotype association: especially in the EEC and AEC/RHS syndromes, 
where mutations are clustered in the DNA binding domain and in the SAM and TI domains, 
respectively. In about 250 patients we and others have described 74 different mutations causing 
five different syndromes and two different non-syndromic conditions. This still increasing number 
of patients allows the delineation of the phenotypic and genotypic pictures of different p63- 
associated disorders. In addition, evidence is accumulating that other genetic factors influence 
the final p63 mutant phenotype.
Several examples show that the same mutation can lead to different clinical conditions. AEC and RHS 
syndromes share three mutations: p.I510, p.S541 and c.1859delA (27,28,31,32,34,36). Often the 
clinical distinction between RHS and AEC syndrome is solely based on the presence or absence 
of ankyloblepharon, which in fact is not the discriminating feature between these two conditions 
(11). Also LMS and ADULT syndrome seem to be caused by the same mutation p.G134D (authors' 
unpublished data) (26), as well as EEC syndrome and Non-syndromic cleft lip/palate due to the 
p.R313G mutation (authors' unpublished data) (8). Also several frameshift mutations are found, 
interestingly always with variable phenotype, thus causing EEC, LMS, AEC or RHS syndrome. The 
possible explanation may be a misdiagnosis in sporadic cases, because of the phenotypic vari­
ability, likely, however frameshift mutations are exceptionally sensitive to the effects of modifier 
genes. An example of family-dependent clinical phenotype is the arginine p.280 mutation, which 
can be mutated to cysteine or histidine and lead either to the non-syndromic SHFM4 (2 families) 
or more often to syndromic ectodermal dysplasia with SHFM and orofacial clefting (EEC) (9 fami­
lies) (5,6,29,51). Surprisingly, the penetrance is reduced in SHFM families, but not in EEC families, 
which also indicates a modifier effect somewhere else in the genome.
The phenotypic variation between the p63-linked diseases is large, furthermore the phenotypic 
variation within one disease is also considerable. It is clear that variability within families may be 
ascribed to a combination of modifier genes, and stochastic processes. No such modifier genes 
have yet been identified for the p63 syndromes described in this review. However, modifiers 
have been identified for the phenotypic effects of p53 gene mutations in human cancer, and at 
least one of these has also been shown to affect p63 protein levels and transcription (52,53). 
Other candidate modifier genes may be found in pathways that are known to affect specific phe­
notypes. For instance, genetic variation in the IRF6 gene could be tested as a risk factor for cleft 
lip in p63 mutant families (48-50).
Furthermore, variation between families likely reflects differential downstream effects for each 
of these mutations. There are many possible ways in which this can be achieved, as the p63 
protein is expressed in several isoforms, which are involved in different cellular functions during 
the embryonal development but also later on. The variation in the phenotypes caused by each 
of the five EEC hotspot mutations is also striking. The EEC hotspot mutation data, where clear 
phenotypic variation is seen between the mutations inside a single clinical syndrome, might 
reflect that different target genes are affected by each of the hotspot mutations. W hether this is 
so, needs to be examined in more detail in animal models or cellular systems. Clearly, these EEC 
mutations cannot just be simple loss-of-function or dominant negative mutations, but gain-of 
function mutations are likely involved, as was described for p53 mutations in transgenic mice 
(54-56).
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Finally, the finding that some mutations such as p.R280C/H have different phenotypes between 
families, but the same phenotype consistently within families suggest the influence of cis-acting 
polymorphisms, either in p63 itself or within a genetically linked gene on chromosome 3q. Such 
functional polymorphisms have not yet been described, but here too, there are precedents 
for the existence of such polymorphisms in both p53 and p73 (57,58). Each of these possible 
mechanisms for phenotypic modulation will require functional hypotheses that can be verified 
in experimental systems, and ultimately be tested for their impact on the many families that are 
affected by these clinically often severe malformations.
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Abstract
Heterozygous mutations in the transcription factor gene p63 cause at least six different syndromes 
with various combinations of ectodermal dysplasia, orofacial clefting and limb malformations. 
Here we will present an update of mutations in the p63 gene together with a comprehensive 
overview of the associated clinical features in 227 patients. These data confirm the previously 
recognized genotype-phenotype associations. Moreover, we report that there is a large degree 
of clinical variability in each of the p63-associated disorders. This is illustrated by the differ­
ent phenotypes that are seen for the five hotspot mutations that explain almost 90% of all EEC 
syndrome patients.
Ectodermal dysplasias (EDs) constitute a large and complex group of developmental syndromes, 
comprising more than 170 different clinical conditions. The combined incidence of ED is approxi­
mately seven in 10,000 births. Causative genes for EDs have been identified in approximately one 
fifth of EDs. One group of EDs is associated with orofacial clefting and split-hand/foot malfor­
mation (SHFM). Ectrodactyly, ectodermal dysplasia and cleft lip/palate syndrome (EEC, OMIM 
604292) is the prototype of these syndromes, which is caused by heterozygous mutations in the 
p63 gene. A number of EEC-like syndromes has been described, five of which are also caused by 
mutations in the transcription factor gene p63: Ankyloblepharon-ectodermal defects-cleft lip/ 
palate (AEC, OMIM 106260), Limb mammary syndrome (LMS, OMIM 603543), Acro-dermato- 
ungual-lacrimal-tooth syndrome (ADULT, 103285), Rapp-Hodgkin syndrome (RHS, OMIM 129400) 
and non-syndromic Split hand/foot malformation (SHFM4, OMIM 605289).
Figure 1. Ectodermal dysplasia (ED) combined with orofacial clefting and limb malformations are the three 
hallmarks of p63 syndrome family. EEC, the prototype of these syndromes combines all three main symptoms, 
whereas the others lack mainly one of the hallmarks. LMS falls into a borderline expressing less ectodermal 
signs than EEC. Ectodermal dysplasia and orofacial clefting are main symptoms in AEC and RHS, whereas limb 
malformations replace the orofacial clefting symptoms in ADULT syndrome.
ntroductior
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These syndromes share at least one of the three main phenotypic hallmarks with EEC syndrome 
(Fig. 1). Previously, syndrome-specific mutation patterns have been identified upon analysis of 
p63 mutations in 78 families, comprising five different syndromes (RHS was not elucidated). Here 
we will provide an update of p63 mutation patterns by providing detailed clinical overviews of 
126 unrelated families in which a causative p63 mutation has been identified. The combined data 
confirm the genotype-phenotype associations that have been previously uncovered. In addition, 
it is becoming clear that phenotypes differ for the five hotspot mutations that account for the 
large majority of patients with EEC syndrome.
E EC  - Prototype of p63 syndromes
EEC syndrome comprises limb malformations, ED and orofacial clefting. Representative limb malfor­
mations are ectrodactyly and syndactyly. ED is seen as light colored, sparse hair and absence of 
eyelashes, eyebrows and alopecia can be observed. Skin is thin and dry, sometimes resembling 
dermatitis. Nails are usually dystrophic and have pits. Also dental changes are reported such as 
hypodontia or anodontia and teeth can be prone to caries, because of enamel defect and salivary 
gland malfunction. Orofacial clefting is frequent, and facial maxillary and mild malar hypoplasia 
can be present. Hearing loss is uncommon. Choanal atresia is rare. Lacrimal duct stenosis con­
tributes to keratitis, which is common in EEC patients, sometimes associated with photophobia. 
Genito-urinary malformations are also part of the EEC: sometimes external and internal genitalia 
are abnormal, but more often malformation has affected kidney, ureters or bladder. Mental 
retardation is rare in EEC, and probably as common as in the general population. These are the 
main symptoms that can be generally observed in EEC syndrome. However, there is a large de­
gree of clinical variability, as we will demonstrate below.
EEC syndrome has been localized to three different chromosomes, although only one causative gene 
has been found (1). EEC1 has been mapped to chromosome location 7q21 both by the identifica­
tion of chromosomal abnormalities, translocations and deletions in syndromic SHFM patients 
and by linkage analysis in a single large EEC1 family (2,3). However the chromosome 7 phenotype 
differs from classical EEC in that the patients have fewer ectodermal defects and present sen­
sorineural deafness and ear malformations. EEC2 denotes linkage to chromosome 19 in one large 
EEC family (4,5). EEC3 on 3q27, is characterized by mutations of the p63 gene (1). Interestingly, 
a common p63 mutation, typical for EEC syndrome (p.R227Q) was also found in the EEC2 family, 
indicating that the linkage to chromosome 19 was a spurious finding. Indeed, p63 mutations 
have been demonstrated in 98% of patients with a classical EEC phenotype [(6) and our own 
unpublished data]. Mutations in p63-derived EEC syndrome (EEC3) have been reported previ­
ously in 152 cases. These comprise 26 families and 60 sporadic cases (6-18). All mutations are 
point mutations clustered in the DNA binding domain, except for one frameshift mutation, which 
is located in the Sterile alpha motif (SAM) domain (1). The most frequently mutated amino acids 
residues are p.R204, p.R227, p.R279, p.R280 and p.R304, which cover 86.8% of all EEC syndrome 
cases. These mutation hotspots are the same as previously reported (19) and mimics p53 muta­
tion hotspots entirely, except for the p.R227 residue. All of the hotspot missense mutations are C 
to T transitions at CpG islands.
A compilation of the manifestations of the 152 p63-associated EEC patients provides a more 
complete picture of the main characteristics observed in patients, the mutation patterns and 
mutation-specific phenotypes (Table 1). Ectodermal tissues, such as hair, teeth, nails and lacrimal
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ducts are affected in about one half of the EEC patients, whereas abnormal skin was reported 
only in one third of the patients. Clefting of lip and palate is present in approximately 40% of the 
patients. Isolated cleft lip or cleft palate was observed only in rare instances (two and four cases, 
respectively). Limb malformations are a main component of the syndrome with ectrodactyly in 
two thirds of EEC cases and syndactyly less frequent in about 40% of patients. Minor character­
istics in EEC are mammary gland and/or nipple hypoplasia, which are present in approximately 
15% of the cases. Urinary and kidney problems may cause serious morbidity, and these were 
reported in 15% (Table 1).
E EC  hotspot mutations demonstrate 
mutation-specific phenotype patterns
Each of the five EEC hotspot mutations was found in 24-31 patients. Remarkable phenotypic dif­
ferences can be observed for these different mutations. Amino acid p.R204 is located in the 
beginning of the DNA binding domain and was mutated from arginine to tryptophan, glutamine 
or leucine. All patients were clinically diagnosed as EEC except for one patient with p.R204Q who 
was considered to have the Limb mammary syndrome, apparently because of mammary gland 
hypoplasia (Table 1). The p.R204 mutation phenotype is very similar to the overall EEC syndrome 
phenotype. Exceptions are a lower frequency of hypohidrosis and orofacial clefting (Fig. 2B).
Amino acid p.R227 is known to be mutated from arginine to glutamine, and was observed in 25 EEC 
patients and one with LMS. Mutations of this amino acid are rarely associated with orofacial 
clefting. Only two patients had clefts and these involved only the palate. This is striking since ap­
proximately 40% of all EEC patients present clefting, almost always both cleft lip and cleft palate. 
Patients with p.R227 mutations also have fewer limb defects. Ectrodactyly was present in 40% 
(11/28) versus 68% for the EEC group as a whole. Syndactyly was never reported. On the other 
hand, kidney and urinary problems are quite common in p.R227 mutation carriers occurring in 
11/28 patients (40% vs. 12% for EEC patients with other mutations). Hypohidrosis is also common, 
whereas no hearing impairment is detected (Fig. 2C). These characteristics indicate that this amino 
acid p.R227 differs importantly from the other hotspot mutations in terms of function. Interesting­
ly, arginine p.227 is the only p63 mutation hotspot that does not have a homologous p53 mutation 
hotspot as well (1).
At the end of the DNA binding domain there are three EEC mutation hotspots in close proximity: 
p.R279, p.R280 and p.R304. Each of these has its own typical phenotype pattern. p.R279 can mu­
tate from arginine to histidine, cysteine or glutamine. All 24 mutations occurred in EEC syndrome 
patients, except for one patient who was diagnosed as Rapp-Hodgkin syndrome (20). Interestingly 
this is the only EEC mutation, which can give rise to ankyloblepharon, as reported in two cases, 
indicating limited overlap with AEC syndrome (15). Other specific characteristics for the p.R279 
mutation are a high incidence of ectrodactyly (18/23) and perhaps hypohidrosis (4/23) (Fig. 2D).
The next amino acid p.R280 is known to be mutated from arginine to cysteine, histidine or serine. 
Symptoms mimic the common EEC pattern, with frequent skin signs and frequent syndactyly 
(17/27). Interestingly, no sweating, hearing or kidney problems were reported in patients with a 
p.R280 mutation (Fig. 2E). The last EEC hotspot mutation is at amino acid p.R304, which can be mu­
tated to tryptophan, glutamine or proline. The most striking finding in patients with this mutation is 
a very high percentage of orofacial clefting (22/27 patients), frequent occurrence of syndactyly and 
of hearing impairment (Fig. 2F).
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Table 1. Phenotypic characteristics of five human ectodermal dysplasias associated with p63 mutations.
Families Patients Hair
Lacrimal
duct
Nail Skin Teeth Cleft Lip
Cleft
Palate
Ectrodactyly Syndactyly
Hypo- 
hyd rosis
iviammary
gland/nipple
hypoplasia
Ankylo­
blepharon
Urinary/
Kidney
Hearing
impairment
Reference
EEC
P.L162P 1 2 2 0 1 0 2 1 1 2 2 0 0 0 0 0 #
P.Y163C 1 1 1 1 1 1 1 0 1 0 1 1 1 0 0 0 (19)
P.V202M 2 2 1 1 1 1 1 1 1 2 0 0 0 0 0 0 (16,19)
P.R204L/Q/W 16 26* 16 13 15 9 11 7 7 17 11 1 3 0 4 2 (1,6,13,15,19)
P.H208Y 1 1 1 1 1 1 1 0 0 0 1 0 0 0 0 0 #
P.R227Q 6 25 17 19 14 6 18 0 1 11 0 8 7 0 8 0 (19)
P.C269Y 1 2 2 1 1 0 0 2 2 2 2 0 0 0 0 0 (6)
P.S272N 1 1 1 1 0 0 1 1 1 1 1 0 1 0 0 1 (1)
P.C273Y 1 1 1 0 0 0 0 1 1 1 1 0 0 0 0 0 (19)
P.R279C/H/Q 16 23** 11 13 9 6 11 11 11 18 7 4 4 2 2 1 (1,8,11,13-15,19)
P.R280C/H/S 9 31 20 8 10 12 13 8 8 23 17 0 2 0 0 0 (6,9,17,19)
P.R304P/Q/W 21 27 16 20 16 7 12 22 22 20 16 1 1 0 7 5 (1,6,7,10,13,14)
P.C306R/Y 2 2 2 1 2 2 1 2 1 2 2 1 1 0 1 0 (1,18)
P.C308S/Y 2 2 2 2 2 2 1 0 0 0 2 0 1 0 1 0 (6)
P.P309S 1 1 1 1 1 1 1 0 0 1 0 0 0 0 0 0 (6)
P.D312G/H/N 3 3 3 3 2 3 3 3 3 3 2 1 0 0 0 1 (6,12)
c.l572insA 1 1 0 1 0 0 1 1 1 1 0 0 1 0 0 1 (1)
P.L563P 1 1 1 0 1 0 1 0 0 0 1 0 0 0 0 0 #
Total 86 152 98 86 77 51 79 60 61 104 66 17 22 2 23 11
Percentage 66 57 52 34 53 39 40 68 43 11 14 1 15 7
* ED of two patients not described in details, not taking to account in %. ** ED of one patient not described in detailes, not taking to account in %. # Authors unpublished data
ADULT
P.N6H 1 1 0 0 1 0 1 0 0 0 1 0 1 0 0 0 (27)
P.R298G/Q 4 14 8 10 14 14 14 0 0 9 8 1 11 0 0 0 (22-26)
Total 5 15 8 10 15 14 15 0 0 9 9 1 12 0 0 0
Percentage 53 67 100 93 100 0 0 60 60 7 80 0 0 0
Mammary gland hypoplasia is common ir 
both LMS and ADULT syndrome
LMS was the first p63 syndrome linked to chromosome region 3q27 (6,19,21). The LMS phenotype 
comprises malformations of the hands and/or feet and hypoplastic nipples and/or mammary 
glands. Ectodermal defects are much less prominent than in EEC syndrome and there are no 
hair and skin anomalies. Patients from six families have been described with this syndrome, four 
of these are sporadic cases making it difficult to establish whether they are real LMS patients 
or examples of variable expressivity of other p63 syndromes. Indeed, two cases diagnosed as 
LMS, have mutations that are typical of EEC syndrome: p.R204Q and p.R227Q. Nonetheless, 
the only large LMS family reported to date is clearly different from EEC (21), and this family and 
two further LMS patients have mutations that have never been observed in EEC. In contrast to 
EEC syndrome, LMS patients rarely have any hair and skin involvement and if clefting is present, 
it is always limited to the palate. Mammary gland and/or nipple hypoplasia or aplasia is more 
frequent in LMS than in EEC (100% and 29% of LMS cases; Table 1). Hypohidrosis is relatively 
frequent (29%).
ADULT syndrome is clinically very sim ilar to LMS, because mammary hypoplasia plays a main role 
in both syndromes. Nevertheless, there are clear differences. First of all, orofacial clefting 
has not been observed in ADULT patients, whereas nail, skin and teeth are affected in almost 
every case. Hypohidrosis is present in about 30% of LMS patients and was reported in ADULT 
syndrome in only 7% (1/14). (Table 1).
ADULT syndrome is usually caused by "an ADULT syndrome hotspot" point mutation affecting amino 
acid p.R298 in exon 8 at the end of the DNA binding domain. There are five unrelated families with 
p.R298Q/G mutation each expressing more or less similar ADULT syndrome characteristics (22-26). 
The first ADULT syndrome family was described to have intensive freckling (22,23). Other ADULT 
syndrome families did not show increased freckling and therefore freckling does not seem to be 
a component of this syndrome. A further ADULT mutation p.N6H was reported in the alternative 
N-terminus (27). LMS and ADULT syndromes overlap, and differentiating them can be difficult, 
especially in sporadic cases (26).
A E C  and Rapp-Hodgkin syndrome
Two other syndromes belong to the p63 syndrome family. Hay-Wells syndrome, also known as
Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome (AEC), which was first reported by 
Hay and Wells (28). Its main symptoms are ankyloblepharon (fusion of the eyelids), ectodermal 
defects and cleft lip and palate. About 75% of patients have severe skin erosions at birth, with some 
AEC patients reported to have up to 70% denuded skin which resembles a second-degree burn 
(29). Normal neonatal skin is slowly recovered. By 4-5 years age erosions have usually disappeared 
except for the head and auricular region. Alopecia is also often linked to Hay-Wells syndrome as 
are absence of eyelashes and eyebrows. Clefting occurs approximately in 80% of AEC patients, 
mostly cleft palate or cleft lip and palate. It should be noted that the denominative ankyloblepha­
ron occurs only in 44% of AEC cases. Hearing loss has been reported in about 40% of the patients. 
AEC patients have nail and teeth defects in about 75-80% of cases. About half of the patients have 
lacrimal duct atresia. Sweating abnormalities and mammary gland and/or nipple hypoplasias are 
rarely observed.
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Table 1. (continues)
Families Patients Hair
Lacrimal
duct
Nail Skin Teeth Cleft Lip
Cleft
Palate
Ectrodactyly Syndactyly
Hypo- 
hyd rosis
Mammary
gland/nipple
hypoplasia
Ankylo­
blepharon
Urinary/
Kidney
Hearing
Reference
impairment
LMS
P.G76W 1 27 Oof 21 7 of 15 7 of 21 Oof 21 3 of 21 - 6 of 22 21 of 27 - 7 of 21 27 of 27 - - (19,21)
P.R204Q* 1 1 0 1 1 0 1 0 0 0 1 0 1 0 0 0 #
P.R227Q* 1 3 3 3 3 3 2 0 0 0 0 0 3 0 3 1 #
c.l576delTT 1 1 0 0 0 0 1 0 1 1 0 0 1 0 0 0 (19)
P.K632X 1 1 0 1 1 0 1 1 1 1 1 1 1 0 0 0 #
c.l743delAA 1 1 1 1 1 1 0 0 1 1 1 0 1 0 0 0 (6)
Total 6 34 4 13 13 4 8 1 9 24 3 8 34 0 3 14
Percentage 14 59 46 14 29 3 31 71 9 29 100 0 10 0
RHS
P.R279H* 1 1 1 1 1 1 1 0 0 0 1 1 0 0 1 0 (20)
P.I510T 
(+ P.P472T)
1 1 1 1 1 1 0 0 1 0 1 0 0 0 0 0 (32)
P.S541P/Y 2 2 2 2 2 1 2 2 2 0 1 0 1 0 0 1 (31,39)
p.l709delA 1 1 1 0 1 0 1 0 1 0 0 1 0 0 1 0 (20)
p.l721delC 1 1 1 0 1 0 1 0 0 0 0 1 0 0 0 0 #
p.l787delG 1 1 1 1 0 1 1 0 1 0 0 0 0 0 0 1 (38)
p,1859delA 1 3 3 3 0 0 3 1 2 0 0 0 0 1 0 0 (14)
Total 8 10 10 8 6 4 9 3 7 0 3 3 1 1 2 2
Percentage 100 80 60 40 90 30 70 0 30 30 10 10 20 20
3' ss il0/e 11 1 3 3 1 3 3 3 0 1 0 0 0 0 0 3 0 (9)
P.I510T 1 1 1 1 1 1 1 0 0 0 1 0 0 1 0 0 (32,37)
P.L514F/V 2 2 2 2 2 2 1 1 2 0 0 0 0 2 1 2 (33)
P.C522G/W 2 2 1 0 0 2 1 2 2 0 1 0 1 0 1 1 (33)
P.G530V 1 1 1 0 0 1 1 1 1 0 1 0 0 0 0 1 (33)
P.T533P 1 2 2 2 2 0 2 0 2 0 1 0 1 2 0 0 (33)
p.534insPhe 1 1 1 0 1 1 0 1 1 0 0 0 0 0 0 0 (29)
P.Q536L 1 1 1 0 1 0 1 0 1 0 0 0 0 0 0 0 (33)
P.I537T 2 2 2 1 2 2 2 1 2 0 0 1 0 2 1 1 (19,33)
c.l742delC 1 1 1 1 1 1 1 1 1 0 0 1 0 0 0 1 (19)
Total 13 16 15 8 13 13 13 7 13 0 4 2 2 7 6 6
Percentage 94 50 81 81 81 44 81 0 25 13 13 44 38 38
*Typical EEC syndrome mutation, # Authors unpublished data.
A. Com m on EEC phenotype (n=152)
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Figure 2. EEC hotspot mutations allow  the specific phenotype delineation. Striking differences are especially 
between orofacial clefting and limb malformations,
One striking difference to the other p63 syndromes is the absence of limb malformations, which is 
almost complete, a few patients having only mild syndactyly. The clinical picture of AEC syndrome 
patients is thus unmistakably different from other p63-derived syndromes, with the exception of 
RHS (see below).
Rapp-Hodgkin Syndrome (RHS) was only recently shown to be a member of the p63 syndrome 
family. It was first described in 1968 by Rapp and Hodgkin (30). Kantaputra et al (31) linked this 
syndrome to defects in the p63 gene. The ectodermal dysplasia in Rapp-Hodgkin syndrome 
manifests as sparse, fine hair with progressive alopecia, nail defects, hypodontia, lacrimal duct 
atresia and dry skin with a decreased number of sweat pores causing hypohidrosis.
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Figure 2. EEC hotspot m utations allow  the specific phenotype delineation. Striking differences are especially 
between orofacial clefting and limb malformations.
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Milder skin symptoms in RHS are probably the main clinical distinction between Hay-Wells and 
Rapp-Hodgkin syndrome. Presence of ankyloblepharon supports a diagnosis of AEC. However, since 
more than half of all AEC patients have no ankyloblepharon, a lack of this anomaly should not be 
considered as distinguishing for RHS (14,32). Syndactyly has been reported in 30% of the RHS cases, 
whereas among AEC patients it has been described only once (1/16 or 6%) (33). In both syndromes 
clefting in lip and/or palate is equally frequent. Genito-urinary defects are more common in RHS and 
AEC than in EEC syndrome, affecting every fourth patient. Also hearing impairment is more common 
in RHS and AEC than it is in EEC syndrome, 20, 38 and 7% of patients being affected, respectively.
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Figure 2. EEC hotspot mutations allow  the specific phenotype delineation. Striking differences are especially 
between orofacial clefting and limb malformations.
SHFM
Like EEC syndrome, non-syndromic Split hand/foot malformation (SHFM) has been linked to several 
chromosomal loci in the human genome. In our experience, about 10% of SHFM patients have 
a p63 mutation, referred to as SHFM4 (34). To date eight SHFM mutations have been described, 
which are dispersed along the p63 gene. Various types of mutations are seen: splice-site muta­
tion (3'ss intron 4), missense mutations (p.R58C, p.K193E, p.K194E, p.R280C/H) and stop-muta­
tions (p.Q634X, p.Q639X) (6,34,35).
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Genotype-phenotype associations
Table 1 summarizes the clinical data on 227 patients with a causative p63 mutation, allowing the 
delineation of the typical phenotypic appearance of each syndrome. Moreover, especially in EEC 
and AEC syndromes mutations cluster in specific protein domains, providing molecular support 
for their phenotypic distinction. EEC mutations are missense and are dispersed along the DNA 
binding domain with just five hotspots involving some >80% of patients. There are two muta­
tions outside the DNA binding domain, a point mutation (p.L563P) at the end of Sterile alfa motif 
(SAM) domain and a frameshift mutation (c.1572insA) at the beginning of the SAM domain. It 
has been predicted, that EEC mutations disturb the binding of the p63 protein to DNA, which 
leads to a loss of transactivation (1). In contrast, missense mutations in the SAM domain are 
mainly found in AEC (12/16), although a splice-site mutation at the intron 10/exon 11 boundary 
and two frameshift mutations were also detected. A SAM domain is mainly found in develop­
mental genes and is thought to participate in protein-protein interactions (36). Very likely AEC 
mutations in the SAM domain inhibit these specific protein-protein interactions.
Clinical variability: One mutation can leac 
to two syndromes
Mutations in AEC and RHS are dispersed along SAM and Transactivation inhibitory (TI) domains, and 
the same amino acid mutations have been reported in both syndromes. For instance amino acid 
residue p.I510 located at the beginning of the SAM domain was found to be mutated in two 
sporadic cases (32). The AEC patient had mild ankyloblepharon, severe erythrematous plaque on 
the scalp, which improved by age of four months, sparse hair which later became wiry, coarse 
and curly, sparse eyebrows and eyelashes, hypodontia and decreased enamel, bilateral choanal 
atresia and absence of lacrimal puncta. He had mild cutaneous syndactyly and dysplastic nails, 
mild microretrognathia and asymmetric ears, intact palate and no history of heat intolerance 
(37). The other patient presented with persistent erythematous lesions on the scalp, back and 
genitalia, cleft palate, lacrimal duct atresia, syndactyly, nail dysplasia and hair defects and ante­
rior displaced anus. Although their phenotypes are quite similar, they were diagnosed as having 
AEC and RHS, respectively. This distinction appears to have been based on the presence of anky­
loblepharon in the first patient. Both patients were carrying the same mutation p.I510T, although 
the RHS patient also carries a p63 polymorphism p.P472T that was also in his healthy mother. It 
is presently unknown whether this rare p.P472T polymorphism has any effect on the phenotype.
A second mutated amino acid residue p.S541, has also been reported to cause either AEC or RHS.
The p.S541P/Y mutation was seen in an RHS family and p.S541F in an AEC syndrome patient 
(31,32,38,39). A third example is c.1859delA occurred in a family where one individual had 
ankyloblepharon, cleft palate and ectodermal dysplasia, and two other affected members only 
ectodermal dysplasia with or without clefting (14). Overall the data suggest that AEC and RHS are 
one single syndrome with clinical variability.
However, there is a good example of one p63 mutation causing two distinct syndromes. p.R280 
mutations to cysteine and histidine were described in EEC syndrome and in a large SHFM family 
(6,9,17,34). So far, when arginine mutates to serine, it causes only EEC (6). The phenotype is fully 
consistent within families carrying each of these p.R280 mutations. Either there is full-blown 
EEC syndrome or isolated SHFM. In the latter families, non-penetrance is observed (34), which
7C
is never seen in EEC syndrome patients. This strikingly consistent phenotype within families 
suggests the involvement of a modifier allele close to the p63 gene on chromosome 3. Perhaps a 
polymorphism within the p63 gene itself is responsible for this effect.
Conclusions
In this study we present the results of mutation analysis in 227 patients with a p63-associated ED 
syndrome and their common phenotypic characteristics. An additional eight families are known 
with a causative p63 mutation presenting with isolated SHFM. Our study documents 30 different 
mutations that can cause EEC syndrome, of which 5 are responsible for 86% of the patients. Most 
of the mutations that were found in the other syndromes differ from the EEC mutations and are 
specific for each of the respective disorders. In addition, we show that there is a specific pheno­
type for each of the five p63 hotspot mutations. For example, there is a complete lack of cleft 
lip/palate in patients with a p.R227 mutation, who instead have a high incidence of urogenital 
problems. Another example is the mutation p.R304, which gives rise to orofacial clefts in 80% of 
the cases, whereas this occurs in only 40% for EEC syndrome as a whole. This clinical variability 
may cause difficulties in arriving at the correct clinical diagnosis, especially in single patients. Yet, 
there are also clear examples where one mutation can cause two different disorders, which is 
most obvious in p.R280 mutations, which are seen in EEC syndrome and in non-syndromic SHFM. 
This study did not identify any clear differences between the AEC and RHS syndromes. Pheno­
types of these syndromes resemble each other very much, the main difference being the more 
frequent, but certainly not consistent occurrence of ankyloblepharon in AEC syndrome. Because 
these syndromes can be due to same mutations (32), we propose to group them into a single 
entity.
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Abstract
The ADULT syndrome (Acro-dermato-ungual-lacrimal-tooth, OMIM 103285) is a rare ectodermal dys­
plasia associated with limb malformations and caused by heterozygous mutations in p63. ADULT 
syndrome has clinical overlap with other p63 mutation syndromes, such as EEC (OMIM 604292), 
LMS (OMIM 603543), AEC (106260), RHS (129400) and SHFM4 (605289). ADULT syndrome 
characteristics are ectrodactyly, ectodermal dysplasia, mammary gland hypoplasia and normal 
lip and palate. The latter findings allow differentiation from EEC syndrome. LMS differs by milder 
ectodermal involvement. Here we report three new unrelated ADULT syndrome families, all with 
mutations of arginine p.298. On basis of 16 patients in five families with p.R298 mutation, we 
delineate the ADULT syndrome phenotype. In addition, we have documented a gain-of-function 
effect on the ANp63a isoform caused by this mutation. We discuss the possible relevance of oral 
squamous cell carcinoma in one patient, who carries this p63 germline mutation.
Introduction
Various combinations of limb anomalies, ectodermal dysplasias and orofacial clefts character­
ize heterozygous mutations in the transcription factor gene p63. The prototype p63 mutation 
syndrome is EEC Syndrome, which is characterized by Ectrodactyly, ectodermal dysplasia, and 
cleft lip/palate (OMIM 604292). Ectrodactyly, a severe median cleft in hands and feet is often 
associated with syndactyly in these patients, but syndactyly can also be the sole limb defect. 
Ectodermal dysplasia can be found in various combinations of sparse hair, dry skin, hypodontia, 
dysplastic nails and alterations in sebaceous glands, mammary glands and nipples. Orofacial 
clefting is the third hallmark of the EEC syndrome and usually manifests as cleft lip with cleft 
palate. Symptoms in the other five inherited syndromes with p63 mutations are overlapping, but 
each of these syndromes has its own characteristic combination of phenotypic features. For in­
stance, ankyloblepharon is almost limited to the Hay-Wells syndrome (Ankyloblepharon-ectoder­
mal defects-cleft lip/palate, OMIM 106260). Mammary gland hypoplasia and nipple hypoplasia 
are frequent findings in Limb mammary syndrome (LMS, OMIM 603543) and in Acro-dermato- 
ungual-lacrimal-tooth syndrome (ADULT, OMIM 103285) but are rare in other p63-related condi­
tions (1). ADULT syndrome is further distinguished from other p63 syndromes by absence of 
orofacial clefting and by prominent ectodermal signs. Abnormal hair or skin abnormalities have 
not been reported among LMS patients. Facial clefting in LMS is of another type than that in EEC 
syndrome: cleft palate only, whereas no facial clefts have been found among reported ADULT 
families (2-6). In one family, extensive freckling has been reported to be a typical characteristic 
of ADULT syndrome, and this was also mildly present in two further ADULT syndrome patients 
(2,4,7).
The causative gene in all these disorders, p63, is crucial during embryonic development, mostly in 
the development of limbs and other ectodermal derived tissues. The pattern of mutations in six 
different p63 related syndromes shows genotype-phenotype correlations. The most pronounced 
genotype-phenotype correlation is in the EEC and Hay Wells syndromes. All EEC missense muta­
tions are clustered in the DNA binding domain and disrupt binding to DNA (8). In contrast, all mis­
sense mutations reported for Hay-Wells patients are in the Sterile alpha motif domain, and have 
been shown to disrupt interaction with other proteins (9). LMS and ADULT syndrome have their 
own unique mutated amino acid residues. In the original Limb mammary syndrome family a point 
mutation was found in the coding region of the second transactivation domain (p.G76W) (3).
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Only two amino acid residues are known to be mutated among ADULT syndrome patients: 
asparagine p.6, which is in the putative second transactivation domain and arginine p.298, which 
locates in the DNA binding domain (4,5,7). Although p.R298 is in the DNA binding domain, it is 
functionally different from the EEC mutations, because its substitution by glutamine does not lead 
to a loss of DNA binding, but instead to a gain of transactivation activity of the ANp63y isoform 
(6). Here we report three further ADULT syndrome families with p.R298 mutations, either a 
p.R298Q or p.R298G. We discuss the consistent phenotypic features associated with these gain- 
of-function mutations.
Materials and methods
Patients and families
In a small Finnish family three family members, one in each generation, present with an EEC-like 
disorder. Their limb malformations vary from severe four-limb ectrodactyly and syndactyly in the 
oldest person (Fig. 1A-B) to unilateral syndactyly in the child of the third generation.
Figure 1. Limb and ectodermal phenotype in ADULT syndrome patients w ith p.R298 mutation. Limb malfor­
mations in p.R298 patients can vary much. A-B. Deep median cleft and syndactyly in the limbs of the Finnish 
ADULT syndrome patient (I/1) with p.R298G mutation. C-D. Mildly affected limbs in the Italian patient (II/1) 
with p.R298Q mutation. E-F. Severely affected hands and non-affected feet of Danish ADULT patient (II/1) with 
p.R289Q mutation. G. Excessive freckling in Danish patient (I/1). H. Hypodontia and loss of permanent teeth in 
Danish patient (I/1). I. Hypoplastic nipples in Danish patient (II/1). For a color figure see Appendix 2.
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All patients have a similar pattern of malformations in ectodermal derived tissues as described in 
the original German ADULT syndrome family (2,4). Atrophic, dry skin is present, but freckling was 
not seen. Breast hypoplasia is found in adult female patients. The nine-year-old patient has only 
widely spaced nipples and congenital lacrimal duct obstruction. All affected individuals have very 
blond, thin and sparse hair. Nails are reported to be dysplastic, and one or several teeth were 
lacking. A malignant tumour in the mouth of one of the patients was diagnosed at age 60. Histo­
logical examination confirmed a squamous cell carcinoma (SCC). Otherwise the medical history is 
unremarkable for all patients.
In a small Italian family, mother and son have symptoms similar to those described above for the 
Finnish family, and previously reported for a German family (2,4). The son has absence of the 
middle finger in his right hand and cutaneous syndactyly in both feet together with right foot 
polydactyly (Fig. 1C-D). His mother has normal limbs. Both affected individuals have lightly 
pigmented, dry and very photosensitive skin. Dermatitis has occurred in both individuals. Both 
mother and son have dysplastic nails with pits. The mother has oligodontia (dysplastic and hyp­
oplastic teeth), whereas the son has only small teeth. The mother also has breast hypoplasia and 
absence of the right nipple, and the son has hypoplastic nipples. The son has tear duct obstruc­
tion and his mother absence of tears and chronic conjunctivitis, probably due to obstructed 
tear ducts. The mother was recently diagnosed with autoimmune thyroiditis and paroxysmal 
supraventricular tachycardia. The maternal grandfather of the son died at the age of 36 from a 
clear-cell renal carcinoma. He had lightly pigmented hair and skin, and he was highly photosensi­
tive, like his family members. Otherwise no EEC-like symptoms are reported for the grandfather.
In a Danish family, father and daughter have symptoms similar to those described above for the 
Finnish and the Italian family. Ectrodactyly and syndactyly is present in the hands and one foot 
of the father and ectrodactyly is present in the hands of the daughter (Fig. 1E-F). Both father and 
daughter have nail dystrophy in all nails. Their skin is dry and thin, and excessive freckling of the 
entire body surface is present (Fig. 1G). Father and daughter both have hypodontia and dysplas­
tic teeth (Fig. 1H). The daughter has hypoplastic nipples (Fig. 1I). The hair is unaffected in this 
family. The father has blocked tear ducts, as has his daughter, who was operated on when she 
was a child. There is no orofacial clefting in these patients.
M utation Analysis
From the Finnish family blood samples were obtained from three patients and the proband's healthy 
sister after a written informed consent was obtained. Genomic DNA was extracted using a Nucle­
on Extraction & Purification Kit (Amersham Biosciences). The exons, which have been reported to 
contain most pathogenic mutations of , were amplified by PCR and the products were purified by 
GFXTM PCR DNA and Gel Band Purification Kit (Amersham Biosciences) and sequenced directly 
using an ABI PRISMTM 377 automated sequencer (Applied Biosystems). The observed sequence 
change was confirmed with a restriction fragment analysis using Haelll enzyme (New England 
BioLabs). Fifty-four control persons were tested for the presence of the pathogenic mutation. 
Mutation analysis for the Italian family was performed as described by Duijf et al (6).
From the Danish family blood samples were obtained from two affected and two nonaffected mem­
bers after a written informed consent was obtained. Genomic DNA was extracted from periph­
eral blood samples using a standard salting-out method.
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All exons and exon-intron boundary regions were sequenced on both strands. Primers were 
removed by treatment with 1U shrimp alkaline phosphatase (USB, Cleveland, OH, USA) and 
10U Exonuclease I (New England Biolabs) followed by sequencing using the BigDye Terminator 
Kit (Applied Biosystems, Foster City, CA, USA) and analysed on an ABI 377 sequencer (Applied 
Biosystem).
Functional analysis o f p .R298G mutation
We performed a transactivation assay to see whether the p.R298G mutation causes a gain-of- 
function effect for ANp63y isoform similar to the p.R298Q-mutation (6). Mutagenesis and 
transactivation assays were performed as described previously (6). Site-directed muta­
genesis for introduction of the p.R298G mutation was performed with oligonucleotide 5'- 
cgcaagtcctgggcggacggtgctttgag-3' and its reverse complement as described previously (8).
Immunohistochemical staining
A four-micrometer-thick section was cut from the formalin-fixed paraffin-embedded oral mucosa SCC 
sample. Immunohistochemical staining was performed using a TechMate500 immunostaining 
machine and a peroxidase/diaminobenzine (DAB) multilink detection kit (DAKO, Denmark). The 
section was stained with 4A4 monoclonal antibody (1:180) (a gift from Dr. F. McKeon, Harvard, 
USA) and counterstained with Mayer's haematoxylin.
Results
Mutation analysis
Mutation analysis of the p63 gene was carried out by direct sequencing of p63 exons in the probands 
of the Finnish, the Italian and the Danish family. In the Italian and the Danish family a heterozy­
gous transition from a guanine to an adenine was found at nucleotide position c.893. This muta­
tion is located at the beginning of exon 8 and causes a change from CGA to CAA at codon p.298. 
This mutation is identical to one that was originally identified in the German ADULT syndrome 
family and predicts an amino acid change from arginine to glutamine (p.R298Q) (6,10). Later 
this mutation was also reported by Chan et al (7). In the Finnish family a novel p63 mutation was 
found at the same codon p.298: a heterozygous point mutation changing a cytosine to a guanine 
at nucleotide position c.892, which creates a change from CGA to GGA at codon p.298 and a 
predicted amino acid change from arginine to glycine (p.R298G) in the DNA binding domain. 
Fifty-four control samples were tested for the mutation with a restriction fragment analysis with 
the restriction enzyme HaeIII, which cleaves the wildtype amplicon, but not the mutated DNA 
fragment. None of the control samples or healthy family members carried the p.R298G mutation. 
Both mutations fully segregated with the phenotype in the three families.
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Figure 2. Transactivation of the wild-type p63, p.R298Q and p.R298G mutant isoforms. Transactivation as­
says are performed in extracts from SaOs-2 cells, which were transfected with wild-type, p.R298Q or p.R298G 
mutant constructs. The relative transactivation activity is given with respect to the p53 expression vector. 
TAp63y wild-type is the only isoform, which is known to be able to transactivate p53 response elements.
Here, both p.R298Q and p.R298G mutations cause a gain of activation on ANp63y isoform, whereas the other 
mutated isoforms resemble the wild-type p63 behaviour. Transactivation activity data of TAp63y p.R298Q/G 
mutation constructs is not shown.
Transactivation studies
According to the structural model of the DNA binding domain of p63, the arginine at position p.298 
does not locate close to binding DNA (6). Indeed, transactivation studies have established that 
the p.R298Q mutation does not impair transactivation activity as do EEC causing mutations (6,8). 
Instead, the ANp63y isoform carrying the p.R298Q mutation has highly increased transactivation 
activity as compared to its wildtype counterpart. To investigate whether this effect is specific 
for this amino acid substitution we decided to test the effect of the newly identified p.R298G 
mutation in transactivation assays. Functional analysis of the p.R298G mutation also yielded an 
exceptionally high transactivation activity, very similar to the activity, which was observed for the 
p.R298Q ADULT syndrome mutation (Fig. 2). It thus appears that the functional consequences of 
these mutations are comparable.
Immunohistochemical studies
Immunohistochemical staining using the 4A4 monoclonal antibody showed strong p63 accumulation 
in the undifferentiated squamous cell carcinoma of the p.R298G-patient (Fig. 3).
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Table 1. ADULT syndrome characteristics caused by p.R298 mutations are compared to other alle lic syndrome failures3 and other reported ADULT syndrome features 
(p.N6H and p.R298Q) (2 ,4 ,5 ,7).
Italian Danish
Phenotypic features0 Finnish p.R298G p.R298Q p.R298Q German p.R298Q p.R298G p.N6H
EEC A EC RHS LMS ADULT 1/1 n / i
m /i 1/1 n / i 1/1 H/1 m/3 m /io IV/2 IV/6 IV/8 IV/10 y / i y/2
F F F F M M F M M F M F F M M M F
Limb
Hand malformation ++ + + ++ ++ + + + - + + + + + + - - - + - + +
Foot malformation ++ + + ++ ++ + + - - + + - - + + + -/+ - + - - +
Polydactyly -/+ - - - -/+ - - - - + - - - - - - - - - -
Skin
Dry and thin + ++ ++ -/+ +++ + + + + + + + +
Neurodermatitic signs ++ - - - + + - - + + + + + + + + +
Sweat glands + + + + -/+ + - - - - - - +
Freckling - - - - ++ - - - - - + + + + + + + + + - +/- +
Photosensitivity - - - - -/+ - - - + + - -
Hair
Thin and sparse ++ +++ +++ - ++ + + + - -/+ - - + +
Alopecia (frontal) - + - - - - - - - + + - - + + - -
Nail
Dysplasia ++ ++ ++ ++ +++ + + +b +bc +bc + + + + WG + + + + WG + +
Teeth
Hypodontia ++ ++ + + ++ + + + + + + - - + - + - - - + +
Loss of permanent teeth ++ + - - - + + + + + + + +
Oligodontia ++ + + + + +d + + +
Breast and nipple
Hypoplasia + + -/+ +++ ++ + + w s + + - + + + + + + + +
Eye
Lacrimal duct obstruction ++ ++ ++ ++ ++ + - + -/+ + + + (+) + - + + + - - + +
Eyelid fusion - ++ -/+ - - - - - - - - -
Bilateral ptosis - - - - -/+ + - - - - - -
Conjunctivitis + + + - - + + - -
Orofacial clefting
Cleft palate ++ ++ ++ + - - - - - - - - - - - - - - - - -
Cleft lip and palate ++ ++ + + - - - - - - - - - - - - - - - - -
Other
Aibinoid appearance -/+ - - - (+) + - -
Otitis (ear infection) + + - - - + + - -
Mild face dysmorphism + + + - + - - - -/+ + - - +
Microretrognathia + + + - -/+ - - - - + - -
Note: +++ consistent, ++ frequently observed, + occasionally observed, -/+ rarly observed, - never observed. Blank fields: no data available.
aBased on a compilation of 227 patients by Rinne et al (1). F=female, M=male, WS=widely spaced, WG=watch glass nails, b=pits, c=brittle, d=small teeth.
Figure 3. Undifferentiated oral squamous cell carcinoma (SCC) of the Finnish ADULT syndrome (p.R298G) pa­
tient. The SCC oral mucosa (on the left) shows strong p63 immunoreactivity, whereas the p63 expression in the 
healthy mucosa is strongest in the basal layer and gradually decreased in the suprabasal layers (on the right). 
(Magnification is 200x.) For a color figure see Appendix 2.
Clinical evaluation o f patients with a mutation at p.R298
Having established that the p.R298G mutation has similar functional effects as the p.R298Q muta­
tion, we next draw a comparison of the clinical manifestations in the Finnish family with the 
p.R298G mutation and the patients with the p.R298Q mutation. The clinical observations in pa­
tients from the three families in this study are summarized in Table 1. These features are scored 
against the typical phenotypic symptoms of each of the six syndromes that are associated with 
p63 mutations: EEC syndrome, AEC syndrome, Rapp-Hodgkin syndrome, LMS, ADULT syndrome, 
and SHFM. It appears that the phenotype of patients from the Finnish family is most similar to 
the ADULT syndrome phenotype. However, also some differences can be noted, such as the lack 
of neurodermatitic signs and the squamous cell carcinoma in one individual. The same is true for 
the Italian and the Danish families with the p.R298Q mutation. Patients from the Italian family 
have the typical hallmarks of ADULT syndrome, but differ because of the normal hair phenotype, 
conjunctivitis, photosensitivity and albinoid appearance. The Danish family differs from the origi­
nal ADULT family because of the lack of hypohidrosis, but presents the excessive freckling.
Discussion
We have identified a p63  mutation in three unrelated families affecting arginine p.298 in the DNA 
binding domain of p63. One mutation, p.R298G, was not detected before, but we have demon­
strated that it is functionally equivalent to the p.R298Q mutation in two families diagnosed as 
ADULT syndrome, and to the second and third family reported here (2,6,7). Comparison of all 16 
patients with a p.R298 mutation allows a better delineation of the ADULT syndrome phenotype.
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Hand and/or foot malformations are observed in all ADULT patients except one (15/16). Ecto­
dermal dysplasia is present in all individuals with p.R298 mutation and always affects the 
nails, teeth and skin. Nails are dysplastic, discoloured, brittle and/or have pits. Hypodontia, 
oligodontia and/or small teeth are a common combination, in addition to loss of permanent 
teeth in young adulthood. The skin is mostly dry and thin, sometimes with neurodermatitic 
signs. Also frequently observed are defects of the mammary glands, hair and lacrimal ducts. 
Mammary gland and/or nipple hypoplasia is present in 12 out of 16 patients, including males. 
Some ADULT patients show signs that may be family-specific traits. For example, photosensi­
tivity and hypopigmentation are only seen in the Italian family. Also, the extensive freckling, 
which stands as one of the typical hallmarks of ADULT syndrome, is observed in the original 
ADULT syndrome family, in the Danish family, and a very mild version (freckling on cheeks) is 
reported in a sporadic ADULT syndrome case (2,7). Even in the original ADULT syndrome fam­
ily the freckling is not a consistent feature. Therefore, it is possible that other genetic factors 
contribute to this part of the phenotype either as a major gene or as a modifier. Finally, oral 
SCC was seen in one of the patients, but its relation to the p63 p.R298Q mutation is obscure 
(see below).
In conclusion, ADULT syndrome is the most likely clinical diagnosis in a patient with ectrodactyly, 
mammary gland hypoplasia, neurodermatitic signs, prominent ectodermal dysplasia and normal 
lip and palate. This specific combination of clinical features is a-typical for EEC syndrome. How­
ever, the high degree of clinical variability in EEC syndrome may confuse a correct clinopathologi- 
cal diagnosis, especially for isolated patients. Presence of clefting or absence of mammary gland 
involvement is indicative of EEC syndrome. LMS is clinically very similar to ADULT syndrome, but 
differs by much milder ectodermal involvement. Absence of neurodermatitic signs such as freck­
ling or hypopigmentation does not preclude a diagnosis of ADULT syndrome.
Having defined the common features associated with mutations at p.R298, it is of interest to 
compare these with the single ADULT syndrome patient with another mutation, p.N6H (Table 
1) (5). The p.N6H patient has ADULT signs such as limb malformation, nipple hypoplasia and 
lacrimal duct obstruction, nail dysplasia and hypodontia. However, she does not have hair ab­
normalities, alopecia or skin involvement. This patient has freckling, but this was absent in two 
of the five families with p.R298 mutations. We believe that freckling may not be a discriminat­
ing factor in ADULT syndrome characteristics. Altogether p.N6H mutation causes a syndrome, 
which equally resembles ADULT syndrome and Limb mammary syndrome. Thus, this patient 
cannot be confidently classified as either ADULT or LMS. The location of the p.N6H mutation, in 
the beginning of ANp63, could indicate LMS syndrome, since the p.G76W mutation is only 15 
amino acids downstream in ANp63. (The numbering of these mutations is based on different 
p63 isoforms.)
We have shown the functional consequences of the p.R298 mutation in vitro. This mutation induces 
transactivation activity for an ANp63y isoform, which usually does not have this capacity. 
Although the mechanism of the gain-of-function effect is still unclear, this observation has led 
to the identification of a putative second transactivation domain uniquely present in the AN- 
isoforms (6). Here, we have shown that the gain-of-function effect is not specific to p.R298Q. The 
p.R298G substitution has the same functional effect. This result indicates that the mechanism of 
these mutations depends on the removal of arginine p.298, and consequently the disruption of 
p63 properties that are mediated through this amino acid, and not so much by novel properties 
that are brought about by the substituted amino acid.
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Since p63 is a family member of the well-known tumour suppressor gene p53, it was suspected to 
have a role in cancer development from its discovery. There are several reports of strong p63 
accumulation in basal cell carcinomas and squamous cell carcinomas (11-15). Also, the undiffer­
entiated squamous cell carcinoma (SCC) of the mouth of the ADULT patient (p.R298G) described 
in this article showed strong p63 accumulation (Fig. 3). A clear-cell-renal carcinoma was reported 
for the maternal grandfather of the Italian family, but we were unable to establish whether he 
was a carrier of the p.R298Q mutation. So far only one EEC patient with p63 mutation (p.D312G) 
has been described to have a cancer, a malignant B-Cell Lymphoma (16). These are the only 
reported descriptions of human p63 patients developing cancer, suggesting that individuals 
with a germline p63 mutation have little or no increased risk to develop cancer. A recent study 
with heterozygous p53, p63 and p73 knockout mice studies reported that the life span for each 
genotype was reduced and incidence of the tumours was increased (17). Loss of heterozygos­
ity of each of the p53 family members was observed in these tumours. Interestingly, squamous 
cell carcinoma was observed in ten percent of heterozygous p63 mutant mice. Complete loss of 
heterozygosity in this cancer type further suggested a tumour-suppressor role for p63. This ob­
servation is in sharp contrast to previous suggestions that p63 acts as an oncogene and accumu­
lates in tumours, notably in SCCs as in the present patient with an p.R298Q mutation (11-15). An 
oncogenic activity for p63 would also be in line with the gain-of-function activity that is brought 
about by the p.R298 amino acid substitutions. Nevertheless, since SCCs are common (7-11% 
lifetime risk (18)) we cannot conclude that there is a causal relationship between the SCC and the 
p63 mutation in the present ADULT syndrome patient.
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Abstract
Heterozygous mutations in the p63 gene underlie a group of at least seven allelic syndromes, inclu­
ding Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome (AEC) and Rapp Hodgkin 
syndrome (RHS), which involves varying degrees of ectodermal dysplasia, orofacial clefting and 
limb malformations. Mutations in the AEC and Rapp Hodgkin syndromes cluster in the 3' end of 
the p63 gene. Previously reported mutations are mainly missense and frameshift mutations in 
exons 13 and 14, affecting the p63a-specific SAM (Sterile alpha motif) and TI (Transactivation 
inhibitory) domains. A patient cohort affected by AEC syndrome was evaluated during Internatio­
nal Research Symposium supported by the National Foundation for Ectodermal Dysplasias. Nine­
teen patients underwent full clinical evaluations and 18 had findings consistent with a diagnosis 
of AEC syndrome. These 19 patients, along with 5 additional relatives had genomic DNA analysis. 
Twenty-one of the 24 participants from 12 families were found to have mutations in the p63 
gene. Eleven different mutations were identified; 10 were novel mutations. Eight were missense 
mutations within the coding region of the SAM domain. Three other mutations were located in 
exon 14 sequences, which encode the TI domain. The effects of the mutations in the SAM and TI 
domains are poorly understood and functional studies are required to understand the patholo­
gical mechanisms. However, AEC and RHS mutations in the 5' and 3' ends of the p63 gene point 
towards a critical role of the Ap63a isoform for the AEC/RHS phenotype.
Introduction
Heterozygous mutations in the p63 gene (TAp63 mRNA, Genbank AF075430) underlie a group of at 
least seven human developmental disorders, characterized by different combinations of ectoder­
mal dysplasia, orofacial clefting and limb malformations (1-7). Manifestations in these syndro­
mes are overlapping, but different enough to be considered discrete syndromes. Some of these 
syndromes present a strong genotype-phenotype correlation, whereas correlation in the other 
syndromes is more ambiguous. Hay-Wells syndrome, also known as Ankyloblepharon-ectoder­
mal defects-cleft lip/palate syndrome (AEC, OMIM 106260), and Rapp Hodgkin syndrome (RHS, 
OMIM 129400) are highly similar disorders and possibly variable manifestations of the same cli­
nical entity (8,9). Typical characteristics for AEC and RHS are ankyloblepharon filiforme adnatum 
(eye lid fusion), severe skin erosion at birth and abnormal hair (pili torti or pili canaliculi) and the 
presence of cleft palate with or without cleft lip. Severe limb malformations such as ectrodactyly 
are less commonly observed in these conditions.
Mutations in AEC and RHS syndromes cluster in the 3' end of the p63 gene. These mutations are 
mainly missense and frameshift mutations in exons 13 and 14, affecting the p63a-specific SAM 
(Sterile alpha motive) and TI (Transactivation inhibitory) domains. Although, AEC and RHS syndro­
mes have always been linked to the a-tail of the p63 gene, we have recently discovered three 
novel mutations in the 5' end of the p63 gene (10). Two of these novel mutations only affect the 
ANp63-isoforms (not the longer TAp63-isoforms), indicating that the specific disruption of the 
ANp63a-isoform is the key to the AEC and RHS syndrome phenotypes.
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Table 1. p63 mutations identified in 24 patients of NFED cohort.
Sam ple M utation  (DNA) M utation  (p rote in ) Exon Dom ain
1 c.1630G>T p.D544Y#* 14 SAM
2 c.1793G>T p.R598L* 14 TI
3 c.1682G>A p.G561D * 14 SAM
4 c.1682G>T p.G561V* 14 SAM
5 c.1793G>T p.R598L* 14 TI
6 c.1682G>A p.G561D * 14 SAM
7 c.1793G>T p.R598L* 14 TI
8 Unaffected fam ily m em ber
9 c.1802A>T p.D601V* 14 TI
10 c.1682G>A p.G561D * 14 SAM
11 Unaffected participant
12 c.1793G>T p.R598L* 14 TI
13 c.1578C>A p.F526L* 13 SAM
14 c.1793G>T p.R598L* 14 TI
15 c.1631A>T p.D544V* 14 SAM
16 c.1652C>T p.P551L* 14 SAM
17 c.1578C>A p.F526L* 13 SAM
18 c.1634T>C p.L545P* 14 SAM
19 c.1682G>T p.G561V* 14 SAM
21 c.1610T>C p.I537T 13 SAM
22 c.1846delC p.R616fs* 14 TI
23 c.1846delC p.R616fs* 14 TI
24 Unaffected fam ily m em ber
25 c.1846delC p.R616fs* 14 TI
Domain abbreviations: SAM (Sterile alpha motif) and TI (Transactivation inhibitory domain). 
# This mutation likely affects the splicing of exon 14.
*Novel p63 mutations, which are not published before.
Materials and methods
The National Foundation for Ectodermal Dysplasias convened the International Research Symposium 
for Ankyloblepharon-ectodermal defects-cleft lip/palate (AEC) syndrome at Texas Children's Hos­
pital in Houston, TX, with financial support through the NIH. Nineteen patients with a suspected 
diagnosis of AEC syndrome underwent full multidisciplinary evaluations via a Baylor College of 
Medicine IRB-approved protocol. Eighteen of these patients were found to have clinical charac­
teristics consistent with a diagnosis of AEC syndrome; one did not have a phenotype that was 
consistent with this diagnosis. An additional five relatives also participated, but their participati­
on was limited to laboratory investigation only. In total, 24 participants from 12 different families 
had genomic DNA analysis to assess for mutations in the p63 gene. Since all known AEC/RHS 
causing mutations have been found in exons 3', 4, 13 and 14 in the p63 gene, these exons were 
investigated by direct sequencing. The mutation analysis was described elsewhere (3).
Results and discussior
Mutations were identified in 21 samples (Table 1). Three individuals did not have an identified
mutation in the p63 gene. Two of these are unaffected relatives, and one is a patient with a phe­
notype slightly different than AEC/RHS. This individual may have mutation elsewhere in the p63 
gene or in another yet unknown ectodermal dysplasia gene.
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The number of solved patients from this NFED cohort is remarkably high, as our previous studies 
showed causative p63 mutations in only ~75% of patients with an AEC/RHS like phenotype. Alto­
gether, we found 11 different mutations, of which only one mutation (in patient 21) p.I537T has 
been described previously in AEC syndrome families (5,11,12).
Eight of the mutations reported here (p.F526L, p.I537T, p.D544Y, p.D544V, p.L545P, p.P551L, p.G561D 
and p.G561V) are missense mutations within the coding region of the SAM domain (Fig. 1). Such 
mutations are characteristic for AEC/RHS, since 57% (16 out of 28) of the known AEC/RHS muta­
tions create amino acid substitutions in the SAM domain (5,8,9,11,13-17). However, two of these 
missense mutations (p.D544Y, p.D544V) are flanking the intron 13-exon 14 boundary and may 
cause a splice site defect of exon 14. In patient 1 the first nucleotide of codon p.544, guanine at 
nucleotide position c.1630 is changed to thymine; and in patient 15, the second nucleotide of 
this codon, adenine at nucleotide position c.1631 is changed to thymine. To predict the influence 
of these mutations, we tested these sequences in two splicing prediction programs (NetGene2 
and Berkeley Drosphila Genome Project). The prediction programs suggest that the c.1630G>T 
mutation (p.D544Y) is most likely affecting the acceptor splice site of exon 14, whereas the 
c.1631A>T mutation (p.D544V) does not. Unfortunately, the consequences on the p63 cDNA 
level cannot be determined since the patient cDNA is not available.
Three other new mutations are located in exon 14 sequences, which encode the TI domain of the 
p63 protein (Fig 1). In total, about 18% (5 out of 28) of previously identified AEC/RHS mutations 
are deletions in the TI domain causing a frameshift and an extended protein product (3,9,11,18­
22). The newly identified p.R616fs mutation has a similar predicted effect.
ANp63a '1 DNA binding HS3 SAM TID
H. s a p ie n s  CSIVSFLARLGCSSCLDYFTTQGLTTIYQIEHYSM DDLASLKIPEQFRHAIW KGILDHRQ
M. m u sc u lu s  CSIVSFLARLGCSSCLDYFTTQGLTTIYQIEHYSM DDLASLKIPEQFRHAIW KGILDHRQ
R . n o r v e g ic u s  CSIVSFLARLGCSSCLDYFTTQGLTTIYQIEHYSM DDLASLKIPEQFRHAIW KGILDHRQ
G. g a l l u s  CSIVSFLARLGCSSCVDYFTTQGLTTIYH IEHYSM DDLVSLKIPEQFRHAIW KGILDHRQ
D . r e r i o  N SISSFLLRLGCSACLDYFTAO GLTN IYO IEN YN LED LSRLKIPTEFO HIIW KG IM EYRO
h . lh * f s s p s h l l r t p s s a s t v s v g s s e t r g e r v iT a v r f t l r q t i s f p p r d e w n d f n f d m d - - a r r n k q q r ik e e g e
M. LHDFSSPPHLLRTPSGASTVSVGSSETRGERVIDAVRFTLRQTISFPPRDEWNDFNFDMD— SRRNKQQRIKEEGE
R . LHDFSSPPHLLRTPSGASTVSVGSSETRGERVIDAVRFTLRQTISFPPRDEWNDFNFDMD— SRRNKQQRIKEEGE
G. LHDFSSPPHLLRTPSGASTVSVGSSETRGERVIDAVRFTLRQTISFPPRDEWNDFNFDMD— ARRNKQQRIKEEGE
D. TMEFSPPPHILRTSSGTSTVSVGSTEARGERVIDAVRFTLROTISFPPRDDW TDFSFDLAPDSRRNKOORIKEEGE
Figure 1. Multiple sequence alignment of p63a-tail represents the highly conserved SAM and TI domains.
The nine amino acids, which were found to be mutated in this study, are indicated by black arrow and amino 
acid number. These amino acids are much conserved, which suggest their role as pathogenic mutations. Stars 
illustrate known missense mutations and dots known deletions or insertions. In total, 18 amino acids are known 
to be mutated in SAM and TI domains, and seven deletions or insertions are reported.
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More surprising is the detection of two missense mutations, p.R598L and a p.D601V, which are 
located in the middle of the TI domain. These are the first missense mutations in the TI domain. 
Including this study, a total of 38 different mutations in AEC/RHS has been reported. Mutations 
are clustered in the AN-specific amino-terminus and a-specific carboxy-terminus of the p63 
protein, which points towards a critical role of ANp63a isoform for the AEC/RHS phenotype and 
pathogenesis. Moreover the expression pattern in epithelial tissues of ANp63a is in agreement 
with the phenotypic malformations in AEC/RHS patients.
Functional consequences of AEC/RHS mutations have been reported in a few studies. One very 
likely effect is distorted binding of mutant SAM domain to its interacting proteins and its diverse 
consequences. It has been reported that SAM domain mutations abolish binding to Apobecl- 
binding protein 1 (ABBP1). ABBP1 belongs to the RNA processing machinery and controls splicing 
of Fibroblast growth factor receptor 2 (FGFR2), which is likely to be altered because of mutations 
in SAM domain (23). Another possible effect is linked to transactivation. Since ANp63a protein 
can act as an activator or a repressor, it is likely that AEC/RHS mutations can alter the repressor 
or activator function of the p63a protein (24-27). Our recent study shows that AEC/RHS causing 
mutations in the 5' end of the p63 gene lose the activator function of ANp63a, and have even 
dominant negative activity against the wild type p63 protein (10). Mutations in the TI domain 
might also influence the repressor function. While these effects have been shown for some of 
the known AEC/RHS mutants, other mutations may cause other still unknown consequences af­
fecting the same pathway and causing the same disease.
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Abstract
Missense mutations in the 3' end of the p63 gene are associated with either RHS or AEC syndrome. 
These mutations give rise to mutant p63a protein isoforms with dominant effects towards their 
wild type counterparts. Here we report four RHS/AEC-like patients with mutations (p.Q9fs, 
p.Q11X, p.Q16X), that introduce premature termination codons in the N-terminal part of the p63 
protein. These mutations appear to be incompatible with the current paradigms of dominant- 
negative/gain-of-function outcomes for other p63 mutations. Moreover it is difficult to envisage 
how the remaining small N-terminal polypeptide contributes to a dominant disease mechanism. 
Primary keratinocytes from a patient containing the p.Q11X mutation revealed a normal and 
aberrant p63-related protein that was just slightly smaller than the wild type p63. We show that 
the smaller p63 protein is produced by translation re-initiation at the next downstream methi­
onine, causing truncation of a non-canonical transactivation domain in the AN-specific isoforms. 
Interestingly, this new AANp63 isoform is also present in the wild type keratinocytes albeit in 
small amounts compared to the p.Q11X patient. These data establish that the p.Q11X-mutation 
does not represent a null-allele leading to haploinsufficiency, but instead gives rise to a truncated 
ANp63 protein with dominant effects. Given the nature of other RHS/AEC-like syndrome muta­
tions, we conclude that these mutations affect only the ANp63a isoform and that this disruption 
is fundamental to explaining the clinical characteristics of these particular ectodermal dysplasia 
syndromes.
Introduction
The p53 protein and its evolutionary predecessors p63 and p73 constitute a family of key tran­
scriptional regulators in cell growth, differentiation and apoptosis. While p53 is a major player 
in tumorigenesis, p63 and p73 appear to have pivotal roles in embryonic development. p73- 
deficient mice have neurological and inflammatory problems, whereas p63-knockout mice have 
major defects in epithelial, limb and craniofacial development (1-3). These observations suggest 
that p63 has a crucial role in tissue morphogenesis and maintenance of epithelial stem cell 
compartments. Furthermore, p63 has been linked to several important signaling pathways, such 
as Epidermal growth factor (EGF), Fibroblast growth factor (FGF), Bone morphogenetic protein 
(BMP) and Notch, WNT and Hedgehog (4-9).
The p63 gene consists of 16 exons located on chromosome 3q28. At least six different protein iso­
forms can be produced, due to two different promoter sites and three different splicing routes. 
The amino-terminal ends are called TA and AN, and at the carboxy-terminal end, a , P and y 
termini can be synthesized (Fig. 1). Several functional domains have been identified. The central 
DNA-binding domain and isomerization domain are present in all p63 isoforms. The canonical 
transcription activation (TA) domain is located at the amino-terminal end of the TAp63 isoforms. 
The AN-isoforms also contain an amino-terminal transactivation domain, denoted TA2 (10,11). 
The carboxy-terminal end has two additional domains: the Sterile alpha motif (SAM) domain 
and a Transactivation inhibitory (TI) domain, which are both only present in the largest carboxy- 
terminal variant, p63a (12).
Heterozygous mutations in the human p63 gene cause developmental disorders, characterized by 
various combinations of ectodermal dysplasia, limb malformations and orofacial clefting (13,14). 
To date, seven different disorders have been linked to mutations in the p63 gene (15).
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These conditions may have overlapping phenotypic features, but some genotype-phenotype cor­
relations have emerged (16). EEC syndrome (Ectrodactyly, ectodermal dysplasia and cleft lip/ 
palate, OMIM 604292) is the most common p63-linked ectodermal dysplasia (ED). It is character­
ized by three major clinical symptoms: cleft lip and/or palate, ectodermal dysplasia (abnormal 
teeth, skin, hair, nails and sweat glands) and limb malformations in the form of split hand/foot 
(ectrodactyly) and/or fusion of fingers/toes (syndactyly). About 10% of p63-linked patients have 
Rapp-Hodgkin syndrome (OMIM 129400) or AEC/Hay-Wells syndrome (OMIM 106260). These 
two latter syndromes fulfill the criteria of ectodermal dysplasia and orofacial clefting, but do not 
have the severe limb malformations seen in EEC syndrome. Some typical characteristics linked to 
RHS/AEC-like syndromes are eyelid fusion (ankyloblepharon filiforme adnatum), severe skin ero­
sion at birth and abnormal hair with pili torti or pili canaliculi. Indeed, RHS and AEC syndromes 
are very similar and have been suggested to be variable manifestations of the same clinical entity 
(15,17). EEC and RHS/AEC syndromes are good examples of a strong genotype-phenotype asso­
ciation. Mutations in the EEC syndrome are clustered in the DNA binding domain, and most likely 
alter the DNA-binding properties of the protein. By contrast, mutations in RHS/AEC syndromes 
are clustered in SAM and TI domains in the carboxy-terminus of p63a (15-29). The SAM domain 
is involved in protein-protein interactions, whereas the TI-domain can bind intra-molecularly to 
the TA-domain, thereby inhibiting transcription activation (12,30). All p63-linked disorders are in­
herited in an autosomal dominant manner and mutations are thought to have either dominant­
negative or gain-of-function effects (31).
In this article we describe four patients from three families with phenotypes consistent with RHS/ 
AEC syndromes that result from atypical nonsense mutations (p.Q11X, p.Q16X) or a deletion 
mutation (p.Q9fs), all of which lead to a premature termination codon (PTC) in the early amino- 
terminal end of the ANp63-isoforms. These mutations are predicted to give rise to a null allele, 
which contradicts the accepted disease mechanism of other mutations.
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Figure 1. Schematic overview  of the p63  gene and two of its protein products. A. P63 has two different pro­
moter sites resulting in two different N-terminal ends called TA and ANp63. ANp63 lacks the exons 1-3, which 
are present in TA, however it contains an alternative exon 3'. P63 has three C-terminal splicing routes: a, p and 
Y, thus at least six different gene products can be transcribed. B. The domain struc+ture of TA and ANp63 is simi­
lar, only N-terminal transactivation domain is different, called TA and TA2 respectively. Domain abbreviations:
ISO (Isomerization domain), SAM (Sterile alpha motif domain) and TID (Transactivation inhibitory domain). The 
numbering under the domains illustrates the amino acid positions.
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Surprisingly, in keratinocytes from the patient with the p.Q11X mutation we were able to detect 
normal p63 RNA levels of both alleles, but also an additional smaller protein product. Using mo­
lecular studies we could demonstrate that the smaller p63 protein was produced by translational 
re-initiation at the next methionine after the PTC. This causes a deletion of 25 amino acids in the 
ANp63-isoforms, abrogating the TA2 domain, and thus suggesting a crucial role for this part of 
p63 in the pathogenesis of RHS/AEC syndromes.
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Figure 2. Pathogenic mutations in three RHS/AEC syndrome fam ilies. Direct sequencing of genomic DNA from 
four AEC/RHS patients revealed N-terminal mutations in the p63 gene. A . In family 1 a heterozygous nucleotide 
change c.31C>T was found in affected mother and daughter in exon 3'. The upper chromatogram illustrates a 
control sequence and the lower is from the affected mother. B. In family 3, a heterozygous deletion c.26delA 
was detected in the index patient in exon 3'. The upper sequence is a control and the lower is from the patient. 
C. In family 2 a heterozygous nucleotide change c.46C>T (ANp63-isoform) was detected in exon 4 in the index 
patient. The upper chromatogram illustrates a control DNA sequence and the lower is from the patient. D. Chro­
matogram of the sequenced cDNA of keratinocytes from the mother of family 1 reveals the same heterozygous 
nucleotide change detected in the genomic DNA (Fig. 2A). Mutated RNA is present in the cells and is not de­
graded by the nonsense mediated RNA decay as expected. E. The translated sequence of ANp63a (AF075431) 
(capitals) contains two AUG sites (bold, underlined) in the two first exons (exon 3' and 4, | indicates the exon 
boundary). The mutated nucleotides: c.26A, c.31C and c.46C (indicated red and bold) are located between 
these two initiation sites. c.26delA mutation leads to a frameshift, which causes a PTC (indicated by ** * ) only 
5 nucleotides upstream of the second AUG site. c.31C>T changes the codon CAA into a termination codon TAA 
(this PTC is 44 nucleotides upstream from the second AUG). c.46C>T changes codon CAG into a termination 
codon TAG causing a PTC 29 nucleotides upstream of the second AUG. The second initiation codon is flanked by 
a strong Kozak sequence, where the most important nucleotides (purine at position -3 and a guanine at position 
+4) are conserved suggesting its use in translation re-initiation. For a color figure see Appendix 2.
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Results
Identification o f atypical mutations predicting N-terminal 
prem ature stop codons
We identified four patients in three families with a clinical presentation reminiscent of AEC/RHS like 
ectodermal dysplasia syndrome (for details see Material and methods). Direct sequencing of all 
16 exons of the p63 gene revealed three different heterozygous nucleotide changes in affected 
individuals. In family 1, both mother and daughter have a nucleotide change c.31C>T (Fig. 2A) 
(Accession number AF075431) in the first coding exon, the alternative exon 3', that is present 
only in the ANp63 isoform. The c.31C>T mutation changes glutamine to a stop codon at amino 
acid position 11, creating a premature termination codon (PTC) in all ANp63 isoforms.
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Figure 3. ANp63a levels in cultured keratinocytes from a Rapp-Hodgkin syndrome patient. ANp63 and p63a 
expression levels are investigated in undifferentiated keratinocytes by quantitative PCR. The control (black 
bar) is a pool of five control samples and the RHS patient sample (grey bar) is from the mother of family 1 
containing the p.Q11X mutation. Housekeeping genes ACTB, GAPDH and hARP were used in normalization, 
A-B. qPCR with two ANp63 specific primer sets show that ANp63 expression in RHS sample is very similar to 
control, indicating that RNA containing the mutation is not degraded by NMD as expected. C. qPCR with p63a 
specific primer set gives similar results than ANp63 specific sets. Furthermore, similar Ct-values (not shown) 
indicate ANp63a to be the only isoform expressed in undifferentiated cultured keratinocytes.
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In family 3, a deletion of one nucleotide (c.26delA) was identified (Fig. 2B), also located in the 
alternative exon 3' of ANp63 isoforms. This causes a frameshift and a PTC 41 nucleotides down­
stream from the deletion (Fig. 2E). In family 2, a nucleotide change c.46C>T was detected in exon 
4 (Fig. 2C). This mutation causes a change of glutamine to a stop codon at amino acid position 
16 in the ANp63 isoforms and at position 71 in TAp63 isoforms. The genomic change c.46C>T (or 
c.211C>T in TAp63 accession number AF075430) indicates a PTC in both DN and TAp63 isoforms. 
These three mutations were not identified in DNA from any of the unaffected family members nor 
in 300 control DNAs, indicating that they are all pathogenic, resulting in RHS/AEC-like syndromes.
Harmful and deleterious transcripts with a PTC are usually degraded through nonsense-mediated 
decay (NMD). In general, all transcripts containing a PTC upstream of the last exon junction 
complex are recognized and degraded (32). The c.31C>T mutation is present in the first exon of 
ANp63 followed by 11 exon junctions and c.26delA causes a PTC in the second exon (exon 4), fol­
lowed by 10 exon junctions. c.46C>T (c.211C>T) causes a PTC in the second exon of ANp63 and in 
the fourth exon of TAp63, in both cases following 10 exon junctions. According to this paradigm, 
the transcripts with PTCs caused by these mutations should all be degraded by NMD and thereby 
cause p63 haploinsufficiency.
To investigate this phenomenon in more detail we obtained a skin biopsy from the affected mother 
of family 1 and established a keratinocyte culture. p63 RNA expression levels in cultured kerati­
nocytes were determined by quantitative PCR (qPCR) using two different primer sets specific for 
the 5' end encoding AN-isoforms and one primer set for the 3' end of the a-isoforms. All these 
three primer sets gave similar Ct-values suggesting that the major isoform in normal control 
keratinocytes is ANp63a (data not shown). Surprisingly, p63 RNA expression levels in cultured 
keratinocytes from the patient with the p.Q11X mutation were similar to those of controls (Fig.
3), which refutes the p63 haploinsufficiency model. We then sequenced the amplified RT-PCR 
products, which revealed that the nucleotide change c.31C>T was also present in the keratino­
cyte RNA pool. The presence of both alleles (Fig. 2D) argues against NMD.
N-terminal truncation of ANp63alpha due to 
translational re-initiation
Having established that the nonsense mutations do not have an effect on the mutant transcript 
levels, we next determined the consequences of the N-terminal mutations at the protein level. 
Western blot analysis performed on protein extracts from the patient's cultured keratinocytes 
with an antibody specific to the a-tail of p63, revealed an additional ANp63 protein of reduced 
molecular weight (3kDa). A band of similar size was also present at very low levels in keratino­
cytes from control individuals, shown with the p63a-specific antibody in the Western blot in 
figure 4A. To resolve the identity of the smaller protein product, we investigated the nucleotide 
sequence downstream of the mutation. A further ATG codon was identified 44 nucleotides 
downstream of the c.31C>T mutation (Fig. 2E). This is the first ATG codon following the canonical 
AN start codon and is located 75 nucleotides downstream in the same reading frame. The Kozak 
sequence flanking this second AUG is in accordance with a strong translation initiation sequence, 
stronger even than the first AUG codon (Fig. 2E) (33,34). In addition, a translation start prediction 
program estimated this AUG to be an initiation site at score 0.631, a value within normal range of 
bona fide translation (Netstart 1.0 Prediction Server). We hypothesized that the next methionine
107
Chapter 6
downstream of the p.Q11X mutation will be used to reinitiate the translation. A similar mecha­
nism to escape NMD has been demonstrated previously for nonsense or frameshift mutations in 
BRCA1, ATP7A and NEMO  genes (35-39).
To provide further support for the translation re-initiation hypothesis, we performed transfection 
studies in p63 negative Saos-2 cells. We performed transient transfections with a full length 
ANp63a cDNA under a constitutive CMV promoter, pcDNA3_CMV_ANp63a. After transfec­
tions, the expression of each construct was confirmed by immunofluorescent labeling (data not 
shown). Protein lysate of each transfection was analyzed by Western blotting. Firstly, we mutated 
the second methionine at position p26 to isoleucine to investigate whether this methionine is 
involved in translation initiation of the smaller ANp63a fragment. Wild type ANp63a is present 
in two protein bands, however, when methionine at position p.26 is mutated, only the full length 
ANp63a protein was present (Fig. 4B) and the smaller protein variant was undetectable, even 
upon high over-exposure of the blot. Secondly, all three pathogenic mutations (p.Q11X, p.Q16X 
and p.Q9fs) and double mutants (p.Q11X_M26I, p.Q16X_M26I, p.Q9fs_M26I) were introduced 
into the ANp63a constructs. The transfection studies demonstrated a molecular size reduction 
(approximately 3kDa) after introduction of the p.Q11X, p.Q16X or p.Q9fs mutation into cells (Fig. 
4C), which is accordance with the additional protein observed in the patient's keratinocytes (Fig. 
4A). Finally, when introducing the double mutant p.M26I in combination with each pathogenic 
mutation, none of the two protein variants were detected (Fig. 4C). This strongly suggests that 
methionine p.26 is used to initiate the translation of AANp63a in the presence of mutations that 
cause upstream premature stop codons. The shorter protein variant AANp63a was also detected 
in cells transfected with wild-type ANp63a, but at lower levels than the full length protein. This 
phenomenon is similar to keratinocytes from control individuals, although the shorter variant is 
present in much lower levels compared to transfected cells.
Transcriptionallyinactive AANp63alpha
The protein analysis showed that the p.Q11X mutation causes an amino-terminal deletion of 25 
amino acids. To study the transactivational activity of the ANp63 amino-terminus, we tested a 
series of truncation mutations in the ANp63y isoform (A14, A26, A43, A61, A79) for transactiva­
tion activity (Fig. 5A). Full length ANp63y was able to activate an optimized p53 promoter nearly 
6-fold more than the empty vector. In contrast, truncation of the first 14 amino acids completely 
abolished the activation (Fig. 5B). The same inactivating effect was detected for all other trunca­
tion mutations. Thus, 14 unique amino acids at the AN-terminus of p63 constitute a functional 
domain, which has transactivational activity. This is in accordance with previous studies on other 
promoters (10,11,40).
Because ANp63a is the predominant isoform in keratinocytes, we set out to test the ability of the 
p.Q9fs, p.Q11X and p.Q16X mutants to regulate downstream target genes. Keratin-14 (KRT14) 
was recently reported to be a natural target gene of p63, which is upregulated by ANp63a (40­
42). A transactivation assay of p63-negative Saos-2 cells transfected with either ANp63a wild 
type, mutant or a combination of these constructs, together with a KRT14-luciferase-reporter 
construct, revealed that wild type ANp63a was able to activate the KRT14 promoter 2.5 times 
more than the empty vector. This is in contrast to all ANp63a mutant constructs (p.Q9fs, p.Q11X 
and p.Q16X), which were inactive and behaved similar to empty vectors (Fig. 5C). Co-transfec­
tions of each single mutation in combination to ANp63a wild type vector showed no increased
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KRT14-promoter activation (Fig. 5C), indicating a dominant effect of these mutations against the 
wild type. Next we investigated whether the mechanism of action of the mutant ANp63a protein 
might be dose dependent. To that end, we co-transfected Saos-2 cells with the wild type and 
mutant constructs in a 5:1, 1:1 and 1:5 ratio (Fig. 5D). The 5:1 ratio of wild type and p.Q11X mu­
tant was able to activate the KRT14-promoter 2.3 fold, which is similar to the wild type ANp63a 
activation. In contrast, when we increased the amount of mutant p.Q11X construct the activa­
tion was reduced till 1.2 and 0.8 in 1:1 and 1:5 ratios respectively, indicating a dose-dependent 
inhibitory activity. Finally, we tested the dominant effect of mutant ANp63a_p.Q11X towards 
TAp63y isoform (Fig 5E). ANp63a wild type can inhibit the TAp63y activation from nearly 35-fold 
till 5-fold when compared to empty vector. The mutated ANp63a_p.Q11X has a similar inhibitory 
activity as the wild type ANp63a, indicating that the mutated protein can bind to DNA. These 
results show that mutant ANp63a isoforms have dominant effects towards various wild type p63 
isoforms and that they are dose-dependent.
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Figure 4. An additional ANp63a protein product in Rapp-Hodgkin syndrome patient is caused by translational 
re-initiation at methionine p.26. A . The lysate of cultured keratinocytes was run on NuPAGE®Bis-Tris Pre Cast 
Gels System. p63a-specific antibody H-129 [Santa Cruz] was used to detect the signal on nitrocellulose mem­
brane. This experiment demonstrates two ANp63a protein variants in cultured keratinocytes. In control samples 
(lanes 1 and 2), the smaller ANp63a variant is present in small quantities. However, in the Rapp-Hodgkin 
syndrome sample (lane 3) the ratio is about one to one. a-tubulin [Abcam] is used as a loading control. B. The 
second putative initiation site in ANp63, methionine p.26, was mutated to isoleucine in a wild type expres­
sion vector and transiently transfected into p63 negative Saos-2 cells, and harvested 30-48h after transfection. 
The cell lysates were run on 8% SDS-Polyacrylamide gel and blotted to a nitrocellulose membrane. This was 
incubated with p63a-specific antibody H129 [Santa Cruz]. Mock (lane 1) is negative. When transfecting the wild 
type ANp63a (lane 2) two p63 products are clearly present. However, when transfecting the mutation construct 
(p.M26 is mutated into isoleucine), the lower product is missing (lane 3). This indicates that methionine at 
position p.26 can initiate the translation. C. N-terminal RHS and AEC mutations were also introduced to the 
expression vector along with the vector containing the p.M26I mutation. These constructs were transfected into 
the Saos-2 cells and prepared as described above. Lane 1 contains empty vector pcDNA3. Wild type ANp63a 
(lane 2) produces the double band similar to 4B. However, when transfecting the pathogenic mutations p.Q11X 
(lane 3), p.Q16X (lane 5) and p.Q9fs (lane 7) the upper product is completely absent. When a combination of 
pathogenic mutation plus a p.M26I mutation is present (p.Q11X_M26I (lane 4), p.Q16X_M26I (lane 6) and 
p.Q9fs_M26I (lane 8)) no p63a protein product is detected at all. This experiment clearly demonstrates that all 
three pathogenic mutations cause translational re-initiation at methionine p.26.
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Figure 5. Transactivational activity in the N-terminus of ANp63 isoform. A . Multiple sequence alignment 
represents the conservation of N-terminus of ANp63: all three glutamines mutated in RHS/AEC patients and 
the putative second translational initiation codon p.M26 are almost fully conserved. The N-terminal truncation 
mutations are also indicated in this alignment. B. Saos-2 cells were transiently transfected with N-terminally 
truncated p63 cDNA expression vectors (shown in fig. 5A) and p53 promoter activation was measured. The 
truncated proteins lack the N-terminal 14 amino acids (A14 i.e. the residues which are unique for ANp63 
isoforms) or N-terminal 26, 43, 61 or 79 amino acids (A26, A43, A61, A79, respectively). Full length ANp63y can 
activate the p53 promoter approximately six fold, whereas deleting the first 14, 26, 43, 61 or 79 amino acids ab­
rogates the transactivational activity completely. C. Saos-2 cells were transfected with empty vector (pcDNA3), 
ANp63a wild type, ANp63a mutant (p.Q9fs, p.Q11X and p.Q16X) or combination of wild type and mutant, and 
Keratin-14 promoter activation was then measured. The wild type ANp63a is able to activate the Keratin-14 
promoter 2.5 times, whereas none of the ANp63a mutants is able to activate the promoter at all. Neither 
co-transfection of wild type and mutant are able to activate KRT14 promoter, indicating a dominant negative 
effect for the mutants. D. Saos-2 cells were transfected with wild type and p.Q11X ANp63a constructs in dif­
ferent ratios and KRT14 promoter activity was measured. 5:1 ratio of ANp63a wild type and p.Q11X can activate 
KRT14 promoter similar to ANp63a wild type construct, however, when using 1:1or 1:5 ratio, which mimics RHS 
patient situation the activation is repressed and is similar to p.Q11X construct. This supports the hypothesis that 
AANp63a is a dose-dependent regulator of ANp63a. E. Finally, Saos-2 cells were transfected with TAp63y and 
ANp63a isoforms. Wild type TAp63y can activate the p53-promoter 34 times when comparing to empty vector, 
whereas ANp63a cannot activate the promoter at all. Instead, ANp63a wild type inhibits the activity of TAp63y 
in a co-transfection assay. This dominant negative effect against the TAp63y is also detected in the RHS p.Q11X 
ANp63a, indicating that the mutated molecule is able to bind to the promoter.
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Díscussíor
Until now, mutations causing RHS and AEC syndrome have only been described in exons 13 and
14, which encode the SAM and TI domains of the p63a-protein. Here we report three RHS/AEC 
families without any changes in these exons, but with novel pathogenic mutations in the amino- 
terminus of ANp63: p.Q9fs and p.Q11X (in the alternative exon 3') and p.Q16X (in exon 4). The 
first two are present in only the ANp63 isoforms, whereas the latter is present in both ANp63 and 
TAp63 isoforms. All these mutations lead to premature termination codons soon after the first 
translation initiation codon. Despite this, these mutant alleles still produce a p63-related protein 
by re-initiation of translation at the next ATG codon. Recently, similar translation re-initiation pro­
cesses have been reported in genes causing other human inherited diseases, such as breast can­
cer, Menkes disease and Incontinentia pigmenti (36-39). Nevertheless, this is the first time that 
altered N-terminus and translation re-initiation has been linked to p63 and RHS/AEC syndromes.
The mutations reported here are not associated with severe skin phenotype. Absence of skin defects 
is also observed in 60% RHS and 20% of AEC syndrome patients (28). Since we have studied only 
four patients, it cannot be concluded whether the lack of severe skin defects is related to the 
position of the mutations or just a reflection of the normal clinical variety in RHS/AEC. The three 
novel mutations we have reported are of particular interest, as they differ completely from the 
previously identified mutations in Rapp-Hodgkin and AEC syndromes. The 23 pathogenic muta­
tions reported so far in p63 in these disorders are missense mutations, deletions or insertions 
clustered in the a-terminus of p63, changing the composition of the SAM and TI domains (15-29). 
However, our new findings, based on the sites of the p.Q11X, p.Q16X and p.Q9fs mutations, 
imply that ANp63a is the critical isoform causing RHS/AEC syndrome. One of the new mutations 
we report (p.Q16X/p.Q71X) also affects the TA-isoform, although since ANp63a is the only p63 
isoform (>99%) expressed in epithelial tissues, the relevance of TA-isoform disruption remains ob­
scure (8,40). Moreover, the phenotype of the patient carrying the p.Q16X/p.Q71X mutation is not 
significantly different from that of the patients with the other mutations in families 1 and 3. This 
strongly indicates that either an aberrant AN- or a-terminus of p63 cause a condition which is cha­
racterized by ectodermal dysplasia and orofacial clefting, but not developmental limb problems.
It has been shown previously that ANp63a can function both as an activator and a repressor of 
transcription (10,40,43-45). We tested transactivational activity of p.Q9fs, p.Q11X and p.Q16X 
in a transactivation assay on the Keratin-14 promoter, on which ANp63a acts as an activator of 
transcription. Mutant constructs are unable to activate the KRT14 promoter (Fig. 5C), indicating 
that the first 25 amino acids are crucial for the activation. This is in accordance with the results of 
transactivation assays in this paper (Fig. 5B), in which deletion mutants affect the N-terminal TA2 
domain. In addition, in previous assays the N-terminal deletion abrogates the activity to transac- 
tivate p53 target genes and induce cell cycle arrest and apoptosis (10,11). Our TAp63y co-trans­
fection assay show that the p.Q11X mutant can inhibit TAp63y-mediated transactivation (Fig. 5E), 
indicating that this mutant is able to bind to DNA and form heteromers with other p63 isoforms. 
Previously, we have demonstrated that the SAM domain mutant proteins have lost their ability 
to form p63-protein complexes and their ability to bind to DNA (18). Apparently, the AN-mutant 
proteins have retained these properties. It is unclear whether these properties have an effect on 
the phenotype since they are highly similar, except perhaps for the skin phenotype, which is not 
severe in the patients with N-terminal mutation. In addition, the ANp63a co-transfection assay 
shows that all these three mutants can inhibit ANp63a wild type transactivation (Fig. 5C), sug­
gesting that these mutations have a dominant negative effect.
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The first 25 amino acids in the ANp63a are crucial for the correct function of the ANp63-isoforms.
The shorter AANp63a variant was also detected in wild type keratinocytes as well as in ANp63a- 
transfected Saos-2 cells (Fig. 4). In keratinocytes, this new isoform appears to be more abundant 
than any other p63 isoform (TA, P, y) except ANp63a. This indicates that the p63 gene encodes 
more protein isoforms than the six that have been recognized to date (Fig. 1). Therefore, this p63 
variant appears to be a novel translational variant and apparently not deleterious for the cells. 
We hypothesize that in keratinocytes the AANp63a isoform has a regulatory function, which is 
imbalanced in patients because of the increased amount of AANp63a. Our dose-dependent as­
say of ANp63a and AANp63a on KRT14 promoter also showed that elevated amount of AANp63a 
represses the ANp63a activation (Fig. 5D). Thus, the disturbed ratio between the full length and 
shorter p63 variant might be relevant for causing the disease phenotype. Since AEC/RHS is a 
dominantly inherited disease, we propose a dominant-negative effect of the AAN-isoform against 
wild type AN-isoform in either a dimer or tetramer structure. Once the mutated and wild type 
isoform form a functional protein complex, the AAN-isoform may alter the function of this com­
plex, working as a repressor or an activator.
Both AN- and a-terminal mutations can lead to a highly similar clinical phenotype, although the 
molecular mechanisms involved in the pathogenesis are as yet unknown. The TI-domain of 
the a-terminus intra-molecularly binds to the N-terminal TA-domain, even though this has 
not been reported for the AN-terminus of ANp63a (12). It appears however, that both types 
of mutations have an effect on transcription regulation by ANp63a. Here we have shown 
that deletions of ANp63 result in reduced transactivation activity by ANp63a on p53 and p63 
promoters. Previously we have shown that SAM-domain mutants ablate the transactivational 
inhibitory effects of ANp63a towards transactivation by p53 and TAp63y (18). Consequently, 
both N-terminal and SAM-domain mutations associated with RHS/AEC syndrome appear to 
affect transactivation activity by ANp63a isoforms. A systematic screening of the effects of 
constructs with N- and C-terminal mutations on a panel of natural p63 target genes and in 
a relevant cell type, such as in keratinocytes, may give further insight on the precise disease 
mechanism in RHS/AEC syndrome. From the present study, we conclude that the generation of 
an N-terminally truncated ANp63a protein is responsible for causing a Rapp-Hodgkin and AEC 
syndrome-like phenotype.
Material ard  methods
Clinical study
The index patient of family 1 is a 6 year-old girl, who has a unilateral cleft lip and palate. She has 
coarse dry blond hair and fair skin and there is scaling on the forehead, around the nipples and 
on the buttocks. She is anhidrotic. At birth she had a systolic murmur, but on ultrasound was 
found to have a normal cardiac anatomy and the murmur appeared to be innocent. The index 
patient's mother also has ectodermal dysplasia: her hair has a coarse texture and a spiky appear­
ance. Her skin is dry, and she has hypodontia of her primary teeth and her fingernails are dys­
trophic. She has anhidrosis on her trunk and limbs but is able to sweat normally from her palms 
and soles. In addition, she has had frequent urinary tract infections. Unlike her daughter she has 
secondary hearing loss due to a malformation of the external ear canal. She also had a history of 
a malignant melanoma, which had been excised from her right hand.
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The index patient of family 2 is a 2 year-old boy, who was born to non-consanguineous parents of 
Greek-Australian descent. He has a unilateral cleft of the soft palate and left-sided ankyloblepha­
ron filiforme. He has sparse eyebrows and eyelashes in infancy, but no alopecia or dry skin. He 
has small nails, which are not dystrophic. He also has hypoplastic alae nasi. There are no dental 
anomalies or delayed dental eruption.
The patient in family 3 is a 13 year-old girl. She was born with an absent hard palate in her mouth, 
ankyloblepharon filiforme and an atrial septal defect. As an infant she was prone to infections, 
but this later improved. She has upslanting palpebral fissures, a long nose and a small mouth 
with a thin upper lip. She has sparse eyelashes, but extremely thick and bushy hair, which is easy 
to brush. Her hands, feet and nails are all normal.
M utation analysis
Blood samples and skin samples used in this study were obtained after written informed consent was 
obtained. Genomic DNA was extracted from peripheral blood samples by a standard salting-out 
method. All 16 exons of the p63 gene were amplified and sequenced in both directions. Primers, 
which were used to amplify the alternative exon 3' and exon 4 are illustrated in Table 1A.
Cell culture
A skin biopsy (4mm diameter) was taken from the back of the index patient's mother. The skin was 
collected in RMPI [Gibco] medium with Gentamycin (1:1000) [Gibco], Amphotericin (1:100) [Gib- 
co] and Penicillin/Streptomycin [Gibco]. The biopsy was then trypsinized in 0.25% Trypsin-PBS 
[Brunschwig] overnight at 4°C following which the upper epidermal layer was separated from the 
biopsy with tweezers and the dermal surface was scratched smoothly to release the keratino­
cytes. Serum was added to stop the trypsin activity. Next the solution containing the dermal and 
epidermal components was vortexed at low speed for 1 minute. The dermal parts were removed 
and the epidermal cells were added on to irradiated 3T3-J2 cells. Cells were cultured in Green's 
medium: DMEM [Gibco], Ham's F12 [Gibco] (2:1) supplemented with 10% fetal bovine serum 
(FBS) [Hyclone], 4 mM L-Glutamine [ICN Biomedicals], 100 U/ml penicillin [Gibco], 100 mg/ 
ml streptomycin [Gibco], 25 mg/ml adenine [Calbiochem], 5 mg/ml insulin [Sigma], 0.4 mg/ml 
hydrocortisone [Calbiochem], 1,4 ng/ml triiodothyronine [Sigma], 0.1 nM Cholera toxin [Sigma]. 
Epidermal growth factor (EGF) (10 ng/ml) [Sigma] was added to the medium three days after 
starting the keratinocyte culture. The medium was refreshed every second day until the culture 
reached 80-90% confluence. The primary keratinocyte stocks were stored in liquid nitrogen.
Mouse fibroblast cell line 3T3-J2 was used as a feeder layer for the keratinocytes in Green's me­
dium. Pure 3T3-J2 cells were cultured in DMEM w/o pyruvate [Gibco] containing 10% calf serum 
supplemented by iron [Hyclone] and 100 U/ml penicillin [Gibco] and 100 |ag/ml streptomycin 
[Gibco]. 3T3 cells were irradiated at 3500 cGy about 20 hours before adding keratinocytes.
Keratinocytes were cultured at 37°C in 5% CO2 in keratinocyte growth medium. This medium 
consists of Keratinocyte Basal Medium, 0.15mM Ca2+ [Cambrex], supplemented with 0.1mM 
ethanolamine [Sigma], 0.1mM phosphoethanolamine [Sigma], bovine pituitary extract (0.4%)
[Bio Whittaker], 10ng/ml EGF [Sigma], 5mg/ml insulin [Sigma], 0.5|jg/ml hydrocortisone [Calbio-
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A  G enBank num ber Exon
Table 1. Oligonucleotide sequences.
Forw ard  (5' > 3') Reverse (5' > 3') P rim er for
NT_005612.15 p63  Exon 3' gcctcctcatgcctatagttg tcttacagccaccacagaaaa PCR, sequencing
NT_005612.15 p63  Exon 4 gatccgtggcttcagcgg aagcccatccttggacttgg PCR, sequencing
B G enBank num ber Isoform Forw ard  (5' > 3') Reverse (5' > 3') P rim er for
A F_0 75431 ANp63 ctggaaaacaatgcccagac gggtgatggagagagagcat RT-PCR
C G enBank num ber Isoform /gene Forw ard  (5' > 3') Reverse (5' > 3') P rim er for
A F_0 75431 ANp63 caatgcccagactcaatttagtga tgctggtccatgctgttcag RT-qPCR
AF_075431 ANp63 ttgtacctggaaaacaatgcc tgctggtccatgctgttcag RT-qPCR
A F_0 75431 p63a tccatggatgatctggcaagt gcccttccagatcgcatgt RT-qPCR
NM _001101 ACTB actggaa cggtga aggtga ca agggacttcctgtaacaacgca RT-qPCR
NM _001002 hARP caccattgaaatcctgagtgatgt tgacaagcccaaaggagaag RT-qPCR
NM _002046 GAPDH tgcaccaccaactgcttagc ggcatggactgtggtcatgag RT-qPCR
D Plasmid Change Forw ard  (5' > 3') Reverse (5' > 3') Prim er for
pcD N A3_M m _AN p63a p .Q U X  (c.31C>T) gaaaacaatgcccagacttaatttagtgagccacagt actgtggctcactaaattaagtctgggcattgttttc Mutagenesis
pcD N A3_M m _AN p63a p.Q16X (c.46C>T) caatttagtgagccatagtacacgaacctgg ccaggttcgtgtactatggctcactaaattg Mutagenesis
pcD N A3_M m _AN p63a p.Q9Xfs (c.26delA) ctggaaaacaatgcccgactcaatttagtgag ctcactaaattgagtcgggcattgttttccag Mutagenesis
pcD N A3_M m _AN p63a p.M 26l (c.78G>A) gctcctgaacagcatagaccagcagattcag ctgaatctgctggtctatgctgttcaggagc Mutagenesis
pcDN A3_M  m_AN p63y A14 ccacagtacacgaacctggggctcc catccgcggggcaggggtcccggaa Mutagenesis
pcDN A3_M  m_AN p63y A26 gaccagcagattcagaacggctcc catccgcggggcaggggtcccggaa Mutagenesis
pcDN A3_M  m_AN p63y A4 3 cacgcacagaatagcgtgacggcgc catccgcggggcaggggtcccggaa Mutagenesis
pcDN A3_M  m_AN p63y A61 tttgatgccctctctccatcccctg catccgcggggcaggggtcccggaa Mutagenesis
pcDN A3_M  m_AN p63y A79 cacagcttcgatgtgtccttccagc catccgcggggcaggggtcccggaa Mutagenesis
chem], 100U/ml penicillin [Gibco] and 100|ag/ml streptomycin [Gibco]. The medium was changed 
every second day until the culture reached confluent state.
Transfection conditions
Human osteoblast cell line Saos-2 was used for transient transfections. Saos-2 cells were cultured 
in DMEM [Gibco] supplemented by 10% fetal calf serum [Sigma], 1% natrium-puruvate [Gibco], 
1% Glutamax-1 [Gibco] and 100 U/ml penicillin [Gibco] and 100 ^ /m l streptomycin [Gibco]. 
Approximately 1.5 x 105 Saos-2 cells were seeded in one well of a 6-well tissue culture plate. Ef- 
fectene transfection reagent [Qiagen] was used to transfect the pcDNA3, pcDNA3_Mm_ANp63a 
(43) wild type and its mutant versions p.Q11X, p.Q16X, p.Q9fs, p.M26I and double mutant 
p.Q11X_M26I, p.Q16X_M26I and p.Q9fs_M26I constructs into Saos-2 cells. The same method 
was used for co-transfections, where either pcDNA3_ANp63a wild type was transfected to­
gether with each single mutant (p.Q11X, p.Q16X, p.Q9fs) ANp63a construct or pcDNA3_TAp63y 
wild type was transfected together either with wild type or mutant (p.Q11X) pcDNA3_ANp63a 
construct. The cells were collected 30-48 hours after transfection.
For transfections of the ANp63 truncation mutations (A14, A26, A43, A61, A79), Saos-2 cells were 
plated on 18 mm round glass coverslips and a total of 2 ^g plasmid DNA was transfected using a 
Calcium phosphate precipitation protocol (46).
Luciferase assays
Subconfluent Saos-2 cells were transfected as described above at a 1:2 ratio between the reporter 
construct (firefly luciferase under control of Keratin-14 promoter) (kind gift of Dr B. Andersen 
and Dr E. Candi) and the wild type or mutant (p.Q11X, p.Q16X, p.Q9fs) pcDNA3_ANp63a or a 
combination of wild type and mutant vector. In addition, 50ng of Renilla luciferase construct 
was co-transfected in each transfection to normalize for transfection efficiency. After 30 hours 
the transfection luciferase activities were measured using a Dual Luciferase Reporter Assay 
System [Promega] according to the manufacturer's instructions. The level of activation was 
calculated in comparison to transfections with an empty pcDNA3 vector.
Transfections for the TAp63yco-transfection assay were carried out as described above at a 1:3 ratio 
between the reporter construct (P-galactosidase reporter under p53 promoter) and expres­
sion construct (pcDNA3_Mm_TAp63y wild type, pcDNA3_ANp63a wild type or p.Q11X mutant 
construct, or in co-transfections TAp63y in combination with ANp63a w t or mutant). In addi­
tion, 5ng of Renilla luciferase construct was transfected in each transfection to normalize for 
transfection efficiency. After 30 hours the transfection P-galactosidase and luciferase activities 
were measured using a Luminescent beta-galactosidase detection kit II [Clontech] and a Renilla 
Luciferase Reporter Assay System [Promega] according to the manufacturer's instructions. The 
level of activation was calculated in comparison to transfections with an empty pcDNA3 vector. 
Transactivation assays of the truncation mutations were carried out as described previously 
(43).
115
Chapter 6
M utagenesis
Pathogenic mutations of interest were introduced into the pcDNA3_ANp63a vector by using Quick­
Change Site-Directed Mutagenesis kit [Stratagene] according to the manufacturer's instructions. 
The p.Q11X, p.Q16X, p.Q9fs and p.M26I mutations were introduced in this vector. The p.Q11X, 
p.Q16X and p.Q9fs mutations were also introduced into pcDNA3_ANp63a_p.M26I mutation 
construct to create double mutations. Mutagenesis primers are shown in Table 1D. The correct 
sequence of each clone was determined by direct sequencing of the entire cDNA insert.
N-terminal deletion mutations were introduced into pcDNA3_Mm_ANp63y vector by using ExSite 
PCR-based site-directed mutagenesis procedure [Stratagene] according to the manufacturer's 
instructions. The sequences encoding amino acids 2-14, 2-26, 2-43, 2-61 and 2-79 (amino acid 
numbers referring to ANp63 protein) were removed using oligonucleotides described in Table 
1D. The obtained clones were screened for the presence of the respective deletions by direct 
sequencing using primers flanking the deletions.
Sample preparation and immunoblotting
Transfected Saos-2 cells and keratinocytes were harvested in PBS and centrifuged at 4°C at 3000 RPM 
for 10 minutes. The pellet was lysed in lysis buffer containing: 50mM Tris-HCl pH 7.8, 10% glyc­
erol [Invitrogen], 0.5% Nonidet-P40 [Brunschwig], and 5mM Ethylene glycol-bis-tetraacetic acid 
(EGTA) [Fluka], and freshly added 10mM P-mercaptoethanol [Sigma], 0.5mM Phenylmethane- 
sulfonyl fluoride (PMSF) [Fluka], 1 Mg/ml Pepstatin A [Fluka] and 1x Protease inhibitory cocktail 
[Roche], for 20 minutes on ice. Immunoblotting was performed using the NuPAGE®Bis-Tris Pre 
Cast Gel System [Invitrogen] following the manufacturer's instructions. Samples were run on a 
4-12% NuPAGE Bis-Tris gel in MOPS buffer [Invitrogen]. p63a-specific polyclonal antibody H-129 
(1:500) [Santa Gruz] was used to detect p63 and a mouse monoclonal a-Tubulin antibody DM1A 
(1:5000) [Abcam] was used as a loading control. Alexa-680 goat-anti-rabbit secondary antibody 
[Molecular Probes] and IrDye-800 goat-anti-mouse secondary antibody [Rockland] were both 
used in 1:5000 dilution. The signal detection was performed by Odyssey scanner [Licor].
RNA isolation
Keratinocytes were cultured in Keratinocyte growth medium (KGM) and harvested either at conflu­
ent state or after 48h differentiation. Total RNA isolation was performed using the RNeasy mini 
kit [Qiagen] according the manufacturer's instructions. RNA was treated with DNase I while 
bound to the RNeasy column to remove residual traces of genomic DNA [Qiagen]. The integrity 
of the RNA was assessed on an agarose gel, and the concentration and purity were determined 
with a ND-1000 spectrophotometer [Nanodrop].
Reverse transcriptase PCR
Two Mg of total RNA was transcribed into cDNA as described earlier (47). cDNA was amplified with a 
forward primer specific to alternative exon 3' of p63 gene and a reverse primer specific to exon 
4 with a total number of 35 cycles. Primer sequences are in Table 1B. The RT-PCR product was
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electrophoresed in an agarose gel and purified using the Qiaquick gel extraction kit [Qiagen]. This 
cDNA product was sequenced with reverse primer by using a 3730 DNA Analyzer from Applied 
Biosystems.
Quantitative PCR (qPCR)
Quantitative PCR was performed on the iQ-apparatus (MyiQ single-color real-time detection system 
[Biorad]) by using iQ SYBR®Green Supermix [Biorad] according to the manufacturer's protocol.
All primer pairs were designed such that they cover either separate exons or that one is spanning 
an exon-exon boundary. All primers were validated in triplicate by use of serial cDNA dilutions, 
and were confirmed for 100% ± 5% efficiency. Differences in the expression of a gene of interest 
between two samples were calculated by 2“ Ct method (48,49). To normalize the amount of cDNA 
we used three housekeeping genes: beta-Actin (ACTB), hARP (human Acidic ribosomal protein) 
and GAPDH (Glyceraldehyde-3-phosphate dehydrogenase protein). All samples were used in 
duplicate and housekeeping genes were run on the same plate in the iQ-apparatus as the gene of 
interest. Primer sequences are provided in Table 1C.
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Abstract
Heterozygous mutations in the p63 gene are associated with phenotypically related disorders com­
prising ectodermal abnormalities and limb defects. We identified p63 target genes and binding 
sites responsible for ectodermal defects by genome-wide profiling of p63 binding using ChlP- 
seq and expression analysis in human primary keratinocytes from patients with p63 mutations.
In a patient with Split hand/foot malformation type 1 (SHFM1), we identified a novel de novo 
microdeletion that includes a p63 binding site functioning as a c/s-regulatory element to control 
expression of the distally located DLX5/DLX6 genes essential for limb development. Our data 
demonstrate that target genes and regulatory elements detected in this study can serve as pow­
erful tools to identify causative mutations of unresolved ectodermal disorders.
Introduction
Transcription factor p63, a member of the p53 family, is a master regulator of ectodermal devel­
opment. The key function of p63 in ectodermal development is underscored by phenotypic 
features in p63 knockout mice (1,2) and by p63 knock-down zebrafish (3). The developmental 
defects in animal models are reminiscent of those in p63-associated human disorders. Heterozy­
gous mutations in p63 give rise to at least seven dominantly inherited clinical conditions with 
three major characteristics, split hand/foot malformation (SHFM), orofacial clefting (OFC) and 
ectodermal dysplasia (ED) which manifests as defects in skin, hair, teeth, nails and exocrine 
glands (4,5). The most prominent of these disorders is the EEC syndrome which combines all of 
the three phenotypic hallmarks and is almost invariably caused by missense mutations in the 
DNA binding domain of p63 (6). Mutations of p63  have been found in only a minority of other 
disorders, such as in isolated cleft lip/palate (0.1%) and in isolated SHFM4 (10%) (6). In addition, 
there is a large group of ectodermal dysplasia syndromes with phenotypic defects that resemble 
p63-associated syndromes (7). The genetic basis of many of these p63-related conditions, 
referred to as the p63  phenotype network, is presently unknown. There is ample evidence that 
diseases clustered within such phenotype networks are caused by mutations in functionally 
related genes that constitute a gene network (8). Elucidation of functional interactions among 
genes within the p63 gene network, their encoded proteins and regulatory elements which 
control expression of these genes may reveal new candidate genes for genetic disorders from 
the p63 phenotype network.
Identifying the disease-related p63 target genes is an important step to dissect the p63 gene 
network. Previous studies have focused on individual genes based on their known functions, 
expression patterns or related disease phenotypes. Proximal promoter regions of these genes 
were tested for p63 binding and their regulation by p63. These approaches resulted in a number 
of direct target genes of p63, such as Dyston/n (9), KRT14 (10), DLX5 and DLX6 (11). Several 
recent studies aimed to identify targets of p63 on genome wide scales using either expression 
array or Chromatin Immuno-precipitation (ChIP) in combination with DNA array analysis (ChIP- 
on-chip) (12-16). However, due to different cellular systems and techniques, overlap of the 
reported target genes is very small or difficult to determine. Moreover, none of these studies 
used physiological human material, and therefore contribution of the reported target genes to 
the phenotypes of p63-linked patients remains unclear. Furthermore, transcriptional regulation 
of p63 target genes by short- and long-range regulatory elements has not been investigated and 
could be of importance, as regulatory elements have been shown to control spatial-temporal
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expression of developmental genes (17-19). We have therefore integrated genome-wide profil­
ing approaches in a physiologically relevant disease model to resolve the p63 disease-related 
regulatory network.
Skin is prominently affected in p63-associated disorders, and ANp63a, the most common isoform of 
p63, is highly expressed in the basal layer of epidermis that consists mainly of keratinocytes. We 
established human primary keratinocyte cultures (HKCs) from control individuals and patients 
with p63 mutations as our major model system to elucidate p63 disease networks under physi­
ological conditions. Using a combination of genome-wide DNA-binding profiling by ChIP followed 
by deep sequencing (ChlP-seq) and expression array analysis in primary keratinocytes from EEC 
patients, our work is the first systematic study to search for target genes and regulatory elements 
of p63 that are relevant to the pathology of p63-associated and clinically related disorders. We 
show the proof of principle of this approach by identifying the loss of a p63 binding site within a 
cis-regulatory element for DLX5/6 genes essential in limb development in an SHFM1 patient. Our 
approach has yielded a highly informative catalogue of p63 target genes and regulatory elements 
comprising the p63 gene network, which will serve the genetic research community in the identi­
fication of causative mutations in related developmental disorders where the causative genes are 
yet to be identified.
A
wtl
14S
wt2
ChlP-seqChlP-on-chip
■ TSS flanking
■ intragenic
■ <25kb
■ intergenic
Figure 1. Characterization of identified p63 binding sites. A . A screenshot of chromosome 3 using UCSC 
genome browser shows similar DNA-binding profiles from our ChlP-seq analysis of two normal human primary 
keratinocyte cell lines (w t l and wt2). The p63 binding sites analyzed with MACS (20) using P  value 1x10-9 are 
shown in the row 'ChlP-seq', and previously reported p63 binding sites in ChlP-on-chip analysis (14) are shown 
in the row 'ChlP-on-chip'. B. Distribution of the p63-binding site location relative to RefSeq genes. Locations of 
binding sites are divided into: TSS flanking region (5 kb upstream of TSS, first exon and first intron), intragenic 
region (all introns and exons except first), < 25 kb (5-25 kb upstream or 25 kb downstream of last exon), or 
intergenic regions (everything else).
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Results
Genom e-wide p63 binding profile in human primary keratinocytes
To identify direct target genes of p63 in a physiologically relevant cell system, we obtained high­
resolution global binding profiles of p63 from two independent control HKC cell lines established 
from unrelated control individuals (wt1 and wt2) using ChlP-seq.Analysis of the sequenced 
reads in these two profiles using peak recognition algorithm of Model-based Analysis of ChlP- 
Seq (MACS) (20) with a strict P value threshold (10-9) gave a highly significant overlap of 11,425 
peaks (P < 1E-300) (Fig. 1A). We considered the overlapping 11,425 peaks as trustworthy binding 
sites of p63 in HKCs, and continued with further analysis. From a selection of 17 binding sites of 
various peak heights (11-286 reads), we unambiguously validated 16 sites by ChlP followed by 
qPCR analysis (ChlP-qPCR) with two antibodies recognizing different epitopes of the p63 protein 
(Supplementary Table 1, Supplementary Fig. 1), showing that the obtained binding profile is 
highly reliable. Among identified binding sites, 2468 are present in the 5807 binding sites (40%) 
reported previously using the ChlP-on-chip technique in a cervical carcinoma cell line (14). 
Considering different cell types and techniques used in the DNA-binding profiling, the overlap of 
these two studies is remarkable. Moreover, our ChlP-seq analysis appears to be more sensitive 
to detect binding sites and has a higher resolution with a median peak width of 356 bp (Supple­
mentary Table 1) compared to 1467 bp in ChlP-on-chip (14).
More than 1,400 out of 11,425 detected binding sites overlapped with transcription start site (TSS) 
flanking regions between 5kb upstream of the TSS and the end of the first intron of genes, which 
is highly significant compared to random distributions (P < 0.001) (Fig. 1B). ln total, 10,852 genes 
have one or more p63 binding sites within 25 kb up- and down-stream. GO annotation of these 
10,852 genes using DAVlD (21) showed enriched functional categories, mainly in development 
but also in other biological processes such as intracellular signaling cascade, cell adhesion and 
cell death (Supplementary Table 2).
To assess the motifs in the detected binding sites, we applied a de novo m otif prediction pipeline 
(see Material and methods for details). We identified a highly significant motif (Supplementary 
Fig. 2A, Supplementary Table 3), which is similar to the reported p63 and p53 motifs (Supple­
mentary Fig. 2A-E) (14,15,22,23). We combined our previously developed p53scan algorithm (23) 
with the newly identified p63 Positional Weight Matrix (PWM), hereafter referred to as p63scan. 
We compared the p63scan to the previously described motif algorithms p63MH (22) and 
p53scan (23) using a Receiver Operator Curve (ROC). The performance of our p63scan showed 
clearly a higher sensitivity for motif recognition without compromising the specificity (Supple­
mentary Fig. 3F). Using p63scan, we found that 10,659 out of the total 11,425 detected binding 
sites (93%) contain at least one p63 motif (False Discovery Rate, FDR 10%), indicating that the 
identified binding sites in this study are highly specific for direct binding of p63.
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Figure 2. Expression analysis of normal human prim ary keratinocyte lines and patient cell lines carrying EEC 
mutations. A . Expression of each individual core probe sets (Supplementary Fig. 4) shows that expression of 
exon 3' and exons 4-14, which correspond to the ANp63a isoform, were at least 105-fold higher than exons 
1-3 and exon 15. B. Overlap of differentially expressed genes in 3 EEC patient cell lines. Expression analysis of 
5 independent normal human primary keratinocyte lines and 3 patient lines carrying EEC mutations, p.R204W 
p.R304W or p.R279H, was performed on Affymetrix Human Exon 1.0 ST Array, and differentially expressed 
genes were analyzed using ANOVA model (P value < 0.05). ln total, these patients shared 328 genes that were 
differentially expressed when comparing to the control group. C. Out of 328 genes, 155 showed consistent 
expression change more than 1.5-fold. Among them, 89 of the genes were down-regulated, and 66 genes were 
up-regulated in EEC patients.
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Differentially regulated genes in keratinocytes 
from  normal individuals and EEC patients
To identify genes regulated by p63, we studied genome-wide expression profiles by using Affymetrix 
Human Exon 1.0 ST arrays in our disease model, HKCs established from three unrelated EEC syn­
drome patients carrying p.R204W, p.R279H and p.R304 W mutations and five control individuals 
(for clinical details see Supplementary Table 4). This array utilized probe sets representing each 
exon (Supplementary Fig. 4B and 4C), allowing expression analysis of different isoforms. The 
results clearly demonstrated that ANp63a is the only isoform expressed at a high level in HKCs 
(Fig. 2A, Supplementary Fig. 4).
Hierarchical clustering analysis showed that gene expression in five normal control samples was simi­
lar and clustered away from that in three mutants p.R204W, p.R304W and p.R279H (Supplemen­
tary Fig. 5). We applied an ANOVA model using a P value threshold of 0.05 to identify differential­
ly expressed genes. We identified 328 genes that showed significant and consistent changes in 
the same direction among all three EEC patients compared to the controls, henceforth referred 
as differentially expressed genes (Fig. 2B, Supplementary Table 5). Among these genes, 155 
genes (89 up- and 66 down-regulated) showed fold changes higher than 1.5-fold (referred to as 
genes with 1.5-fold change) (Fig. 2C, Supplementary data). With independent RT-qPCR analysis, 
we validated 16 out of 20 genes with the highest differential expression or which were known 
to associate with p63-resembling phenotypes (Supplementary Table 7 and 8). ln GO annotation 
analysis of 328 differentially expressed genes using DAVlD (21), specific development-related GO 
terms such as ectodermal development and morphogenesis of an epithelium were shown to be 
the most significant (Supplementary Table 9).
To identify direct target genes of p63 that are abnormally regulated by mutant p63 in EEC patients, 
we reasoned that genes with changed expression and with p63 binding sites nearby are the best 
candidates of this subgroup of p63 targets. Therefore, we examined how many differentially 
expressed genes in our array analysis are in the vicinity of a p63 binding site. We found that 198 
out of 328 differentially expressed genes (60%) have p63-binding sites in the gene or in the re­
gion within 25 kb of the gene (Table 1, Supplementary data), which represents an enrichment of 
2.3-fold for all genes with binding sites (P = 9.31E-19). Compared to the 10-20% of the regulated 
genes that contain p63 binding sites reported previously (14), our DNA-binding and expression 
analyses were more effective in predicting direct target genes of p63. GO annotation of these 
198 genes revealed similar development-related terms to that from our expression analysis (Sup­
plementary Table 11). We considered these 198 genes as potential direct target genes of p63.
Table 1. Over-representation of genes w ith p63 binding sites among genes w ith significant changes in patient 
keratinocytes.
Gene groups Total genes Genes w ith binding sitesa P  value"
A: With significant changes (P value < 0.05) 328 198 9.31E-19
B: A + Fold change > 1.5 fold 155 92 1.49E-08
C: B + Consistently down-regulated 66 49 3.50E-10
D: B + Consistently up-regulated 89 43 0.0168
a Genes with binding sites are genes that have at least one p63 binding site either in the gene or within 25 kb genomic 
region of the gene. b Hypergeometric analysis.
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average PhastCons conservation average PhastCons conservation
Figure 3. Conservation of p63 binding sites and motifs in vertebrates. The percentage of p63 binding sites 
(y-axis) is shown for decreasing PhastCons conservation scores (x-axis). A . The average PhastCons conserva­
tion score of 100-nucleotide regions centered at the summit of 11,425 p63 binding peaks (peaks 100), of 198 
peaks located near 328 differentially regulated genes in three patients (reg_peaks 100), and of 100,000 regions 
randomly chosen from the whole genome (random 100). B. The average PhastCons conservation score of 10nt 
p63 motifs from 10,675 motifs in the p63 peaks detected in the genome (peaks motifs), from 294 motifs near 
differentially regulated genes (reg_peaks motifs), and from 7,600 motifs found in random genomic regions 
(random motifs). For a color figure see Appendix 2.
Subsequently we investigated the number of genes with binding sites in 155 genes with 1.5- 
fold change including both 89 up- and 66-down regulated genes (Table 1), and asked whether 
differences in p63 motifs can lead to different regulation by p63. By searching for p63 motifs in 
the binding sites near genes, we found that there are typical p63 motifs in binding sites of both 
up- and down-regulated genes and there is no major difference between them (Supplementary 
Fig. 6). These data are consistent with gene activation or repression being determined by other 
co-factors rather than motif recognition by p63.
Evolutionary conservation o f p63 binding sites
As a member of the p53 gene family showing evolutionary divergence in vertebrates, p63 has a
single copy in the vertebrate genomes (24). We therefore assessed the evolutionary conservation 
of the identified p63 binding sites and p63 motifs in these binding sites in vertebrates.
The identified binding sites are significantly more conserved than random sequences of the same 
size. Remarkably, the conservation scores of all binding sites are only slightly lower than that of 
the binding sites near the differentially expressed genes (Fig. 4). This suggests that p63 binding 
sites which are not close to differentially regulated genes are also functionally relevant. Similarly, 
p63 motifs in identified binding sites are more conserved than random expectation and the con­
servation conservation scores from p63 motifs are higher than those from the binding sites (Fig. 
3A and 3B).
Transcriptional regulation by p63 through identified binding sites
To test whether p63 regulates transcription through the identified binding sites, we cloned genomic 
regions containing p63 binding sites near or in the interesting potential targets in a luciferase 
reporter construct and tested their transactivation activities in transient transfection assays in 
Saos2 cells. Out of total 14 tested binding sites, 12 binding sites were shown responsive to p63.
13C
Figure 4. Reporter assays on several identified p63 binding sites in ChIP-seq analysis. Left panel, screenshot 
from UCSC genome browser of p63 binding peaks in two independent human primary keratinocyte cell lines 
(w t l and wt2). The p63 binding sites analyzed with MACS (20) are shown in the row 'ChIP-seq', and previ­
ously reported p63 binding sites in ChIP-on-chip analysis (14) are shown in the row 'ChIP-on-chip'. The asterisk 
represents the binding sites that were tested in transfection assays. Right panel, indicated binding sites of p63 
were cloned in a luciferase reporter construct and tested for their ability to regulate transcription in Saos2 cells. 
For all shown constructs, ANp63a activates transcription through the tested binding sites and EEC mutations in 
ANp63a abolish transactivation. Transactivation through the binding site upstream of the IRF6  gene is shown 
elsewhere (manuscript under review).
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Figure 5. Association of p63 potential target genes w ith diseases. A. Genes identified in ChIP-seq and expres­
sion analyses and the 198 potential direct target genes (overlap, differentially expressed genes with binding 
sites) were examined using OMIM disease base to determine their associated diseases (871, 79 and 55 OMIM 
IDs, respectively) and the affected feature terms in these diseases. The similarity scores from diseases associ­
ated with each group of genes are indicated with dashed lines. Diseases associated with genes identified in 
expression analysis (red) and the potential direct target genes (overlap, purple) showed very similar affected 
features and are not distinguishable from each other. Diseases linked to genes identified from ChIP-seq analysis 
(blue) also showed significantly similar features. The same number of diseases associated with each group of 
genes are randomly selected from the OMIM database. The distribution of the similarity scores from these ran­
domized diseases are calculated and shown in solid lines. B. Over-represented feature descriptions in diseases 
associated with 198 potential target genes. For a color figure see Appendix 2.
Binding sites in or near the FABP7, GPX2, INPP4B, DLX3, DCN-LUM and IRF6 genes are responsive 
to p63, as wild type p63 activates transcription through these binding sites. In contrast, the EEC 
syndrome mutations p.R204W, p.R279H and p.R304W disrupted the transactivation activity (Fig. 
4 and data not shown). These data are consistent with p63 binding to the identified binding sites 
to regulate transcription, and that EEC mutations disrupt DNA-binding of p63 and affect tran­
scriptional regulation.
Association o f p63 gene network with disease phenotypes
Having established a list of p63 target genes, we investigated whether these genes contribute to 
patient phenotypes. An OMIM database search for diseases associated with identified target 
genes identified 32 out of 198 potential direct target genes which have already been associated 
with diseases with similar features to p63-related disorders. Examples include TGFBI/corneal dys­
trophy, IRF6/orofacial clefting, DFNA5/deafness and LAMB3/skin disease (Supplementary data). 
Most of these phenotypic features were seen in all three EEC syndrome patients from whom the 
HKCs were derived. In total, 871 and 79 OMIM disease IDs are associated with genes identified 
from ChIP-seq and expression analyses, respectively, and 55 disease IDs are associated with the 
198 potential direct targets (Fig. 5A, Supplementary data). To assess how these diseases are 
related to each other, we looked for the affected features in these diseases and analyzed their 
similarities (Fig. 5A and 5B).
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AFigure 6. Function analysis of p63 binding sites at SHFM1 locus on chromosome 7. A . A screenshot of UCSC 
genome browser shows the p63 binding profile from two HKC cell lines (w t l and wt2) and several strong bind­
ing sites were identified near DLX5 and DLX6 on chromosome 7. Ultra-high Comparative Genomic Hybridiza­
tion array analysis performed with DNA of a SHFM1 patient showed a chromosomal deletion of 880 kb on 
chromosome 7 (95,390,000-96,270,000, hg18, the orange arrow) which includes DSS1, SLC25A13 and part of 
DYNC1I1 but not DLX5 and DLX6. Breakpoints and 20kb averaged log2 ratios were visualized in the genome 
browser. A previously reported minimal deletion determined by markers D7S527 and D7S1796 (30) is marked 
with a green arrow. B. The p63 binding site SHFM1-BS1 was tested in transient transfection assays. Transcrip­
tion of the luciferase reporter gene was strongly activated by ANp63a through SHFM1-BS1 binding site and the 
activation was abolished by p63 EEC mutations p.R204W, p.R279H and p.R304W (left panel). Activation was 
also abolished when point mutations were introduced into the p63 binding motif in the SHFM1-BS1 binding site 
(right panel). C. SHFM1-BS1 was cloned in reporter constructs carrying the GFP or the LacZ gene to generate 
transgenic zebrafish and mice, respectively. Expression of the GFP gene in zebrafish and the LacZ gene in mice 
showed that SHFM1-BS1 can control gene expression at the apical ectodermal ridge (AER), ear and forebrain, 
The red fluorescence expressed in the muscles in the first zebrafish panel corresponds to the positive control of 
transgenesis.
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The similarity scores (0.27) of feature descriptions associated with differentially expressed genes 
(expression) and with 198 potential direct targets (overlap) are significantly higher than random 
expectation (P < 1E-5) and not distinguishable from each other (Fig. 5A). Interestingly, the simi­
larity score for the features derived from genes mapped by ChIP-seq binding sites is also signifi­
cantly higher than random distribution (P < 1E-5) (Fig. 5A). The significant similarity of features 
extracted from DNA-binding profile suggests that the majority of the identified binding sites are 
relevant to developmental defects. Indeed, the over-represented feature descriptions of these 
diseases are similar to those of EEC syndrome caused by p63 mutations: epithelium, adhesion 
and extracellular matrices (Fig. 5B). Thus, the identified direct target genes of p63 are likely to be 
responsible for the phenotypes of p63-related diseases, the p63 phenotype network.
Regulatory elements to control gene expression in orofacial development
Our ChIP-seq and expression analyses revealed a large difference in the number of regulated genes 
(10,852 versus 328). One explanation for this is that some of the binding sites function as regula­
tory elements to control gene expression in other processes than proliferation and differentia­
tion of adult keratinocytes. We hypothesized that a proportion of the binding sites have a role 
in tissue- or development-specific transcription regulatio n. Therefore, we examined a common 
feature of p63-associated disorders, cleft lip/palate, which could result from abnormal gene 
expression in early development. In the databases of human diseases (POSSUM database) and in 
mouse models (Mouse Genome Informatics, The Jackson lab), 358 genes are found to be associ­
ated in cleft lip/palate (Supplementary data). Among them there are 145 genes with p63 binding 
sites, which represent an enrichment over genes with binding sites in the entire genome (P = 
7.29E-8). Most of these genes (347 out of 358 genes) do not show differential expression change 
in our expression analysis of HKCs (Supplementary data). One notable exception to this is the 
IRF6 gene, for which we showed that p63 activates transcription through a binding site located 
10-kb upstream of the transcription initiation site (manuscript under review). Interestingly, IRF6 
has an important role in skin as well as in palatal development and heterozygous IRF6 muta­
tions are associated with developmental defects in both organ structures (25,26). Hence, our 
data strongly indicate that p63 regulates gene expression at a certain stage of development and 
disruption of expression may lead to developmental defects.
A microdeletion in SHFM1 includes a p63 binding site 
acting as a cis-regulatory element
In addition to orofacial development, we assessed the role of p63 binding sites in human limb ab­
normalities. Split hand/foot malformation (SHFM) is one of the common features in p63-related 
patients. Genes have been associated with SHFM, including p63 on chromosome 3 (SHFM4) (4) 
and Dactylin on chromosome 10 (SHFM3) (27). The SHFM1 locus on chromosome 7 contains 
DLX5 and DLX6 which have been shown as target genes of p63 and are co-expressed with p63 in 
the apical ectodermal ridge (AER) of the developing limbs (11). In mice, simultaneous deletion 
of both genes but not of either gene individually produces limb defects (28). Similarly, deletions 
in SHFM1 patients identified so far invariably contain the DLX5 and DLX6 genes as well as the 
DSS1 gene (29,30). Surprisingly, we identified a novel 880kb chromosomal deletion at 7q21.3 
in a SHFM1 patient comprising DSS1, SLC25A13 and part of DYNC1I1 but leaving the DLX5 and 
DLX6 genes intact (Fig. 6A). Compared with the previously reported minimal chromosomal dele­
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tion (29,30), the only full-length gene in the overlap region is DSS1 which has been shown to be 
expressed in the mesenchyme of late developing limbs, craniofacial primordium and skin but not 
in ectoderm (30). Furthermore, there is no evidence so far that DSS1 has a role in early stages 
of limb development. Therefore, we hypothesized that the p63 binding sites in the identified 
overlapping region are responsible for the limb defects in the SHFM1 patient. To test this hypoth­
esis, we searched for p63 binding sites in this region and identified that binding site SHFM1-BS1 
(Fig. 6A) was highly responsive to p63 in transient transfection assays. Transactivation activity 
was completely abolished by p63 EEC mutations and by mutations in a p63 binding motif in the 
binding site (Fig. 6B). Moreover, we tested the genomic region containing this binding site in 
transgenic reporter assays in zebrafish and mice for their ability to control gene expression as 
regulatory elements. In both organisms, the reporter genes under the control of the chromo­
somal regions containing SHFM1-BS1 showed the same expression pattern in the apical ectoder­
mal ridge (AER), ear and forebrain (Fig. 6C). Reporter expression in AER that directs limb (or fin) 
growth and patterning correlates perfectly with the expression of p63, DLX5 and DLX6 during 
embryonic limb development (11). Taken together, our data clearly demonstrated that p63 
binding sites identified in HKCs can function as regulatory elements to control gene expression in 
embryonic limb development and suggest that disruption of proper gene regulation controlled 
by p63 binding sites leads to developmental defects.
Discussior
In the current study, we investigated the p63 gene network in relation to the p63 phenotype network 
to open new possibilities for elucidation of p63-related diseases. We took two genome-wide ap­
proaches to obtain DNA-binding and expression profiles in a physiologically relevant cell system 
to find target genes and regulatory elements of p63. Our list of target genes not only expands 
the repertoire of p63 target genes, but more importantly, it reveals novel p63 targets that are 
directly relevant to the disease mechanism. The association of many target genes with diseases 
that share similar features to p63-associated syndromes suggests that abnormal regulation of 
these target genes is responsible for the phenotypic defects in p63 patients. Furthermore, we 
showed that the binding sites identified in adult keratinocytes can regulate gene expression as 
regulatory elements during embryonic development, and that loss of these regulatory elements 
can lead to abnormalities in developmental disorders.
Although there is a clear overlap of binding sites in our ChIP-seq and the previous ChIP-on-chip study 
reported by Yang et al. (14), our data from HKCs appears to represent functional p63 binding 
sites more accurately. We have demonstrated that the large majority of the identified binding 
sites (more than 10,000 out of 11,425) contain a p63 motif which is very similar to that defined 
in the ChIP-on-chip analysis (14). This result indicates that p63 is directly bound to most of the 
binding sites in our study and not merely through association with protein complexes. Further­
more, we have observed that conservation of the binding sites (Fig. 3) and similarity of disease 
features associated with genes mapped by these binding sites (Fig. 5) are significantly higher 
than random expectation and they are only slightly lower than that from differentially regulated 
genes. Together, these data indicate that most binding sites obtained in this study are biologically 
functional.
In contrast to the large number of DNA-binding sites, our expression analysis detected only 328 
genes differentially regulated in EEC patients (Fig. 2). There are several non-exclusive possibilities
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to explain this difference. Firstly, the number of differentially regulated genes is small because 
only a subgroup of p63 target genes display commonly altered expression in analyzed EEC pa­
tients. In support of this hypothesis, GO annotation analysis of the differentially regulated genes 
in our study gave very specific functions related to ectodermal development (Supplementary 
Table 9). This is in contrast to general functional terms present in previous expression studies 
with RNAi knock-down of p63 which might affect all p63 target genes (12,14-16). Secondly, map­
ping binding sites to genes is based on the distance between binding sites and genes, which is a 
commonly used method in current studies (14). However, as recent genome studies indicated, 
the regulatory elements such as the ones identified by p63 binding can function over long 
distance, and sometimes even over regions covering other genes (19). Some genes may also be 
regulated by multiple regulatory elements. Lastly, as our analyses (motif search, GO annotation, 
conservation and disease feature similarities) indicate that the majority of the identified p63 
binding sites are functional, these binding sites may represent regulatory elements that function 
in other tissues than adult skin keratinocytes. In agreement with this hypothesis, our reporter 
analysis in animal models showed that binding sites identified in adult keratinocytes control gene 
expression in AER, ear and forebrain during embryonic development (Fig. 6), which suggests 
that p63 binding is partially tissue-independent. Consistently, our data on p53 DNA-binding and 
expression analyses showed that combining differentially expressed genes from several cell types 
increases the overlap with genes mapped by DNA-binding profiling (ML, unpublished results/ 
manuscript in preparation). Recently, tissue-specific binding sites have been reported for p300 
(31), probably because DNA-binding of p300 represents activated transcription. Based on our 
data, we propose that DNA-binding of sequence-specific transcription factors such as p63 (and 
p53) is not sufficient for tissue-specific gene activation. DNA-binding and gene activation might 
be two separate events and p63 might bind to some target sites without activating the corre­
sponding genes. This hypothesis is also supported by our observation that we have not found a 
clear difference in p63 binding motifs in up- versus down-regulated genes (Supplementary Fig.
2 and Fig. 6). Other transcription factors interacting with p63 may be involved in 'decision mak­
ing' in a tissue- and developmental stage-specific pattern. We have not found over-represented 
motifs from other transcription factors in p63 binding sites, suggesting that other transcription 
factors do not bind to the same binding sites as p63. However, co-factors can also play a role in 
transactivation via protein-protein interactions.
Our functional analysis of the p63 binding site, SHFM1-BS1, has shown that this regulatory element 
can control expression of DLX5/6 genes during embryonic limb development and loss of this 
control leads to limb defects in an SHFM1 patient (Fig. 6). Identification of this single regulatory 
element for both DLX5 and DLX6 is consistent with limb defects in mice being observed only 
when both genes are deleted (30). Interestingly, we also observed specific expression in the 
ear controlled by SHFM1-BS1 (Fig. 6). As deafness is also a feature observed in SHFM1 patients 
who have a deletion covering SHFM1-BS1 (32), our data are consistent with SHFM1-BS1 being 
important for inner ear development. These observations establish for the first time that disrup­
tion of a specific long-range regulatory element is the disease mechanism in SHFM1. This disease 
mechanism is novel and represents one of only three disease mechanisms responsible for SHFM 
known to date. Previously, SHFM3 was shown to be associated with partial Dactylin duplications 
(27) and SHFM4 to p63 sequence mutations (4). The mechanisms for SHFM2 (33) and SHFM5 
(34) remain unknown.
Another example of such regulatory elements identified by p63 binding sites is a p63 binding site 
upstream of IRF6 that serves as an enhancer element to regulate expression of IRF6 (manuscript
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under review) (35). One SNP in this binding site has been associated with increased risk of cleft 
lip (35). Additionally, we found that more than 100 genes have been shown to be involved in 
clefting phenotypes in the mouse models whereas no mutations in these genes have been found 
in human diseases (Supplementary data). As many of these genes contain p63 binding sites, 
these sites can be used to screen for mutations or microdeletions that give rise to the clefting 
phenotype. Therefore, we propose that p63 binding sites can also be used as regulatory ele­
ments to study etiology of p63-related developmental disorders.
In summary, we have initiated elucidation of p63 gene networks in relation to p63 disease pheno­
type networks. Our study has provided a comprehensive resource of potentially relevant genes 
as well as regulatory elements in p63-related diseases. We have also shown loss of the regulatory 
element SHFM1-BS1 identified by a p63 binding site as the novel disease mechanism for SHFM1. 
Identified target genes and regulatory elements of p63 can therefore be used as tools to screen 
for mutations and micro-deletions for unresolved p63-related diseases in both fundamental stud­
ies of disease mechanisms and clinical diagnostics.
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Methods
Human primary keratinocyte culture
Skin biopsies from the trunk were taken from EEC patients and healthy volunteers to set up the 
primary keratinocyte culture (36). Keratinocyte cultures in Keratinocyte Growth medium (KGM) was 
previously described (37).
RNA extraction and cDNA synthesis
RNA isolation and cDNA synthesis was performed as described (37). Details can be found in supple­
mentary information.
Affymetrix expression array and data analyses
Quality of the total RNA was tested by using the Agilent 2100 Bioanalyzer (Agilent Technologies). Two 
microgram of total RNA from 48-hour differentiated keratinocytes was used for hybridizations on the 
Gene Chip Human Exon 1.0 ST Array (Affymetrix) according to the manufacturer's protocol (Gene 
Chip® Whole Transcript (WT) Sense Target Labeling Assay Manual). Partek® (Partek® Genomic Suite 
software, version 6.4 Copyright © 2008 Partek Inc., St. Louis, MO, USA) was used for extracting core 
exon expression and core transcript summaries were calculated using the mean intensities of the 
corresponding probe sets. The ANOVA model was applied on the log2 intensities and P values were 
generated for expression differences for the three pair wise comparisons of each of the individual 
patients versus the controls. Detailed data analysis can be found in supplementary information.
ChIP and ChIP-seq
ChIP experiments with HKCs were performed using a modified protocol as described (23) (details 
in supplementary information). ChIP-seq analysis was performed on a Solexa sequencing machine 
(Illumina) as described previously (38). Peak recognition was performed using MACS (20) with 
default settings and a P value threshold of 1E-9, giving 18,133 peaks and 14,963 peaks in ChIP-seq 
tracks of wt1 and wt2, respectively. Peaks were mapped to RefSeq genes, downloaded from the 
UCSC Genome Browser, to determine genomic location. The ChIP-seq data and associated peaks are 
deposited in NCBI's Gene Expression Omnibus (39) and are accessible through GEO Series accession 
number GSEXXXXX (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSEXXXXX).
Motif search
To determine the p63 motif, three motif prediction tools were run on 2285 (20%) randomly selected 
200-bp peak sequences (centered at the peak summit as reported by MACS): MotifSampler (40), 
Weeder (41) and MDmodule (42). The significance of the predicted motifs was determined by scan­
ning the remaining 80% of the peak sequences. P values were calculated using the hypergeometric 
distribution with the Benjamin-Hochberg multiple testing correction. All motifs with a P value <
0.001 and an absolute enrichment of at least > 1.5-fold compared to background were determined 
as significant. Details of motif search can be found in supplementary information. We calculated 
the ROC AUC for all significant motifs and chose the best performing motif based on the ROC AUC 
(Supplementary Table 8). The PWM of this motif was used with the p53scan algorithm and an op­
timal threshold, determined by the maximum f-measure as described previously (23). The p63scan 
algorithm can be dowloaded from http://www.ncmls.nl/bioinfo/p63scan/.
Quantitative PCR
Quantitative PCR primers were designed using Primer 3 (http://frodo.wi.mit.edu). qPCR reactions 
were performed in the 7500 Fast Real Time PCR System apparatus (Applied Biosystems) by using iQ 
SYBRa Green Supermix (BioRad) according to the manufacturer's protocol. Analysis of qPCR data
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and qPCR primers for cDNA and ChIP analyses are described in supplementary information.
Analysis of potential target genes associated with phenotypic 
defects using human and mouse disease bases
The mapping of genes to diseases was taken from the Online Mendelian Inheritance in Man (OMIM) 
disease database (43). To identify overrepresented features, the OMIM free-text disease descriptions 
were first converted into lists of features using text mining (44). Further information can be found in 
supplementary information. Human diseases associated with orofacial clefting were taken from the 
Pictures Of Standard Syndromes and Undiagnosed Malformations (POSSUM) database (45) (POS­
SUM (c) Murdoch Children's Research Institute, Parkville, Victoria, Australia), and mapped to genes 
through their OMIM IDs. Mouse clefting-associated phenotypes and associated genes were taken 
from the Jackson Laboratory's Mouse Genome Database (http://www.informatics.jax.org/) (46).
Evolutionary conservation of binding sites
To assess the evolutionary conservation of the 11,425 sites bound by p63, the phastCons (47) conser­
vation track was downloaded from the UCSC Genome Browser. Conservation based on 44 vertebrate 
genomes was chosen because the p63 gene has 1-1 orthologs throughout the vertebrates. The 
conservation for a region was calculated as the average conservation of each nucleotide therein.
Mapping deletion in a SHFM patient using ultra-high 
Comparative Genomic Hybridization
To detect chromosome 7 aberrations, high resolution NimbleGen HG18 chromosome 7 specific 
385K arrays were used (B3738001-00-01; Roche NimbleGen Systems, Madison, Wisconsin, USA).
The 385K average probe distance was 365bp. DNA labeling, array hybridization, post-hybridization 
washes and scanning were performed according to the manufacturer's instructions (Roche Nimble­
Gen). The acquired images were analyzed using NimbleScan V2.4 extraction software (Roche Nim­
bleGen). For each spot on the array, the log2 Cy3 (patient)/Cy5 (reference pool) ratio was calculated 
using the segMNT algorithm, which also applied an automatic segment detection. A 50x averaging 
window was generated, resulting in 20kb segments for this array. Breakpoints were determined 
with SignalMap V1.9 software (Roche NimbleGen) and 20kb averaged log2 ratios were visualized in 
the UCSC genome browser.
Constructs and transactivation assays
The genomic regions of p63 binding site peaks were cloned into a modified SmaI site in pGL3- 
Enhancer Vector with a firefly luciferase reporter gene followed by a SV40 enhancer. Wild-type and 
mutant p63 are cloned in a pcDNA backbone construct. Detailed information for the constructs is 
described in supplementary information. Transfection and luciferase assays were described previ­
ously (37).
Functional reporter analyses in zebrafish and mice
Human genomic fragments containing the SHFM1-BS1 p63 binding site were cloned into the ZED 
vector and transgenic zebrafish were generated as reported (48). Three or more independent stable 
transgenic lines were generated for each construct. Experimental details can be found in supple­
mentary information. For the generation of transgenic mice, the genomic fragments were trans­
ferred into a vector containing the human minimal beta-globin promoter, lacZ and a SV40 polyade- 
nylation signal. Constructs were linearized and the vector backbone removed prior to microinjection 
into the pronucleus of one-cell mouse embryos. F0 embryos of 11.5-13 dpc stages were harvested 
and stained for lacZ activity.
139
Chapter 7
Reference List
1. Yang, A, Schweitzer, R, Sun, D, Kaghad, M, Walker, N, Bronson, RT, Tabin, C, Sharpe, A, Caput, D, 
Crum, C, and McKeon, F.(1999) p63 is essential for regenerative proliferation in limb, craniofacial 
and epithelial development. Nature 398: 714-718.
2. Mills, AA, Zheng, B, Wang, XJ, Vogel, H, Roop, DR, and Bradley, A.(1999) p63 is a p53 homologue 
required for limb and epidermal morphogenesis. Nature 398: 708-713.
3. Bakkers, J, Hild, M, Kramer, C, Furutani-Seiki, M, and Hammerschmidt, M.(2002) Zebrafish Delt- 
aNp63 is a direct target of Bmp signaling and encodes a transcriptional repressor blocking neural 
specification in the ventral ectoderm. Dev Cell 2: 617-627.
4. Celli, J, Duijf, P, Hamel, BC, Bamshad, M, Kramer, B, Smits, AP, Newbury-Ecob, R, Hennekam, RC, 
Van, BG, van, HA, Woods, CG, van Essen, AJ, de, WR, Vriend, G, Haber, DA, Yang, A, McKeon, F, 
Brunner, HG, and van, BH.(1999) Heterozygous germline mutations in the p53 homolog p63 are 
the cause of EEC syndrome. Cell 99: 143-153.
5. Rinne, T, Brunner, HG, and van, BH.(2007) p63-associated disorders. Cell Cycle 6: 262-268.
6. Rinne, T, Hamel, B, Bokhoven, H, and Brunner, HG.(2006) Pattern of p63 mutations and their 
phenotypes-update. Am J Med Genet A 140: 1396-1406.
7. Priolo, M.(2009) Ectodermal dysplasias: an overview and update of clinical and molecular-func­
tional mechanisms. Am J Med Genet A 149A: 2003-2013.
8. Oti, M, Huynen, MA, and Brunner, HG.(2008) Phenome connections. Trends Genet 24: 103-106.
9. Osada, M, Nagakawa, Y, Park, HL, Yamashita, K, Wu, G, Kim, MS, Fomenkov, A, Trink, B, and Sid- 
ransky, D.(2005) p63-specific activation of the BPAG-1e promoter. J Invest Dermatol 125: 52-60.
10. Romano, RA, Birkaya, B, and Sinha, S.(2007) A functional enhancer of keratin14 is a direct tran­
scriptional target of deltaNp63. J Invest Dermatol 127: 1175-1186.
11. Lo Iacono, N, Mantero, S, Chiarelli, A, Garcia, E, Mills, AA, Morasso, MI, Costanzo, A, Levi, G, 
Guerrini, L, and Merlo, GR.(2008) Regulation of Dlx5 and Dlx6 gene expression by p63 is involved 
in EEC and SHFM congenital limb defects. Development 135: 1377-1388.
12. Carroll, DK, Carroll, JS, Leong, CO, Cheng, F, Brown, M, Mills, AA, Brugge, JS, and Ellisen,
LW.(2006) p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol 
8: 551-561.
13. Vigano, MA, Lamartine, J, Testoni, B, Merico, D, Alotto, D, Castagnoli, C, Robert, A, Candi, E, 
Melino, G, Gidrol, X, and Mantovani, R.(2006) New p63 targets in keratinocytes identified by a 
genome-wide approach. EMBO J  25: 5105-5116.
14. Yang, A, Zhu, Z, Kapranov, P, McKeon, F, Church, GM, Gingeras, TR, and Struhl, K.(2006) Rela­
tionships between p63 binding, DNA sequence, transcription activity, and biological function in 
human cells. Mol Cell 24: 593-602.
15. Della Gatta, G, Bansal, M, mbesi-Impiombato, A, Antonini, D, Missero, C, and di, BD.(2008) Direct 
targets of the TRP63 transcription factor revealed by a combination of gene expression profiling 
and reverse engineering. Genome Res 18: 939-948.
16. Trink, B, Osada, M, Ratovitski, E, and Sidransky, D.(2007) p63 transcriptional regulation of epithe­
lial integrity and cancer. Cell Cycle 6: 240-245.
17. Alonso, ME, Pernaute, B, Crespo, M, Gomez-Skarmeta, J, and Manzanares, M.(2008) Understand­
ing the regulatory genome. Int J Dev Biol 53:1367-1378.
18. Lettice, LA, Heaney, SJ, Purdie, LA, Li, L, de, BP, Oostra, BA, Goode, D, Elgar, G, Hill, RE, and de, 
GE.(2003) A long-range Shh enhancer regulates expression in the developing limb and fin and is 
associated with preaxial polydactyly. Hum Mol Genet 12: 1725-1735.
19. Kleinjan, DA and van, H, V.(2005) Long-range control of gene expression: emerging mechanisms 
and disruption in disease. Am J Hum Genet 76: 8-32.
14C
20. Zhang, Y, Liu, T, Meyer, CA, Eeckhoute, J, Johnson, DS, Bernstein, BE, Nussbaum, C, Myers, RM, 
Brown, M, Li, W, and Liu, XS.(2008) Model-based analysis of ChIP-Seq (MACS). Genome Biol9: 
R137.
21. Dennis, G, Jr., Sherman, BT, Hosack, DA, Yang, J, Gao, W, Lane, HC, and Lempicki, RA.(2003) 
DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: 3­
22. Perez, CA, Ott, J, Mays, DJ, and Pietenpol, JA.(2007) p63 consensus DNA-binding site: identifica­
tion, analysis and application into a p63MH algorithm. Oncogene 26: 7363-7370.
23. Smeenk, L, van Heeringen, SJ, Koeppel, M, van Driel, MA, Bartels, SJ, Akkers, RC, Denissov, S, 
Stunnenberg, HG, and Lohrum, M.(2008) Characterization of genome-wide p53-binding sites 
upon stress response. Nucleic Acids Res 36: 3639-3654.
24. Saccone, C, Caggese, C, D'Erchia, AM, Lanave, C, Oliva, M, and Pesole, G.(2003) Molecular clock 
and gene function. J Mol Evol 57Suppl 1: S277-S285.
25. Ingraham, CR, Kinoshita, A, Kondo, S, Yang, B, Sajan, S, Trout, KJ, Malik, MI, Dunnwald, M, Goudy, 
SL, Lovett, M, Murray, JC, and Schutte, BC.(2006) Abnormal skin, limb and craniofacial morpho­
genesis in mice deficient for interferon regulatory factor 6 (Irf6). Nat Genet 38: 1335-1340.
26. Kondo, S, Schutte, BC, Richardson, RJ, Bjork, BC, Knight, AS, Watanabe, Y, Howard, E, de Lima, RL, 
ack-Hirsch, S, Sander, A, Donald-McGinn, DM, Zackai, EH, Lammer, EJ, Aylsworth, AS, Ardinger, 
HH, Lidral, AC, Pober, BR, Moreno, L, rcos-Burgos, M, Valencia, C, Houdayer, C, Bahuau, M, 
Moretti-Ferreira, D, Richieri-Costa, A, Dixon, MJ, and Murray, JC.(2002) Mutations in IRF6 cause 
Van der Woude and popliteal pterygium syndromes. Nat Genet 32: 285-289.
27. de Mollerat, X, Gurrieri, F, Morgan, CT, Sangiorgi, E, Everman, DB, Gaspari, P, Amiel, J, Bamshad, 
MJ, Lyle, R, Blouin, JL, Allanson, JE, Le, MB, Wilson, M, Braverman, NE, Radhakrishna, U, ozier- 
Blanchet, C, Abbott, A, Elghouzzi, V, Antonarakis, S, Stevenson, RE, Munnich, A, Neri, G, and 
Schwartz, CE.(2003) A genomic rearrangement resulting in a tandem duplication is associated 
with split hand-split foot malformation 3 (SHFM3) at 10q24. Hum Mol Genet 12: 1959-1971.
28. Robledo, RF, Rajan, L, Li, X, and Lufkin, T.(2002) The Dlx5 and Dlx6 homeobox genes are essential 
for craniofacial, axial, and appendicular skeletal development. Genes Dev 16: 1089-1101.
29. Scherer, SW, Poorkaj, P, Allen, T, Kim, J, Geshuri, D, Nunes, M, Soder, S, Stephens, K, Pagon, RA, 
and Patton, MA.(1994) Fine mapping of the autosomal dominant split hand/split foot locus on 
chromosome 7, band q21.3-q22.1. Am J Hum Genet 55: 12-20.
30. Crackower, MA, Scherer, SW, Rommens, JM, Hui, CC, Poorkaj, P, Soder, S, Cobben, JM, Hudgins,
L, Evans, JP, and Tsui, LC.(1996) Characterization of the split hand/split foot malformation locus 
SHFM1 at 7q21.3-q22.1 and analysis of a candidate gene for its expression during limb develop­
ment. Hum Mol Genet 5: 571-579.
31. Visel, A, Blow, MJ, Li, Z, Zhang, T, Akiyama, JA, Holt, A, Plajzer-Frick, I, Shoukry, M, Wright, C, 
Chen, F, Afzal, V, Ren, B, Rubin, EM, and Pennacchio, LA.(2009) ChIP-seq accurately predicts 
tissue-specific activity of enhancers. Nature 457: 854-858.
32. Tackels-Horne, D, Toburen, A, Sangiorgi, E, Gurrieri, F, de, M, X, Fischetto, R, Causio, F, Clarkson,
K, Stevenson, RE, and Schwartz, CE.(2001) Split hand/split foot malformation with hearing loss: 
first report of families linked to the SHFM1 locus in 7q21. Clin Genet 59: 28-36.
33. Faiyaz ul, HM, Uhlhaas, S, Knapp, M, Schuler, H, Friedl, W, Ahmad, M, and Propping, P.(1993) 
Mapping of the gene for X-chromosomal split-hand/split-foot anomaly to Xq26-q26.1. Hum 
Genet 91: 17-19.
34. Del Campo, M, Jones, MC, Veraksa, AN, Curry, CJ, Jones, KL, Mascarello, JT, li-Kahn-Catts, Z, 
Drumheller, T, and McGinnis, W.(1999) Monodactylous limbs and abnormal genitalia are associ­
ated with hemizygosity for the human 2q31 region that includes the HOXD cluster. Am J Hum 
Genet 65: 104-110.
141
Chapter 7
35. Rahimov, F, Marazita, ML, Visel, A, Cooper, ME, Hitchler, MJ, Rubini, M, Domann, FE, Govil, M, 
Christensen, K, Bille, C, Melbye, M, Jugessur, A, Lie, RT, Wilcox, AJ, Fitzpatrick, DR, Green, ED, 
Mossey, PA, Little, J, Steegers-Theunissen, RP, Pennacchio, LA, Schutte, BC, and Murray, JC.(2008) 
Disruption of an AP-2alpha binding site in an IRF6 enhancer is associated with cleft lip. Nat Genet 
40: 1341-1347.
36. Rheinwald, JG and Green, H.(1977) Epidermal growth factor and the multiplication of cultured 
human epidermal keratinocytes. Nature 265: 421-424.
37. Rinne, T, Clements, SE, Lamme, E, Duijf, PH, Bolat, E, Meijer, R, Scheffer, H, Rosser, E, Tan, TY, 
McGrath, JA, Schalkwijk, J, Brunner, HG, Zhou, H, and van, BH.(2008) A novel translation re­
initiation mechanism for the p63 gene revealed by amino-terminal truncating mutations in Rapp- 
Hodgkin/Hay-Wells-like syndromes. Hum Mol Genet 17: 1968-1977.
38. Nielsen, R, Pedersen, TA, Hagenbeek, D, Moulos, P, Siersbaek, R, Megens, E, Denissov, S, 
Borgesen, M, Francoijs, KJ, Mandrup, S, and Stunnenberg, HG.(2008) Genome-wide profiling 
of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct 
metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes Dev 22: 
2953-2967.
39. Edgar, R, Domrachev, M, and Lash, AE.(2002) Gene Expression Omnibus: NCBI gene expression 
and hybridization array data repository. Nucleic Acids Res 30: 207-210.
40. Thijs, G, Lescot, M, Marchal, K, Rombauts, S, De, MB, Rouze, P, and Moreau, Y.(2001) A higher­
order background model improves the detection of promoter regulatory elements by Gibbs 
sampling. Bioinformatics 17: 1113-1122.
41. Pavesi, G, Mereghetti, P, Mauri, G, and Pesole, G.(2004) Weeder Web: discovery of transcription 
factor binding sites in a set of sequences from co-regulated genes. Nucleic Acids Res 32: W199- 
W203.
42. Liu, XS, Brutlag, DL, and Liu, JS.(2002) An algorithm for finding protein-DNA binding sites with 
applications to chromatin-immunoprecipitation microarray experiments. Nat Biotechnol 20: 835­
839.
43. McKusick, VA.(2007) Mendelian Inheritance in Man and its online version, OMIM. Am J Hum 
Genet 80: 588-604.
44. van Driel, MA and Brunner, HG.(2006) Bioinformatics methods for identifying candidate disease 
genes. Hum Genomics 2: 429-432.
45. Bankier, A and Keith, CG.(1989) POSSUM: the microcomputer laser-videodisk syndrome informa­
tion system. Ophthalmic Paediatr Genet 10: 51-52.
46. Blake, JA, Bult, CJ, Eppig, JT, Kadin, JA, and Richardson, JE.(2009) The Mouse Genome Database 
genotypes::phenotypes. Nucleic Acids Res 37: D712-D719.
47. Siepel, A, Bejerano, G, Pedersen, JS, Hinrichs, AS, Hou, M, Rosenbloom, K, Clawson, H, Spieth, J, 
Hillier, LW, Richards, S, Weinstock, GM, Wilson, RK, Gibbs, RA, Kent, WJ, Miller, W, and Haussler,
D.(2005) Evolutionary conserved elements in vertebrate, insect, worm, and yeast genomes. 
Genome Res 15: 1034-1050.
48. Bessa, J, Tena, JJ, de, lC-M, Fernandez-Minan, A, Naranjo, S, Fernandez, A, Montoliu, L, Akalin, A, 
Lenhard, B, Casares, F, and Gomez-Skarmeta, JL.(2009) Zebrafish enhancer detection (ZED) vec­
tor: A new tool to facilitate transgenesis and the functional analysis of cis-regulatory regions in 
zebrafish. Dev Dyn 238: 2409-2417.
142
143
Chapter Z
144
Supplementary information
Clinical information. Patient 1 is a 29-year old woman who has dry depigmented skin and white hair. 
She has dystrophic nails and absence of enamel in her teeth. She is anhydrotic and has dacro- 
cystitis secondary to nasolacrimal obstruction. She also has finger syndactyly and cleft lip and 
palate. She has a small dysplastic ears and hearing impairment, double sided hydronephrosis and 
narrowed urethra. She has frequent urinary tract infections. Mammary or nipple abnormalities 
have not been observed. This patient has been reported to carry a heterozygous p.R204W muta­
tion in the DNA binding domain of the p63 gene (1). Patient 2 is a 51-year old man, who has a 
very dry and scaling skin in the nose, back of the hands and back. He has a history of a malignant 
spinocellular epithelioma in his left hand that has been exposed to the sun because of his daily 
work outside. He has dental Prosthesis, his nails are hypoplastic and he has no hair. He has cor­
rected dacryostenosis and cleft lip and palate. He has syndactyly and ectrodactyly in his hands 
and feet. He also has several genito-urinary abnormalities with a double pelvo-uretieric system 
on the right side, narrowed bladder neck, prostate hypertrophy and hypospadias. He has normal 
sweating and normal nipples. This patient has been reported to carry a heterozygous p.R279H 
mutation in the DNA binding domain of the p63 gene (2). Patient 3 is a 59-year old man who 
has a dry, but normally sweating skin. His hair is coarse and he has dental prostheses. He has a 
corrected dycryostenosis on the left side and absence of Meibomian glands in the eye. He has 
ectrodactyly and syndactyly in one hand and foot. And he also has left sided cleft lip and palate. 
He suffers from hearing impairment because of narrowed ear canal and has a history of chronic 
otitis media and a cholesteatoma. He also has several genito-urinary abnormalities: hypospadias, 
prostate hypoplasia, chronic interstitial nephritis and a broadened urethra. This patient has been 
reported to carry a heterozygous p.R304W mutation in the DNA binding domain of the p63 gene
(3). Patient 4 has typical phenotype of Split hand/foot malformation (SHFM) and his DNA was 
used in CGH deletion analysis.
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Supplementary figure 1. ChIP-qPCR analysis of p63 binding in human prim ary keratinocytes using two dif­
ferent p63 antibodies 4A4 (pan-p63) and H129 a-specific). Specific binding of p63 to the tested binding sites 
was observed, including to binding sites at p21WAF/CIP19 and DST which served as positive controls, but not to the 
negative controls myoglobin exon 2 (myo) and a no-gene region (chr11).
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Supplementary figure 2. Comparison of the p63 motif identified in this work w ith previously reported motifs.
A . The p63 motif was identified by de novo motif analysis where 20% of the binding sites were used to predict 
motifs, and the resulting motifs were scored for significance using the remaining 80% of the binding sites 
compared to a set of background sequences. Based on a previously developed p53scan algorithm (4) with this 
newly identified p63 Positional Weight Matrix (PWM), p63scan was developed. B-C. The motifs from p63MH 
(5) and p53scan (4), respectively. D. The performance of p63scan using the de novo identified motif shows far 
superior sensitivity compared to previously reported p63MH without compromising specificity. Compared to 
p53scan, which was deduced from p53 binding sites, p63scan performs also slightly better on p63 binding sites. 
The 80% of the binding site sequences not used for motif prediction, as well as a set of background sequences 
were scanned using the different algorithms. For each individual threshold the fraction of binding sites with a 
motif (sensitivity) as well as the fraction of background sequences with a motif (1 -  specificity) were calculated. 
For a color figure see Appendix 2.
B
D
Supplementary figure 3. Expression of early differentiation markers and in differentiated prim ary keratino- 
cytes. At 48-hour differentiation, the early differentiation markers, Keratin-1 and Keratin-10, were expressed 
similar in human primary keratinocytes established with a control individual and patients with p.R204W and 
p.R304W p63 mutations.
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Supplementary figure 4. Expression analysis of individual exons of the p63  gene. A . Diagram of the genomic 
structure of the p63 gene indicates the most commonly mentioned six isoforms of p63: two alternative promot­
ers give rise to N-terminal TA- and AN- isoforms; three different splicing routes give rise to a, p, and y C-terminal 
isoforms. B. A screenshot of genomic structure of the p63 gene shows the core probe sets used to determine 
exon expression with their corresponding exons. C. The core probe sets and their corresponding exons are 
shown in a zoomed-in screenshot at the 3' end of the p63 gene. For a color figure see Appendix 2.
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Supplementary figure 5. Hierarchical clustering of the expression array samples. Hierarchical clustering analy­
sis showed that expression pattern of five normal control samples were very similar to each other even though 
they were established from 5 different individuals. The replicates of each mutant clustered together and the 
expression pattern of p.R204W and p.R304W mutant cell lines were more similar to each other compared to 
the mutant p.R279H.
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Supplementary figure 6. M otif analysis of binding sites near up- or down regulated genes. The de novo motif 
search on binding sites of up- or down-regulated genes revealed no major difference in p63 motifs. For a color 
figure see Appendix 2.
148
Supplementary Table 1. Validation by ChIP-qPCR of detected binding sites in ChIP-seq analysis.
ChlP-seq ChlP-qPCRd
Chromosomal locdtion Potentidl tdrget gene
Peak height Peak size w t l wt2
chr7:92496280-92496740 CDK6 286 460 6/6 4/4
chrl:208055902-208056327 IRF6 229 426 6/6 4/4
ch r6 :l23 l357 l0 -l2 3 l35865 FABP7 l08 l56 4/4 4/4
chr20:29662l60-29662520 ID1 93 2 7 l 4/4 4/4
chrl0:859288l3-85929380 PCDH21 87 568 4/4
chrll:749525l7-749528l5 mop6 78 299 4/4
chrl2:97562240-97562680 IKIP 53 4 4 l 4/4
chr4:l43545950-l43546350 INPP4b 49 400 6/6 4/4
chrll:l24889250-l24889900 FEZ1 42 330 4/4
chrl:l0057464-l00578 l6 UBE4B 24 353 2/6
chr4:l43942600-l43942970 INPP4b 22 3 7 l 4/8
chr7:l07365280-l07365520 LAMB1 l7 3 4 l 2/2 4/4
chr6:7586275-7586580 BMP6 l6 306 4/4 4/4
chr6:7827300-7827500 BMP6 l5 3 4 l 4/4
chr3:l87276440-l87276780 ETV5 l5 2 0 l 4/6
c h r ll:7 5 ll2 3 8 0 -7 5 ll2 7 2 0 MAP6 l2 330 3/6
chr7:l07444700-l07444900 LAMB1 l l 2 0 l 6/6
a Independent ChIP-qPCR experiments were performed multiple times to validate detected binding sites. As 
the first step, 17 binding sites with the peak heights ranging from 286 to 11 were chosen to be validated in 
one of the primary cell lines w t l, and binding of p63 was unambiguously confirmed at 16 out of 17 tested 
binding sites. Seven out of these 16 confirmed peaks were then again tested in the other cell line wt2 in which 
p63 binding was also confirmed. The numbers below wt1 and wt2 indicate the number of experiments in 
which p63 binding was detected out of the total number of independent experiments. For example, 6/6 
means that p63 binding was shown in all 6 independent ChIP-qPCR experiments. Whether binding detected or 
not is based on the fold enrichment of 3 over an internal negative control regions to which p63 does not bind, 
myoglobin exon 2 region or a no-gene region on chromosome 11.
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Supplementary Table 2. GO annotationsa of genes mapped by binding sites in ChIP-seq analysis.
GO No. Term No. of genes P Valueb
G0:0032502 Developmental process 1356 4.95E-39
G0:0048856 Anatomical structure development 900 2.10E-25
G0:0007275 Multicellular organismal development 958 5.91E-23
G0:0030154 Cell differentiation 774 6.01E-23
G0:0048869 Cellular developmental process 774 6.01E-23
G0:0065007 Biological regulation 1939 3.12E-22
G0:0048519 Negative regulation of biological process 527 1.84E-21
G0:0048731 System development 735 2.03E-20
G0:0048523 Negative regulation of cellular process 501 1.49E-19
G0:0050789 Regulation of biological process 1754 1.70E-18
G0:0016043 Cellular component organization and biogenesis 1062 3.97E-18
G0:0007242 Intracellular signaling cascade 626 1.33E-17
G0:0022610 Biological adhesion 356 4.57E-17
G0:0007155 Cell adhesion 356 4.57E-17
G0:0009987 Cellular process 4314 1.16E-15
G0:0048468 Cell development 522 1.62E-14
G0:0050794 Regulation of cellular process 1612 4.97E-14
G0:0048513 0rgan development 530 1.86E-13
G0:0048518 Positive regulation of biological process 466 1.99E-13
G0:0016265 Death 365 2.81E-13
G0:0008219 Cell death 365 2.81E-13
G0:0043687 Post-translational protein modification 615 2.92E-13
G0:0043412 Biopolymer modification 740 3.34E-13
G0:0006464 Protein modification process 713 5.77E-13
G0:0012501 Programmed cell death 345 2.32E-12
G0:0006915 Apoptosis 342 2.87E-12
G0:0051179 Localization 1174 3.88E-12
G0:0048522 Positive regulation of cellular process 417 1.29E-11
G0:0009653 Anatomical structure morphogenesis 466 1.74E-11
G0:0007167 Enzyme linked receptor protein signaling pathway 144 9.99E-11
a Gene Ontology (GO) annotations was performed using DAVID Bioinformatics Resources (NIH) on 10,852 
genes which 11,425 detected binding sites were mapped to.
b P value was obtained using default setting in DAVID without multiple testing. GO terms which have P values 
below 1 0 10 are shown in the table.
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Supplementary Table 3. Significant motifs predicted using a de novo motif prediction pipeline (MotifSampler, 
W eeder and MDmodule).
Motif Consensus Program
Motif
family
P value 
(genomic)
Enrichment
(genomic)
P value 
(random)
Enrichment
(random)
ROC
AUC
Max f- 
measure
nrCAwGyynnnrCwTGyn MotifSampler p63 0.00E+000 88.7 0.00E+000 39 0.97 0.919
nnrCAwGynnnnrCwTGynn MotifSampler p63 0.00E+000 96.6 0.00E+000 50.4 0.97 0.916
rCAwGynnnnrCwTGy MotifSampler p63 0.00E+000 61.3 0.00E+000 25.1 0.97 0.911
CAwGyn nnnrCwT G MotifSampler p63 0.00E+000 24.7 0.00E+000 11.9 0.95 0.882
nACATGTnnnAACwTGyn MDmodule p63 0.00E+000 129.6 0.00E+000 91 0.95 0.884
ACAwGTynnrACwT MDmodule p63 0.00E+000 16.5 0.00E+000 10.5 0.89 0.82
nGynnrnrCwTG MotifSampler p63 0.00E+000 2.8 0.00E+000 2.2 0.89 0.824
rnrCATGyyn MotifSampler p63 0.00E+000 2.6 0.00E+000 1.6 0.8 0.754
TGTCCAGACATG Weeder p63 0.00E+000 31.3 0.00E+000 14.4 0.8 0.743
CAwGTynnrACw MDmodule p63 0.00E+000 9.5 0.00E+000 6.2 0.79 0.735
GACATGCC Weeder p63 0.00E+000 4.5 0.00E+000 2.8 0.78 0.733
GGCATGTC Weeder p63 0.00E+000 4.4 0.00E+000 2.7 0.78 0.732
GACATGTC Weeder p63 0.00E+000 5.6 0.00E+000 3.3 0.77 0.738
GGCATGTT Weeder p63 0.00E+000 4.5 0.00E+000 2.8 0.76 0.741
nnAACATGCC Weeder p63 0.00E+000 5.4 0.00E+000 4.9 0.76 0.73
TAGGCATGTC Weeder p63 0.00E+000 5.4 5.04E-297 4.6 0.75 0.72
GACATGTCCA Weeder p63 8.44E-253 6.2 1.56E-133 3.6 0.74 0.714
TnGACATGTC Weeder p63 0.00E+000 6.8 1.36E-184 4.2 0.74 0.721
ACATGC Weeder p63 0.00E+000 3.1 0.00E+000 2.4 0.74 0.735
GCATGT Weeder p63 0.00E+000 3.1 0.00E+000 2.4 0.74 0.735
AACATGTC Weeder p63 0.00E+000 4.3 0.00E+000 3 0.73 0.708
CAGACATGTC Weeder p63 1.47E-293 5.8 1.31E-184 3.9 0.73 0.708
ACATGT Weeder p63 0.00E+000 3.1 0.00E+000 2.4 0.72 0.703
GACATG Weeder p63 0.00E+000 1.8 0.00E+000 1.7 0.7 0.709
CATGTC Weeder p63 0.00E+000 1.8 0.00E+000 1.7 0.7 0.714
AACAwGTy MDmodule p63 0.00E+000 3 0.00E+000 2.6 0.65 0.673
wGTTsAnACw MDmodule p63 1.40E-226 2 1.41E-221 1.9 0.6 0.67
CACACACACACACACACA MDmodule
CA-
repeat
2.46E-009 1.6 0.00E+000 490 0.6 0.669
CTTGTynTTwCT MDmodule
Fos/
API
2.47E-057 1.8 1.93E-154 2.8 0.57 0.669
nAmTGAGTnAnT MDmodule 1.21E-068 1.7 1.30E-069 1.8 0.57 N/A
AnTnACwAGTTCATAC MDmodule - 4.47E-018 7 4 .14E-023 9 0.55 0.668
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Supplementary Table 4. General EEC phenotype and the clinical picture of the three EEC patients 
used in this study.
General EEC Patient 1 Patient 2 Patient 3
phenotype p.R204W p.R279H p.R304W
ED
Skin 34% + + +
Hair 66% + +? +
Teeth 53% + + +
Nails 52% + + -/+
Mammary glands 14% -
Sweat gland 11% + _? _?
Lacrimal ducts 57% + + +
Corneal dystrophy ? ? + +
Limbs
Ectrodactyly 68% _ + +
Syndactyly 43% + + +
Orofacial clefting
Cleft lip 39% + + +
Cleft palate 40% + + +
Others
Hearing impairment 7% + +
Genito-urinary problems 15% + + +
Supplementary Table 5. Gene w ith significant expression changes (P < 0.05) in EEC patient keratinocytes
(Appendix 1)
Supplem entary Table 6. Genes w ith consistent significant expression changes more than 1.5-fold (Available 
on request)
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Supplementary Table 7. Validation by qPCR of down-regulated genes obtained in expression array.
Array data Validation by qPCR
Genes Mutations
Fold change Fold change Std
GPX2 p.R279H 28.0 37.7 ±6.1
p.R204W 25.5 35.3 ±8.3
p.R304W 12.9 8.2 ±0.4
ADH7 p.R279H 16.4 21.2 ±2.8
p.R204W 15.7 30.7 ±6.7
p.R304W 13.9 33.4 ±9.2
GBP6 p.R279H 15.1 9.6 ±1.8
p.R204W 9.1 7.6 ±3.0
p.R304W 8.2 2.6 ±0.6
CTSK p.R279H 10.0 9.5 ±3.3
p.R204W 9.9 9.3 ±0.1
p.R304W 5.4 5.0 ±0.7
ETV4 p.R279H 3.4 2.2 ±1.2
p.R204W 3.0 2.1 ±0.1
p.R304W 3.4 2.9 ±0.8
FZD7 p.R279H 3.3 9.8 ±2.9
p.R204W 2.0 3.0 ±0.1
p.R304W 1.6 3.3 ±0.0
PORC p.R279H 2.8 3.2 ±0.9
p.R204W 2.2 2.7 ±0.0
p.R304W 2.5 5.4 0.2
CLDN7 p.R279H 1.9 3.3 ±1.0
p.R204W 1.7 1.2 ±0.0
p.R304W 1.7 1.7 ±0.0
IRF6 p.R279H 2.3 2.5 ±0.4
p.R204W 1.6 1.1 ±0.2
p.R304W 1.7 1.1 ±0.3
CTNNB p.R279H 1.9 1.7 ±0.4
p.R204W 1.6 2.5 ±0.6
p.R304W 1.4 3.5 ±0.0
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Supplementary Table 8. Validation by qPCR of up-regulated genes obtained in expression array.
Genes Mutations
Array data
Fold change
Validation by qPCR
Fold change Std
FABP7 p.R279H 651.1 87.1 ±10.2
p.R204W 76.5 82.7 ±2.3
p.R304W 15.4 90.6 ±1.9
METTL7A p.R279H 5.7 2.4 ±0.6
p.R204W 5.2 4.5 ±0.1
p.R304W 7.6 3.7 ±0.2
LAMB1 p.R279H 2.8 2.0 ±0.6
p.R204W 3.0 2.7 ±0.0
p.R304W 3.0 3.0 ±0.0
ID2 p.R279H 2.9 2.0 ±0.6
p.R204W 2.5 1.2 ±0.0
p.R304W 3.0 2.6 ±0.2
ID3 p.R279H 2.4 1.1 ±0.4
p.R204W 1.9 2.0 ±0.0
p.R304W 2.1 2.0 ±0.2
TGFBI p.R279H 1.9 1.9 ±0.3
p.R204W 1.8 2.7 ±0.5
p.R304W 1.8 1.9 ±0.5
Supplementary Table 9. GO annotationsa of d ifferentially regulated genes in EEC keratinocytes.
GO No. GO term No. of genes P Valueb
G0:0007398 Ectoderm development 11 1.69E-04
G0:0002009 Morphogenesis of an epithelium 8 2.99E-04
G0:0048513 Organ development 35 0.001116
G0:0008544 Epidermis development 9 0.002003
G0:0009888 Tissue development 14 0.002224
G0:0048856 Anatomical structure development 50 0.002496
G0:0007275 Multicellular organismal development 53 0.003247
G0:0048731 System development 42 0.00393
G0:0032502 Developmental process 68 0.004811
a Gene Ontology (GO) annotations was performed using DAVID Bioinformatics Resources (NIH) on 328 
significantly changed genes obtained from expression array analysis of five normal controls and three EEC 
patient keratinocyte cell lines.
b P value was obtained using default setting in DAVID without multiple testing. GO terms which have P values 
below 0.005 are shown in the table.
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Supplem entary Table 10. D ifferentially regulated genes w ith  binding sites nearby
(Available on request)
Supplementary Table 11. GO annotationsa of potential direct target genes.
GO No. GO term No. of genes P  Valueb
G0:0007398 Ectoderm development 8 7.46E-04
G0:0048513 Organ development 25 8.19E-04
G0:0048731 System development 30 0.001697
G0:0048856 Anatomical structure development 34 0.002583
G0:0008544 Epidermis development 7 0.002711
G0:0065007 Biological regulation 66 0.003765
G0:0000074 Regulation of progression through cell cycle 13 0.003961
G0:0051726 Regulation of cell cycle 13 0.004144
G0:0050789 Regulation of biological process 61 0.004171
G0:0048523 Negative regulation of cellu lar process 21 0.004463
G0:0009888 Tissue development 10 0.004693
a Gene Ontology (GO) annotations was performed using DAVID Bioinformatics Resources (NIH) 
on 194 genes which have changed expression in EEC keratinocytes and a p63 binding sites near 
by. b P  value was obtained using default setting in DAVID w ithout multiple testing. GO term s 
which have P  values below 0.005 are shown in the table.
Supplem entary Table 12. Association of diseases w ith genes identified in ChIP and expression analysis
(Available on request)
Supplem entary Table 13. Genes are known to be involved in cleft lip/palate
(Available on request)
Supplem entary Table 14. Prim ers for expression, ChIP analyses and for cloning
(Available on request)
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Supplementary methods
RNA extraction and cDNA synthesis
HKCs at 48-hour of differentiation were used for the expression analysis. At this stage, differentia­
tion markers were similarly expressed in normal and patient keratinocytes (Supplementary Fig.
3). Total RNA was transcribed into cDNA according to the manufacturer's protocol using reverse 
transcriptase PCR iScriptTM cDNA Synthesis kit (BioRad). The cDNA produced was purified by 
NucleoSpin Extract II kit (Macherey-Nagel, Bioke) according to the manufacturer's protocol.
Affymetrix expression array data analyses
The Affymetrix cel-files were first imported into Affymetrix Expression Console version 1.1 where 
control probes were extracted using the default RMA algorithm in order to perform quality 
analysis checks. The Area Under the Curve (AUC) of the Receiver Operator Characteristic was 
calculated using the positive and negative control probes. All arrays had AUC score above the 
empirically defined threshold of 0.85 indicating a good separation of the positive controls from 
the negative controls. Subsequently the cell-files were imported into Partek® (Partek® Genomic 
Suite software, version 6.4 Copyright © 2008 Partek Inc., St. Louis, MO, USA) where only core 
exons were extracted and normalized using the RMA algorithm with GC background correction. 
Core transcript summaries were calculated using the mean intensities of the corresponding 
probe sets. The correspondence of the replicate samples was confirmed using Principle Com­
ponent Analysis (PCA) and Pearson correlation analysis. After grouping the samples by patients, 
an analysis of variance components indicated that the scan date of the samples had a relatively 
large influence on the expression profiles and this was thus used as an additional factor in the 
Anova model. Applying the Anova model on the log2 intensities we generated P values for ex­
pression differences for the three pair wise comparisons of each of the individual patients versus 
the controls. In each comparison we selected only genes with P values < 0.05 and an expression 
difference of at least 1.5 fold. From the intersection of these three lists we then selected only the 
genes that showed the same direction of expression change in all three patients compared to the 
controls.
ChIP and ChIP-seq
Human primary keratinocytes under proliferating condition where p63 is expressed at the high­
est level were used for ChIP and ChIP-seq analysis. were crosslinked with 1% formaldehyde for 
10 minutes and chromatin was collected as described (6). Chromatin was sonicated using a 
Bioruptor sonicator (Diagenode) for 2 times of 8 minutes at high power, 30s ON, 30s OFF. p63 
antibodies 4A4 (Abcam) and H129 (Santa Cruz) were used in targeted ChIP experiments and 
4A4 was used for ChIP-seq analysis. ChIP experiments were performed as previously described
(4). ChIP-seq analysis was performed on a Solexa sequencing machine (Illumina) as described 
previously (7). All 32-bp sequence reads were uniquely mapped to the human genome NCBI 
build 36.1 (hg18) with zero or one mismatch using ELAND (Illumina), resulting in 3.2 and 6 mil­
lion unique reads for the two analyzed samples, wt1 and wt2 respectively. Peak recognition was 
performed using algorithm of Model-based Analysis of ChIP-seq (8) with default settings and a P 
value threshold of 1e-9, giving 18,133 peaks and 14,963 peaks in ChIP-seq tracks of wt1 and wt2, 
respectively. Peaks were mapped to RefSeq genes, downloaded from the UCSC Genome Browser, 
to determine genomic location.
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Motif search
To determine the p63 motif, three motif prediction tools were run on 2285 (20%) randomly selected 
200-bp peak sequences (centered at the peak summit as reported by MACS (8)): MotifSampler 
(9), Weeder (10) and MDmodule (11). We used the 'large' analysis setting for Weeder. MDmod- 
ule and MotifSampler were each used to predict 10 motifs for each of widths between 6 and
20. The significance of the predicted motifs was determined by scanning the remaining 80% of 
the peak sequences and two different backgrounds: a set of random genomic sequences with 
a similar genomic distribution as the peak sequences and a set of random sequences gener­
ated according to a first order Markov model, match in the dinucleotide frequency of the peak 
sequences. P values were calculated using the hypergeometric distribution with the Benjamin­
Hochberg multiple testing correction. All motifs with a P value < 0.001 and an absolute enrich­
ment of at least > 1.5-fold compared to both backgrounds were determined as significant. We 
calculated the ROC AUC for all significant motifs and chose the best performing motif based on 
the ROC AUC (See Supplementary Table 8 for the results). The PWM of this motif was used with 
the p53scan algorithm and an optimal threshold, determined by the maximum f-measure as 
described previously (4). The p63scan algorithm can be downloaded from http://www.ncmls.nl/ 
bioinfo/p53scan/.
Gene Ontology Annotations
Gene Ontology analysis on differentially expressed genes and genes mapped by the nearby binding 
sites was performed using DAVID Bioinformatics Resources (NIH) (http://david.abcc.ncifcrf.gov).
P value was obtained using default setting in DAVID without multiple testing.
Quantitative PCR analysis
For qPCR of cDNA analysis, two or three exon-spanning primer sets for each validated gene were 
used (Supplementary Table 14). Human acidic ribosomal protein (hARP) and Hypoxanthine 
phosphoribosyl-transferase (HPRT) were used as a housekeeping gene to normalize the amount 
of cDNA. Differences in expression of each gene between wild-type and mutant samples (relative 
expression) were calculated by 2“ Ct method (12,13). The relative expression was averaged using 
two or three primer sets. For qPCR of ChIP analysis, one primer set was used for each tested 
binding region (Supplementary Table 14) and ChIP efficiency of certain binding sites was calcu­
lated using percentage of ChIPped DNA against input chromatin.
Analysis of potential target genes associated with phenotypic 
defects using OMIM disease bases
The mapping of genes to diseases was taken from the Online Mendelian Inheritance in Man (OMIM) 
disease database (14,15), downloaded on December 19th, 2008. In order to identify over­
represented features, the OMIM free-text disease descriptions were first converted into lists 
of features using text mining (16). Disease features were defined using the "Anatomy" (A) and 
"Pathological Conditions, Signs and Symptoms" (C23) categories of the 2008 version of the 
Medical Subject Headings hierarchical controlled vocabulary (http://www.nlm.nih.gov/mesh/ 
meshhome.html), excluding the broad first-level terms. Feature overrepresentation in the target 
gene-associated diseases relative to the full OMIM database was determined using the hyper­
geometric enrichment test as implemented in the R statistical software package (http://www.r- 
project.org/).
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Constructs for transactivation assays
The genomic regions of p63 binding site peaks were amplified by PCR with gateway cloning primers 
and cloned into a modified Smal site in pGL3-Enhancer Vector which contains a firefly luciferase 
reporter gene followed by a SV40 enhancer (4). The cloning primers are described in Supplemen­
tary Table 14. Point mutations were introduced into p63-binding motifs of SHFM1-BS1 to gener­
ate mutant p63 binding sites, where the essential cytosine and guanine bases were mutated to 
adenosine. The ANp63a wild-type (Mm_pcDNA_ANp63a) expression plasmid has been de­
scribed previously (17). Point mutations were introduced into this plasmid to generate p.R204W, 
p.R279H and p.R304W mutations.
Functional reporter analyses in zebrafish and mice
Human genomic fragments containing the SHFM1-BS1, SHFM1-BS2 and SHFM1-BS3 p63-bound 
regions were amplified with the primers: SHFM1-BS1F: 5'-CCACAGGGCCTTGTAAACG-3'; SHFM1- 
BS1R: 5'-GATAAAACTCTACCTTGTGGGAGGC-3'; SHFM1-BS2F: 5'-CCAGCCTAAAAATTCACAGTGC-3'; 
SHFM1-BS2R: 5'-GGTGGAAGCAGCCTGAGG-3'; SHFM1-BS3F: 5'-CGGTGACGGAGTGATACCC-3'; 
SHFM1-BS3R: 5'-GAGACTATCCCCCTTCAGGTAGG-3'. The PCR fragments, of 1780, 1682 and 573 
pb, respectively, were subcloned in PCR8/GW/TOPO vector and then transferred, through recom­
bination using Gateway technology, to the ZED destination vector for zebrafish transgenesis (18). 
This vector contains the Xenopus Cardiac actin promoter driving DsRed as a positive control for 
transgenesis. To generate the zebrafish transgenic embryos, we used Tol2 transposon/transpos- 
ase method (19) with minor modifications. 1nl was injected in the cell of 1 cell stage embryos 
containing 50ng/ul of transposase mRNA, 40ng/ul of phenol/chloroform purified ZED constructs 
and 0.05% phenol red. Three or more independent stable transgenic lines were generated for 
each construct. For the generation of transgenic mice, the genomic fragments were transferred 
into a vector containing the human minimal beta-globin promoter, lacZ and a SV40 polyadenyla- 
tion signal. Constructs were linearized and the vector backbone removed prior to microinjec­
tion into the pronucleus of one-cell mouse embryos. F0 embryos of 11.5-13 dpc stages were 
harvested and stained for lacZ activity.
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8,1 p63 isoform specificity in development and disease
During the past few years important new insight has been obtained into some general molecular and 
cellular functions of p63. However, understanding of the function of all different p63 isoforms 
and their putative reciprocal interactions has turned out to be a complex but necessary following 
step. Currently it is known that TA- and AN isoforms are regulated by different promoters, their 
expression pattern is different, and they can both activate and repress the transcription of target 
genes (1-6). ANp63 isoforms are prominently expressed in different epithelial (basal, squamous 
and myoepithelium) tissues e.g. in epidermal, oral, exocrine glands, thymus and urogenital tis­
sues (5,7-9). Within the epithelia, ANp63 isoforms can be found in the basal cell layer (10). All 
but one study (11) show that ANp63a is the first p63 isoform that is expressed in the develop­
ing epidermis (1,11-13). This isoform is most likely important for maintenance of the stem cell 
identity and proliferation (1,11-13). Although TA isoforms have been detected in the epidermis 
as well, their role in epidermal development appears to be less important than that of the ANp63 
isoforms as demonstrated by the lack of ectodermal defects in TA-deficient mice (1,14). We and 
others have demonstrated that AEC and Rapp Hodgkin syndrome mutations are clustered in the 
ANp63a isoforms (TA2, SAM and TI domains) (Chapters 5 and 6), which supports the important 
role of ANp63a in epithelia and ectodermal development.
In contrast to the ANp63a isoforms, specific expression and function of the TAp63 isoforms have 
not been linked to tissues that are generally affected in p63-associated syndromes. Accordingly, 
only one TA-specific mutation has been identified so far. This mutation was found in an isolated 
SHFM patient carrying a missense mutation in the TA-domain (15). Although TA isoforms have 
been detected in the developing epidermis in a few studies, they appear not to be involved in 
the maintenance process of the epidermal stem cells. However, TA isoforms may have a role 
in the terminal epidermal differentiation by counteracting the activities of ANp63a isoforms 
(1,13,14,16). TAp63 isoforms have been detected in heart, testis, kidney, brain and thymus, 
but the relevance for patients with a p63 mutation has not been established (5,10,17,18). High 
expression of TAp63a isoforms has also been detected in primordial germ cells (oocytes), where 
they have a role in DNA damage response (8,14). More studies suggest a role for TA isoforms to 
be involved in pre-apoptotic pathways, e.g. during neural development (18-21). However, no as­
sociation has been detected between p63-syndrome patients and neuronal defects, suggesting a 
less important role for the TAp63 in the p63-linked disease pathogenesis. Whether the apoptosis- 
induction of TAp63 isoforms may contribute to other developmental processes remains to be 
established by careful analysis of the TA-specific knockout.
Our published (Chapter 6 and 7) and unpublished studies on the epidermis of p63-linked patients 
confirm the expression pattern of ANp63a: ANp63a is clearly expressed in the basal and supra­
basal cells, but absent in the upper epidermal layers. We were not able to detect TAp63 isoforms 
in skin biopsies, nor in the cultured human keratinocytes. However, we detected a new isoform 
AAN63a that lacks the first 26 amino acids of the amino-terminal TA2 domain in cultured human 
keratinocytes (Chapter 6). The AANp63a variant is expressed in human control keratinocytes at 
low levels, whereas its expression is similar to the longer ANp63a in cells derived from AEC/RHS 
patients carrying amino-terminal truncating mutations. Possibly, this new isoform is a natural 
dominant-negative regulator of ANp63a, suggesting that maintaining the balance between 
ANp63a and AANp63a is crucial for the proper ectodermal development.
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8 ,2  Clinical variability in p63-associated syndromes and 
disease mechanism
The production of clinically different phenotypes from mutations in the same gene, clinical hetero­
geneity, is the rule rather than the exception in medical genetics. The clinical variability is most 
pronounced when mutations affect different functional domains or when they have opposite 
functional consequences. For instance, loss-of-function mutations in the tyrosine kinase domain 
in the Fibroblast growth fa cto r 2 (FGFR2) cause Lacrimo-auriculo-dento-digital syndrome (LADD, 
OMIM 149730) (22), whereas gain-of-function mutations in immunoglobulin domains in the 
same gene lead to syndromic forms of craniosynostosis (22-25). Similarly, mutations that are 
clustered in different p63 functional domains have probably different effects on the protein 
leading to different functional consequences and finally to different clinical phenotypes. Results 
from our own research and that of other groups have revealed that EEC and ADULT syndrome 
mutations cluster in the DNA binding domain and AEC/RHS mutations either in the TA2, SAM or 
TI domain. For other p63-related diseases a specific domain clustering has not yet clearly been 
established. This is probably because the number of patients in other p63-related disorders is 
small, or because they cluster in specific yet unrecognized functional sites in p63 protein.
Clinical variability has not only been described between the various p63-linked syndromes, but also 
among patients within one p63-linked disease. In EEC syndrome, for example more than 80 
percent of the patients carrying the p.R304 mutation have orofacial clefting, but hardly any of the 
patients carrying the p.R227 have cleft lip/palate (CLP). Moreover, I have demonstrated that clini­
cal variability is even apparent for phenotypes that are caused by the same mutation (Chapter 3). 
Analysis of the five EEC hot spot mutations revealed that all symptoms display variable expressiv­
ity within patients, which is not restricted to EEC syndrome but is seen for all p63-associated con­
ditions. What are the molecular determinants of clinical variability? For the range of syndrome- 
specific mutations, it is possible that the various mutations exhibit overlapping as well as specific 
functional consequences. In case of p63 DNA binding domain (DBD) mutations this could be easily 
brought about by their disruptive effect towards different sets of target genes. Of the five EEC 
syndrome hotspot mutations only p.R279 and p.R304 are directly involved in the DNA binding, 
and possibly lead to loss of binding (26). Other frequently mutated residues (p.R204, p.R227 and 
p.R280) do not directly interact with DNA and can have gain of binding probabilities on more 
restricted set of target gene regulatory elements. This is in agreement with results from our 
unpublished transactivation studies, which demonstrate that hotspot mutants behave differently 
towards expression of target genes. Secondly, it is also possible that p63-mutant proteins have ac­
quired new functions (gain-of-functions effects of the mutations) that exhibit mutation-specificity. 
Indeed, such gain-of-function activities have been demonstrated for analogous hot-spot muta­
tions in p53 (27,28). Thirdly, genetic background in patients, single nucleotide polymorphisms 
(SNP) in modifier genes might play a role leading to different functional consequence and differ­
ent clinical phenotype, even for identical primary p63 mutations. Expression profiling studies on 
patients of different p63-associated syndromes and on several patients of each hot spot mutation 
would give insight to the genes that are affected due to each syndrome and each single mutation, 
and would provide information for explaining the variable clinical appearance.
The underlying disease mechanism in p63-associated syndromes is not yet fully understood. A p63 
gene containing deletion of the long arm of chromosome 3 did not lead to a phenotype similar 
to p63 (29,30), and heterozygous p63 KO-mice did not present a phenotype that resembles p63 
syndrome (16,31).
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Table 1. Possible disease mechanisms in p63-associated diseases.
Dose-dependent
Loss of function Haplo-insufficiency Gain of function Dominant negative
Hereditary Recessive conditions Dominant conditions Dominant conditions Dominant conditions
Evidence
against
- Del 3q27-qter* and 
3q27.3q29* did not lead to 
p63-syndrome phenotype 
(29,30)
- p63~-+ KO did not lead to 
p63-syndrome phenotype
- No p63-deletions found in 
p63-patients (unpublished)
- Stop mutations in p63 do 
not cause NMD
Evidence
for
- ADULT syndrome - p63 molecule active 
mutation p.R298 as tetramer 
(Chapter 4)
- Shown for AEC/RHS
- Protein p63 gene 5' 
accumulation may mutations (Chapter 6) 
indicate that protein
is longer active 
(unpublished)
- p53 hotspot 
mutants show gain of 
function (27,28)
* Includes p 63  gene
These observations provide evidence against dose-dependent mechanism such as haploinsuf- 
ficiency to cause p63-associated disease phenotype. Moreover, absence of p63 gene deletions 
in patients having p63-disease phenotype (our own unpublished data) supports the data that 
p63-disease is not caused by a missing p63 allele. (Table 1)
Mechanisms for dominantly inherited conditions such as gain-of-function or dominant-negative are 
both putative molecular disease mechanisms for p63-linked diseases. Mutant p63 protein might 
have gained a stronger binding to a regulatory element or to a co-factor involved in transcription 
regulation leading to enhanced target gene regulation. It is possible that the mutant p63 protein 
has acquired a completely new function because of new protein conformation i.e. binding to a 
completely new target gene promoter activating its transcription. Conversely, the mutant allele 
may have gotten novel dominant-negative activities acting antagonistically against the wild type 
p63 inhibiting its ordinary function. An example of this are the 5' end mutations in the p63 gene 
in AEC/RHS syndromes leading to AANp63a protein (Chapter 6) that exhibits dominant-negative 
effects towards the wild type ANp63a protein. Dominant negative mutations can be loss of bind­
ing mutations that do not allow the p63-tetramer complex to bind to its target region. It is un­
known how many mutant protein molecules are needed to inactivate the p63-tetramer function. 
Our preliminary unpublished results suggest, however, that in some cases dominant negative 
effect might also be partial. Thus, mutants show reduced binding to regulatory region, but they
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do not fully inactivate the functional wild-type protein (unpublished results). Whether this is 
relevant to the target gene activation has to be investigated in further studies. The p63 patho­
genesis seems to be very complex, and it is possible that p63 phenotypes are caused by different 
mechanisms on molecular level depending on the disease causing mutation (Table 1).
8 ,3  Resolving p63 regulatory networks 
and target genes in ED
To resolve the role of p63 in ectodermal development and pathogenesis in different p63-related 
syndromes, a better picture should be established of regulatory networks, up- and downstream 
of p63. p63 is a master regulator of a wide variety of cellular processes: epithelial development 
and maintenance, morphogenesis, proliferation, senescence, tissue regeneration, cell adhesion 
and cell death (2,6,32-35). Several genome-wide binding and expression studies have been con­
ducted to discover new p63 target genes (6,34,36-38). Unfortunately, the number of potential 
target genes is so high that it is impossible to select those genes that might contribute to the 
p63-phenotype. In addition, the overlap of the genes resulted from these studies is difficult to 
determine because of different cellular systems and techniques.
The approach we have chosen to find p63 regulatory networks and disrupted target genes in differ­
ent p63-syndromes is a combination of genome-wide DNA binding profiling by using Chromatin- 
immuno-precipitation-sequencing (ChIP-seq) and gene expression studies in human primary 
keratinocytes (Chapter 7). This is the first study that uses a relevant human tissue type for the 
p63 regulatory element search and combines it with functional data originating from expression 
profiling in patients keratinocytes. Our genome-wide DNA binding assay resulted in more than
11,000 p63 binding sites in the human genome, which is about two times as much as Yang et 
al detected in cervical carcinoma cell line (6). About 2,500 of these binding sites are the same 
amongst that study and ours. A high percentage (93%) of the binding sites we detected contain 
at least one p63 binding motif, which suggests for a direct binding. Our data propose that p63 
can be bound to its specific consensus sequence without having transcriptional consequences. 
Thus, the binding of p63 to its binding site is not necessarily specific for a certain tissue or 
developmental stage. Other factors are needed in addition to p63 to regulate the initiation of 
the transcription of a target gene. Presumably these co-factors are specific for tissue type and 
developmental stage, and are the "final regulators" of p63 dependent transcription. However, 
p63 regulated transcription can also be controlled by post-translational modifications either by 
inhibiting the DNA binding itself or the binding of the co-factors.
p63 signaling pathways and target genes in EEC syndrome
So far p63 has been linked to several signaling pathways and processes that are important in ecto­
dermal development, such as BMP, Notch, FGF and NFkB (12,39-41). It is likely that p63 as a tran­
scription factor does not have its own 'p63 signaling pathway', but instead is a crucial regulating 
molecule that is involved in a cross-talk between other pathways involved in the epithelial de­
velopment and limb morphogenesis. Components of some above mentioned signaling pathways 
have been reported to be affected either in p63-deficient mice or in vitro p63-mutant cellular 
studies (1,12,13,39,40,42-44). Yet the involvement of major signaling pathways (BMP, Notch, FGF, 
NFkB) in human p63-linked patients and/or p63-disease pathogenesis in vivo has not been dem-
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onstrated. In our expression profiling study with EEC syndrome patients' keratinocytes (Chapter 
7) we have not detected differential expression for any of the genes that have been reported 
in the above mentioned pathways. This can be due to tissue and development-specific gene or 
isoform expression of p63 or other co-factors, or because keratinocytes cannot fully represent 
all in vivo features of skin pathology. However, members of important developmental pathways 
without a known association to p63 during ectodermal development such as Transforming 
growth factor P (TGFP) and Wingless type P-catenin (WNT) signaling pathways were abnormally 
regulated in EEC syndrome patients in comparison to controls (unpublished data). From the 
TGFP-pathway we detected Transforming growth facto r 6 induced protein (TGF6I), Inhibitor o f 
DNA binding 3 (ID3) and Decorin (DCN). From the WNT signaling pathway we detected Frizzled-7 
and Kremen-2. Some of these genes have already been associated with human diseases, such as 
TGFBI and Decorin mutations in corneal dystrophies that are also frequently seen in p63-associ- 
ated disorders (45,45,46). The association into TGFP- and WNT-signaling indicates that p63 can 
regulate genes from these pathways in epidermal cells.
In our expression profiling assay performed on EEC patients keratinocytes 328 genes were signifi­
cantly abnormally expressed compared to controls (P < 0.05) (Chapter 7). Sixty percent (198 out 
of 328) of these abnormally expressed genes in EEC patients have a p63 binding site in a gene 
or within a 25 kb distance of the gene. These 198 genes could be direct target genes of p63 with 
possible link to p63 disease phenotype. Other abnormally expressed genes without a consensus 
binding motif within a 25 kb distance of the corresponding gene are most likely not direct targets 
of p63, but probably influenced through the direct targets of p63. However, some of the abnor­
mally expressed genes can also be regulated by long-distance p63 binding site, which are more 
difficult to link to the gene(s) which are under its control.
A significant number of the 198 genes that we presume to be direct targets of p63 and abnormally 
expressed in EEC patients were developmental genes (Chapter 7). Interestingly genes involved 
in ectodermal, organ, system and tissue development, as well as genes involved in regulation 
of biological process and cell cycle were significantly enriched in our comparative expression 
analyses (P < 0.005). Also the established OMIM disease database search of the 198 putative 
p63 direct target genes resulted in 32 known disease genes (55 disease descriptions). It is very 
convincing that those 32 genes are involved in p63 disease phenotype, since the features associ­
ated with those genes are linked to epithelium and adhesion, and are often seen in p63 patients 
(ED, orofacial clefting, hearing impairment and corneal dystrophy) and genodermatoses. For 
example, mutations in Forkhead box E1 (FOXE1) have been linked to Bamforth-Lazarus syndrome 
(OMIM 241850), which combines ectodermal dysplasia (ED) with cleft/lip palate (CLP) syndrome. 
Mutations in Distal-less hom eobox3 (DLx3) have been linked to Tricho-osseous syndrome (OMIM 
190320) which is an ED syndrome with bone anomalies (47,48). In addition, mutations in 
Collagen XVII type Alpha-1 (COL17A1) and Laminin 63 (LAMB3) have been linked to Herlitz and/ 
or non-Herlitz type of junctional epidermolysis bullosa (OMIM 226700 and OMIM 226650) and 
Keratin 2 to Ichtyosis bullosa of Siemens (OMIM 146800).
Interestingly, we detected a strong p63 binding with a p63 consensus sequence in the known Split 
hand/foot malformation 1 (SHFM1) locus on chromosome 7. This region contains two interest­
ing candidate genes Distal-less homeobox 5 (DLX5) and Distal-less homeobox 6 (DLX6) that did 
not show changed gene expression in keratinocytes of EEC patients. However, our data suggest 
that this locus is a regulatory region that controls expression of DLX5 and DLX6 genes during limb 
development (Chapter 7). Why then was the expression of these genes not changed in the EEC
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patients although they all exhibit limb abnormalities? One obvious explanation is that keratino- 
cytes may not be the appropriate cell type for investigating expression of genes that are impor­
tant in limb development. The intrinsic implication of this explanation is that p63 can be bound 
to its regulatory regions although it does not necessarily have transcriptional consequences. To 
trigger the transcription initiation of a target gene some probably tissue-specific p63 binding co­
factors are needed. This is an intriguing and new observation for p63, which demonstrates that 
expression of wild-type transcription factor that is bound to its regulatory element of a target 
gene might not be active in transcription.
Genetic modifiers involved in p63 pathogenesis
While expression studies like the one we have conducted can provide important information about 
genes that are disrupted by p63 hotspot mutations, it will not resolve the clinical variation that 
has been observed within one hotspot group. This is the variation that can also be seen within a 
family that is carrying the same single pathogenic mutation. The reason why some family mem­
bers are more severely affected than others can be due to environmental factors as well as ge­
netic modifiers, such as polymorphism and rare DNA variant elsewhere in the genome i.e. in p63 
regulatory elements or in the p63 gene itself. Genetic modifiers of the p63 phenotype have not 
been detected yet. To obtain sufficient genetic power to uncover genetic modifiers large numbers 
of patients carrying the same mutation are needed. Unfortunately, most of the p63-linked diseas­
es are sporadic cases or have been found in small families and are therefore not suitable for this 
kind of study. However, a large Limb mammary syndrome family with 27 affected patients could 
represent a useful family for testing the modifier of orofacial clefting, since only six patients of 22 
are known to have cleft palate/bifid uvula (49). Also other genes that are known to be involved 
in non-syndromic orofacial clefting are interesting candidate genes for modifying effects, such as 
MSX1, Poliovirus receptor like 1 (PVRL1) and SUMO1 (50-52). A very interesting candidate is also 
Interferon regulatory factor 6 (IRF6). SNPs in this gene and recently also in the regulatory region 
of this gene have been linked to the non-syndromic type of orofacial clefting (53,54). Moreover, 
studies from our group show that this regulatory region is also a direct binding region for p63, and 
that the IRF6 gene is down-regulated in the EEC patients that all have cleft lip and palate (Chapter
7 and manuscript under review). In the near future we will test the putative association between 
this SNP in the IRF6 binding region and our EEC patients with orofacial clefting, to determine 
whether this IRF6 regulatory SNP is associated with increased risk for CLP in p63-syndromes.
Target genes involved in protein degradation
The identification of direct or indirect target genes by expression profiling is not only important to gain 
insight into ED pathology, but may also shed light onto disease-linked metabolic/biochemical abnor­
malities observed in patients. In our unpublished studies on primary keratinocyte cultures derived 
from p63-linked patients we have detected a clear accumulation of ANp63a protein in EEC syn­
drome patients carrying p.R204W, p.R279H, p.R280C and p.R304W mutations. The ANp63a protein 
accumulation appears to be specific for DNA binding domain mutations observed in EEC syndrome 
patients, since it has not been detected in keratinocyte cultures derived from LMS (p.G76W), RHS 
(p.Q11X) or AEC (p.T533P and p.G561D) syndrome patients (Fig. 1 and data not shown). It is cur­
rently not clear why only mutations in the DNA binding domain give rise to p63 protein accumula­
tion and whether this phenomenon is significant to the pathology of EEC syndrome.
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Figure 1. ANp63a protein accumulation in EEC patients. ANp63a protein accumulates in human primary 
keratinocytes derived from four different EEC patients (arrows), but not in control keratinocytes or keratinocytes 
derived from a patient carrying AEC syndrome mutation
P63 family member p53 is known to be degraded by ubiquitin-mediated proteasomal degradation. 
Mouse double minute 2 homolog (MDM2) is included in the degradation process and forms an 
auto-regulatory negative feedback loop with p53 (Fig. 2A) (55,56). Possibly, a similar negative 
feedback loop exists for p63, which could be involved in p63 accumulation in EEC syndrome 
patients. Indeed, our unpublished data revealed that ANp63a protein levels in keratinocytes 
from EEC patients accumulate, whereas the mRNA levels remained similar to controls, suggest­
ing the involvement of post-translational regulation of the ANp63a protein levels. Therefore, we 
hypothesized that the mutated DNA binding domain of p63 in EEC syndrome patients might not 
be able to bind and regulate (activate or inactivate) a candidate ubiquitin ligase and therefore 
its own degradation might be prevented causing p63 accumulation in the cells derived from the 
EEC patients (Fig. 2B). Recently, E3 ubiquitin ligase NEDD4-like ubiquitin protein ligase ITCH and 
ubiquitin-like protein SUMO-1 have been shown to directly interact with p63a and regulate p63a 
protein stability (57-60,60,61,61). We have established that expression of ITCH and SUMO1 is 
not decreased in keratinocytes of EEC syndrome patients (unpublished data). This result is in 
agreement with the observation that EEC mutations in the p63 DBD are not involved in the direct 
binding of ITCH or SUMO-1 (60,61).
Interestingly, our expression array experiment (Chapter 7) showed significant up-regulation (P < 0.05, 
fold change approximately +1.3) of U-box type E4 ubiquitin ligase UFD2a (alias UBE4B) in all three 
EEC patients in comparison to controls. UFD2a has been shown to interact and stabilize ANp63a 
preventing its ubiquination (59). Therefore the increased amount of UFD2a mRNA in EEC patients 
could increase the steady state level and half-life of ANp63a in EEC syndrome keratinocytes. In 
this model, wild type p63 would repress UFD2a expression and the mutated p63 would increase 
the UFD2a transcription by decreased binding to the UFD2a promoter region (Fig. 2C). In agree­
ment with this model, we have found a p63 regulatory region in the close vicinity of the UFD2a 
gene suggesting that it is a putative direct ANp63a target (Chapter 7). To investigate whether 
UFD2a up-regulation is involved in ANp63a protein accumulation in EEC patients has to be investi­
gated by protein-protein interaction and protein accumulation studies in patient derived material.
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Candidate genes and regulatory elements 
fo r p63-related disorders
The combination of expression, regulatory element and binding data reveal also several genes that 
might be good candidate genes for ectodermal dysplasia syndromes for which the disease gene 
is unknown. Multiple genes, whose family members have been linked to ED are differentially 
regulated in our EEC patients, indicating a potential role for these genes in ectodermal develop­
ment. For instance keratins are generally involved in epidermal development and linked in to 
different skin diseases and ED, and Claudin genes that are involved in formation of tight junc­
tions between epithelial cells might be good candidate genes for ED. Keratin 33B, Claudin 7 and 
Claudin 8 show significantly changed expression in EEC patients. Homeobox genes are involved in 
embryonic segmental patterning and mutations in several homeobox genes are known to cause 
ED. We identified HOXB7 to be significantly changed in EEC patients. Furthermore, the Lumican 
gene is significantly down-regulated in EEC patients. Lumican is similar to Decorin, which is a 
proteoglycan interacting with collagen and mutated in corneal dystrophy. Similar to TGFBI, dis­
rupted expression of Lumican could contribute to the corneal defects that are frequently seen in 
EEC syndrome. In addition, Lumican appears to be a promising target gene to be involved in the 
development of corneal diseases.
Several ED syndromes have a known genomic localization, but a disease gene or genetic cause has 
not yet been discovered. Two different studies on consanguineous Pakistani families show hair 
and nail ED (62,63). Linkage studies revealed homozygous regions in one family on chromosome 
12p11.1-q21.1 with a multipoint LOD score of 3 and in another on chromosome 17p12-q21.2 
with a multipoint LOD score of 4.4. Both areas are large (37.9 Mb and 21.8 Mb, respectively) 
containing keratin gene clusters, however no mutations in the tested keratin genes were found. 
Interestingly, our expression list has eight genes that locate in the chromosome 12 region and six 
genes in the chromosome 17 region. None of the genes in chromosome 12 has been linked to 
hair or nail dysplasia or ectodermal development. Whereas in chromosome 17 there are several 
potential candidate genes: Claudin 7, Keratin 31 and Keratin 33B. The list of genes that are dif­
ferentially expressed in the EEC patients may not only help to find undiscovered ED syndrome 
genes, but also disease genes that have been linked in other single malformations such as split 
hand/foot or kidney, corneal disease or hearing impairment. Although no genes were found in 
the currently known and unsolved split hand/foot loci (SHFM1-2 and 5), we found a strong p63 
binding and p63 consensus site in the SHFM1 locus in chromosome 7. With help of a novel dele­
tion of this locus in a SHFM patient we were able to redefine the SHFM1 locus, so that previous 
candidate genes DLX5 and DLX6 fall outside of this locus. When adapting the p63 binding data 
on this locus we identified a p63 regulatory region in the redefined SHFM1 locus to be respon­
sible for SHFM. This p63 regulatory region can now be used for mutation screening in isolated 
SHFM patients. This result suggests that disease causing defects can also lie outside the coding 
sequence of a gene of interest and are often missed when investigating only the protein coding 
sequence or genes in deleted loci.
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Figure 2. Model of auto-regulatory feedback loop in p53 and p63. A. p53 controls its own degradation through 
MDM2. B. Similar model could be present for p63, which would be disrupted in EEC syndrome patients causing 
p63 protein accumulation. C. In a feedback loop model of p63 and UFD2a, wild type p63 represses UFD2a 
activation leading to its own stabilization. But, through DBD mutation this repression is lost causing UFD2a up- 
regulation, which possibly causes p63 accumulation.
8 .4  Are there unrecognized pathologies associatec 
with human p63 mutations?
p63 expression pattern and p63-derived models suggest that p63 might contribute to other clini­
cal features than ED, limb malformation and orofacial clefting. p63 has been linked to cellular 
senescence and aging in heterozygous p63 knock-out mice (35), that might indicate that p63 
is involved age-related defects. For example, the specific expression of TAp63a in oocytes, its 
involvement in DNA-damage induced oocyte death (14) and premature ovarian failure (POF) that 
has been described in a Rapp Hodgkin syndrome family (64) may reflect a role for p63 in female 
germ line and premature menopause. Corneal defects have also been described in this RHS 
family (64) and in several of our patients, but it is not known whether this is caused by disrupted 
cellular senescence and activation of anti-proliferative processes or by failure of stem cell com­
mitment. In addition, early-onset alopecia, skin defects and hearing impairment could be caused 
by cellular senescence.
TAp63 expression has also been found in the brain (5,18), where TAp63y is involved in naturally oc­
curring sympathetic neuronal death (18). To our knowledge, there is no evidence for an associa­
tion between p63 mutations and the occurrence of neurodevelopmental or neurodegenerative 
disease. However, unknown defects such as mutation in untranslated region, regulatory element 
or larger deletion or duplication in the p63  could play a role in a neuronal disease. TAp63 expres-
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sion in heart (5,17), and recently described heart defects (atrial septal defect and arrhythmogen- 
ic right ventricular dysplasia/cardiomyopathy) in a RHS (Chapter 6) and an ADULT syndrome pa­
tients, respectively, suggest a role for p63  in heart development (65). To understand whether p63 
plays a role in yet unrecognized conditions, such as premature aging, neurodegenerative disorder 
or heart diseases more detailed studies needs to be performed on physiologically relevant tissue 
types, since defects in p63 and pathogenesis might be different in diverse tissues and conditions.
Because p63 belongs to the p53 tumor suppressor gene family it has often been linked to tumor 
development and cancer. A strong p63 accumulation and amplification of p63 chromosomal 
locus 3q26-qter has been detected in squamous and basal cell carcinomas indicating an onco­
genic function for p63 (66,67). In contrast, the heterozygous p63-KO mice study showed loss of 
heterozygosity in tumors suggesting a role as tumor suppressor gene for p63 (68). Other studies 
indicate that ANp63 isoforms are able to induce anti-apoptotic genes and repress pro-apoptotic 
genes, suggesting a role as an anti-apoptotic protein (69,69-71). However, TAp63 isoforms are 
able to directly activate death receptors and mitochondrial apoptotic pathway indicating a role as 
a pro-apoptotic protein (19). Taken together, these results indicate that TA and ANp63 isoforms 
have opposite roles in apoptosis and the balance of these two isoforms can be very important 
in both apoptosis and tumorigenesis. Unlike p53  mutations, somatic p63 mutations have rarely 
been found in human tumors (72,73). Nevertheless, genome-wide association studies in large 
cohorts from Iceland and the Netherlands revealed a SNP close to the p63 gene that confers an 
increased susceptibility for urinary bladder cancer (74). W hether patients with p63  mutations are 
more predisposed to tumors is unclear. In the literature only one patient has been reported to 
carry a p63 germ-line mutation and a malignant B-cell lymphoma (75). Surprisingly, in our studies 
we describe patients with a malignant oral squamous cell carcinoma, malignant melanoma and 
malignant spinocellular epithelioma (Chapters 4, 6 and 7). To determine the incidence of cancer 
in p63 mutation carriers, we have investigated the medical records of 227 p63-linked patients 
(Chapter 2) without finding a significant amount of patients carrying a p63  germ-line mutation 
and having a cancer. Therefore we cannot conclude that the germ-line p63 mutations would be 
causative for the described tumors in the three patients described in Chapters 4, 6 and 7 or that 
patients with a p63 germ-line mutation would be more predisposed to a cancer.
8 .5  Future visions
Research on p63 and its involvement in ectodermal development and ectodermal dysplasia has 
progressed very rapidly in the last few years. p63 is now recognized as an important master 
molecule in ectodermal development and its function has been linked to a variety of cellular 
functions (1,12,41). A number of direct target genes and regulatory elements have already been 
described. However, to complete the p63-puzzle with its upstream regulators, p63 interacting 
proteins i.e. involved in transcription regulation and downstream target genes more research is 
warranted. Research, that I began in this thesis deals with p63 downstream target genes with a 
priority to understand the pathogenesis of p63-associated ectodermal dysplasia syndromes. The 
importance and relevance of these novel target genes in ectodermal development needs sub­
sequent confirmation by other methods, e.g. in mouse models. The last research chapter in this 
thesis already enabled to find p63 wild-type binding sites in the genome. In the near future this 
method will be used for keratinocytes derived from p63 syndrome patients, but also for different 
developmental stages of the epidermis. Future research should also incorporate the differential
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properties of the different p63 isoforms, and address the role and expression of less known and 
understood p63P, p63y and AAp63 isoforms.
What does our p63 research mean for patients? The importance of p63 research for patients has 
so far been to facilitate DNA-diagnostic testing and the consequent improvement of genetic 
counseling. The possibilities for therapeutic intervention are so far limited to cosmetic surgery. 
The discovery of new direct target genes of p63 and p63 genetic modifiers may have its merits 
for further improvement of predictive diagnosis as well as for future therapeutic strategies for 
treatment of p63 patients. If a modifier is involved in creating a certain clinical feature, it can be 
used to predict the phenotype in prenatal research in the future. Predicting a phenotype with 
help of genetic modifiers can be complicated, since combinations of different and independent 
modifiers are likely to account for the final phenotype. However, whole-genome sequencing of 
large numbers of individuals will soon be a common practice which eventually provides in-depth 
knowledge about the plasticity of the human genome and its relations to disease. New p63 tar­
get genes and regulatory elements are also interesting candidates for other ectodermal dyspla­
sias or other characteristics that belong to the p63 phenotype with a yet undiscovered genetic 
cause. An excellent example of this is the p63 regulatory element of DLX5 and DLX6 genes in 
SHFM patients (Chapter 7). Finally, if some of the candidate genes or regulatory elements turn 
out to be novel genetic cause for another ED or disease condition it can be used for establish­
ment of the diagnosis.
W hether a complex p63 phenotype will be rescued in the future by prenatal therapy is unlikely. 
Because no single feature in the p63 phenotype is fully penetrant, it is difficult to determine 
what to rescue, if the phenotype cannot be predicted on the basis of p63  mutation. The disease 
pathogenesis with different p63 isoforms is probably also complex and varied in different tissues 
that all gene defects could be restored. Nevertheless, if pathogenesis of some single features 
is established, it could be possible to rescue some certain developmental processes such as 
hypohidrosis, where sweat gland development or function could be stimulated. Understanding of 
p63 pathology will not only benefit p63-associated patients but also provide useful information 
for patients with similar phenotypic features, wound healing and corneal transplantation, since 
it is expressed in the limbal stem cells and might have a role in regenerative proliferation in the 
cornea (76-78).
8 .6  Concluding remarks
Since the beginning of this thesis, enormous progress has been made in p63 research, including 
upstream regulation of p63 and downstream target genes and pathways regulated by p63. This 
thesis describes a first systematic approach to understand the pathogenesis in p63-associated 
diseases. Although this work is still at an early stage, it has created a solid base for the search for 
target genes relevant to ED syndromes, and it will hopefully lead to a better understanding of the 
complex molecular mechanism of p63-related developmental disorders.
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Summary
Mutations in the transcription factor gene p63 are causative for human developmental syndromes 
characterized by three main hallmarks: ectodermal dysplasia, limb malformations and orofacial 
clefting. Five different dominantly inherited human syndromes and two non-syndromic condi­
tions have been linked to p63 gene defects. The syndromic conditions: Ectrodactyly, ectodermal 
dysplasia and cleft lip/palate syndrome (EEC), Ankyloblepharon-ectodermal defects-cleft lip/ 
palate (AEC), Limb mammary syndrome (LMS), Acro-dermato-ungual-lacrimal-tooth syndrome 
(ADULT) and Rapp-Hodgkin syndrome (RHS), all show overlapping features of the three main 
disease characteristics. In contrast, isolated split hand/foot malformation (SHFM4) and Non- 
syndromic cleft lip/palate (NSCL) only show one of the three main hallmarks. An overview of the 
p63-disease associated phenotypes and known causative gene defects are presented in Chapter
2.
EEC syndrome is the most common p63-associated condition, since approximately 60 percent of all 
p63 mutations have been identified in EEC syndrome patients. In Chapter 3 a population of 227 
clinically described patients carrying a p63 mutation is presented. This overview demonstrates a 
large variation in expressivity between p63-syndromes, within a single syndrome and even within 
patients carrying the same p63 mutation (even in one family). EEC mutations are mainly mis- 
sense mutations clustered in the DNA binding domain, and almost 90 percent of all EEC patients 
carry one of the five hot spot mutations. ADULT syndrome has also been linked to mutations 
in the DNA binding domain (Chapter 4). Mutations found in AEC and RHS cluster in the amino- 
terminal transactivation domain (TA/TA2) or in the carboxy-terminal domains (Sterile alpha motif 
domain, SAM and Transcription inhibitory domain, TI) (Chapter 5 and Chapter 6). A specific 
clustering for other p63-associated conditions has not yet been observed.
P63 encodes at least six isoforms through two different promoters and three differential 3' end splic­
ing routes of the gene. ANp63a is the only isoform that has been detected in human primary 
keratinocytes, and is likely the most important isoform in ectodermal development (Chapter 6 
and Chapter 7). Consistent with this is the specific mutation clustering in the ANp63a isoform in 
the AEC and RHS syndrome patients that also have the most striking ectodermal defects (Chapter
5 and Chapter 6). So far, the role of other p63 isoforms in p63-linked diseases remains unclear.
P63-associated diseases are inherited by autosomal dominant matter. The disease mechanism is not 
fully deciphered, but there is evidence that mutations in p63 have either gain-of-function and/ 
or dominant negative effects depending on the mutation (Chapter 6 and Chapter 8). Due to 
conformational changes, mutant protein can bind to other combinations of target genes leading 
to transcriptional activation or lose its binding activity to its enhancer by disabling the wild type 
p63 function in hetero-tetramer molecule. The complex and variable clinical presentation of p63- 
associated disorders is likely a result of the variable effect of p63 mutations towards expression 
of legitimate and illegitimate target genes.
To discover and understand the (differential) regulation of the p63 target genes in patients, we stud­
ied RNA expression profiling in keratinocytes originated from three EEC patients with p63 hot 
spot mutations in the DNA binding domain (Chapter 7). This study showed that genes involved 
in several developmental categories, regulation of biological processes and cell cycle were 
significantly differently regulated in patients than in controls. This study also indicated several 
putative candidate genes for other yet unsolved ectodermal dysplasias. To fulfill the expression
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profiling study and to discover p63 direct target genes we performed a genome wide DNA bind­
ing study on keratinocytes (Chapter 7). It reveals that transcription factor p63 can bind to more 
than 10,000 binding sites containing a specific p63 binding motive. P63 binding seems not to be 
specific for tissue or developmental stage. The specificity for transcriptional regulation by p63 is 
likely controlled by other factors e.g. binding of tissue-specific co-factors.
There is a lot of new data originated from the expression and genome wide DNA binding profiling 
experiments. Some of this data still needs to be validated and it will hopefully help us to find out 
relevant target genes for p63 disease pathogenesis including understanding of separate pheno­
types, such as various ED features, SHFM and CLP.
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Samenvatting
Mutaties in het transcriptiefactor gen p63 leiden tot erfelijke ziektes die gekenmerkt worden door 
verschillende combinaties van drie hoofdkenmerken: ectodermale dysplasie, afwijkingen van de 
ledematen en gespleten lip en/of gehemelte. Tot nu toe werden vijf verschillende syndromen 
met dominante overerving beschreven die door defecten in het p63 gen kunnen ontstaan.
Deze ziektebeelden, Ectrodactyly, ectodermal dysplasia and cleft lip/palate syndroom (EEC), 
Ankyloblepharon-ectodermal defects cleft lip/palate (AEC), Limb mammary syndroom (LMS), 
Acro-dermato-ungual-lacrimal-tooth syndroom (ADULT) en Rapp-Hodgkin syndroom (RHS), heb­
ben overlappende klinische genmerken van de drie gemeenschappelijke factoren. Daarnaast zijn 
er twee niet-syndromale ziektebeelden bekend die het gevolg zijn van dominante mutaties in het 
p63 gen: geïsoleerde ectrodactyly (splijthand-splijtvoet) (SHFM) en geïsoleerde lip/gehemelte 
spleet (NSCL). Een overzicht van de p63-geassocieerde fenotypen en de daarbij gevonden gende- 
fecten is beschreven in Hoofdstuk 2.
EEC syndroom is de meest bekende p63-geassocieerde ziekte. Ongeveer 60 procent van de p63 
mutaties is gevonden in patiënten met het EEC syndroom. In Hoofdstuk 3 is een overzicht ge­
maakt van de klinische verschijnselen van 227 patiënten met een mutatie in het p63 gen. Deze 
studie liet zien dat er een enorme variatie is van de klinische verschijnselen die gezien werden 
bij patiënten met een p63 mutatie. Deze variatie is het grootst tussen de verschillende "p63-syn- 
dromen", maar er is ook aanzienlijke klinische variabiliteit binnen één syndroom en zelfs tussen 
patiënten met dezelfde mutatie (ook binnen één familie). Deze resultaten suggereren dat aanvul­
lende genetische en/of omgevingsfactoren een modulerend effect hebben op het fenotype van 
de primaire p63 mutatie.
Ondanks de klinische variabiliteit bij p63-geassocieerde aandoeningen is er ook een duidelijk patroon 
van genotype-fenotype associaties. Mutaties in EEC syndroom patiënten veroorzaken bijna altijd 
aminozuur veranderingen in het DNA-bindings domein, en bijna 90% van de EEC syndroom 
patiënten heeft één van de vijf hot spot mutaties. ADULT syndroom mutaties komen ook voor 
in het DNA-bindings domein (Hoofdstuk 4). Mutaties bij patiënten met AEC en RHS syndroom 
clusteren in het amino-terminaal transactivatie domein (TA/TA2) of in de carboxy-terminale 
domeinen (Sterile alpha motif domein, SAM en Transcriptie inhibitie domein, TI) (Hoofdstuk 5 
en Hoofdstuk 6). De syndroom-specifieke clustering van mutaties vormt een basis voor verder 
functioneel onderzoek naar de functionele karakteristieken van het p63 eiwit.
Het p63 gen codeert tenminste zes isovormen als gevolg van het gebruik van twee verschillende pro­
moters en drie alternatieve splicing routes. ANp63a is de enige isovorm die basale epitheelcellen 
van de huid (primaire keratinocyten) gedetecteerd kan worden en is derhalve de meest belan­
grijke isovorm voor de ectodermale ontwikkeling (Hoofdstuk 6 en Hoofdstuk 7). Bij AEC en RHS 
syndromen, die de ernstigste ectodermale afwijkingen van de p63-geassocieerde ziektebeelden 
hebben zijn de mutaties specifiek in de ANp63a isovorm geclusterd. De meeste van deze mutat­
ies verstoren het carboxy-terminale einde van het eiwit dat specifiek is voor de a-isovormen.
In mijn onderzoek heb ik ook enkele mutaties geïdentificeerd in het amino-terminale einde dat 
specifiek is voor de AN-isovormen (Hoofdstuk 6). Dankzij deze mutaties heb ik tevens ontdekt 
dat er een alternatief translatie start codon is voor de synthese van een verkorte vorm van 
ANp63a, welke ook in de afwezigheid van p63 mutaties wordt geproduceerd. Tot op heden is de 
rol van de andere p63 isovormen in p63-geassocieerde ziektebeelden onbekend.
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P63-geassocieerde aandoeningen hebben een autosomale dominante overerving. Het ziekte-
mechanisme is niet volledig opgehelderd, maar er zijn aanwijzingen dat de mutaties de normale 
activiteit van het mutante en het niet-mutante eiwit remmen (dominant-negatief effect), en 
tenminste voor sommige mutaties, ook tot nieuwe activiteiten kunnen leiden ("gain-of-function") 
(Hoofdstuk 6 en Hoofdstuk 8). De dominant-negatieve mutaties leiden tot verlies van de rol van 
het p63 eiwit in de regulatie (activatie en repressie) van transcriptie van specifieke genen. Dit 
effect wordt veelal teweeg gebracht door verlies van binding van p63 eiwitcomplexen (met mu­
tant en normaal p63 eiwit) op specifieke DNA posities in de nabijheid van p63 target genen. Bij 
gain-of-function mutaties kunnen veranderingen in de conformatie van het eiwit er voor zorgen 
dat het mutante eiwit de transcriptie van genen stimuleert die normaal gesproken niet onder 
controle van p63 staan. Het complexe en variabele klinische beeld in de p63-geassocieerde ziek­
tes komt waarschijnlijk door een variabel effect van de p63 mutaties op de transcriptie van zijn 
rechtmatige en onrechtmatige target genen.
Om te onderzoeken hoe de expressie van p63 target genen bij patiënten is veranderd, heb ik vergeli­
jkende RNA expressie studies uitgevoerd in keratinocyten van drie EEC syndroom patiënten met 
een verschillende p63 mutatie en van een aantal controle personen (Hoofdstuk 7). Deze studie 
laat een aantal genen zien die gemeenschappelijk veranderd zijn in expressie bij patiënten ten 
opzichte van controles. Deze genen zijn betrokken bij een aantal biologische processen die rel­
evant zijn voor het mutante p63 fenotype: epitheliale ontwikkeling en aspecten van embryonale 
ontwikkeling. Daarnaast resulteerde deze studie ook tot een aantal kandidaatgenen voor erfelijke 
aandoeningen die fenotypische overlap vertonen met de p63-geassocieerde syndromen. Om te 
bepalen of deze gedereguleerde genen directe of indirecte targets van het p63 eiwit zijn werden 
de bindingsplaatsen voor het p63 eiwit op het gehele humane genoom in kaart gebracht (Hoofd­
stuk 7). Deze studie onthulde dat transcriptiefactor p63 op meer dan 10,000 bindingsplaatsen in 
het genoom heeft. Een significant aantal van deze bindingsplaatsen werd gevonden in de nabi­
jheid van de genen die gedereguleerd zijn in keratinocyten van de EEC syndroom patiënten. Dit 
zijn dus waarschijnlijk directe targets van p63. Daarnaast suggereert het grote aantal bindingsp­
laatsen dat p63 binding niet specifiek is voor een bepaald celtype of fase tijdens de ontwikkeling. 
De specifieke regulatie van p63 in transcriptie wordt waarschijnlijk gecontroleerd door andere 
factoren, zoals binding van weefselspecifieke factoren.
De combinatie van genoom-omvattende bepaling van p63 bindingsplaatsen en expressieanalyse 
heeft een grote hoeveelheid nieuwe data opgeleverd. Hiermee is inzicht verkregen in molecu­
laire processen die belangrijk zijn voor het ontstaan van het mutante p63 fenotype en de enorme 
variatie daarvan. Het is te verwachten dat deze data ook van grote waarde zal zijn voor het iden­
tificeren van nieuwe genen en regulatoire elementen die betrokken zijn bij erfelijke aandoenin­
gen met overlappende fenotypes, zoals ectodermale dysplasieën, schisis en splijthand-splijtvoet.
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Affym etrix
transcript Gene assignment uuG e n e .
IP abbreviation
2923928 Fatty acid binding protein 7 FABP7
3455692 Keratin 2 KRT2
3010503 CD36 molecule (thrombospondin receptor) CD36
3414739 Methyltransferase like 7A METTL7A
3692999 Metallothionein 1G MT1G
3255311 Protocadherin 21 PCDH21
3662201 Metallothionein 1H MT1H
2921402 Solute carrier family 16, member 10 SLC16A10
2806643 Solute carrier family 1, member 3 SLC1A3
3471769 Transmembrane protein 116 TMEM116
3406589 Microsomal glutathione S-transferase 1 MGST1
3928415 Claudin 8 CLDN8
3901041 Thrombomodulin THBD
3376529 HRAS-like suppressor 3 HRASLS3
3727583 Hepatic leukemia factor HLF
3753760 Matrix metallopeptidase 28 MMP28
3062665 MGC72080 pseudogene MGC72080
3067302 Laminin, beta 1 LAMB1
3948640 Fibulin 1 FBLN1
3762083 Distal-less homeobox 3 DLX3
3652424 Eukaryotic elongation factor-2 kinase 4 EEF2K
3761737 Zinc finger protein 652 ZNF652
2468622 Inhibitor of DNA binding 2 ID2
3057755 POM (POM121 homolog, rat) and ZP3 fusion POMZP3
3917204 Chromosome 21 open reading frame 7 C21orf7
2351687 Chitinase 3-like 2 CHI3L2
3063463 Cytochrome P450, family 3, subfamily A, polypeptide 7 CYP3A7
2451958 Pleckstrin homology domain containing, family A, m. 6 PLEKHA6
2685304 Protein S (alpha) PROS1
2509988 Hypothetical protein LOC130576 LOC130576
2435005 Selenium binding protein 1 SELENBP1
3972025 Pyruvate dehydrogenase kinase, isozyme 3 PDK3
Reference
sequence
Chromosomal
location
Fold
Change
R204W
p-value
(R204W)
Fold
Change
(R279H)
p-value
(R279H)
Fold
Change
(R304W)
p-value
(R304W)
NM_001446 6q22-q23 76,45 0,00019 651,07 0,00008 15,44 0,00224
NM_000423 12ql3.13 16,45 0,00189 5,72 0,04108 36,36 0,00051
NM_001001548 7 q ll .2 9,26 0,00860 7,62 0,03251 22,31 0,00174
NM_014033 12ql3.13 5,20 0,00061 5,71 0,00157 7,64 0,00019
NM_005950 16ql3 6,43 0,01133 5,48 0,04040 5,58 0,01579
NM_033100 10q22.1-q22.3 3,71 0,02212 8,40 0,00771 4,33 0,01407
NM_005951 16ql3 5,40 0,00205 5,89 0,00504 5,02 0,00256
NM_018593 6q21-q22 4,46 0,03393 5,50 0,04863 5,41 0,02137
NM_004172 5pl3 3,20 0,00002 3,48 0,00005 5,03 0,00000
BC048796 12q23.13 2,58 0,03236 3,87 0,02026 4,53 0,00447
NM_145791 12pl2.3-pl2.1 3,34 0,00346 4,58 0,00349 2,77 0,00758
NM_199328 21q22.11 3,24 0,00790 2,89 0,03158 3,41 0,00646
NM_000361 2 0 p ll.2 2,19 0,00738 4,13 0,00130 3,09 0,00126
NM_007069 Ilq l2 .3 -q l3 .1 3,71 0,00006 2,44 0,00166 3,11 0,00013
NM_002126 17q22 2,05 0,02084 4,39 0,00233 2,80 0,00434
NM_024302 17qll-q21.1 2,92 0,00195 3,38 0,00328 2,90 0,00200
NR_002822 7q21.3 3,50 0,00318 2,55 0,03130 3,03 0,00574
NM_002291 7q22 3,04 0,01098 2,84 0,03612 2,97 0,01204
NM_006486 22ql3.31 2,45 0,01395 3,71 0,00735 2,55 0,01158
NM_005220 17q21.33 2,45 0,03091 2,87 0,04007 3,30 0,00970
NM_013302 16pl2.1 1,77 0,00699 4,56 0,00015 2,09 0,00203
NM_014897 17q21.32 2,23 0,00230 3,69 0,00063 2,44 0,00137
NM_002166 2p25 2,46 0,01214 2,89 0,01620 3,00 0,00495
NM_012230 7 q ll.2 3 2,18 0,01143 1,98 0,04793 3,80 0,00085
AF269162 21q22.3 2,69 0,00266 1,99 0,03545 3,02 0,00154
NM_001025199 lp l3 .3 2,38 0,00011 2,35 0,00044 2,97 0,00003
NM_000765 7q21-q22.1 1,87 0,00383 2,67 0,00133 2,97 0,00022
NM_014935 lq32.1 2,48 0,00222 2,19 0,01323 2,83 0,00110
NM_000313 3 q ll.2 1,99 0,01828 2,90 0,00764 2,55 0,00461
AF435957 2q23.2 2,51 0,00972 2,47 0,02723 2,36 0,01320
NM_003944 Iq21-q22 1,96 0,03566 2,67 0,02092 2,70 0,00732
NM_005391 Xp22.11 1,71 0,03833 3,32 0,00341 2,23 0,00752
Affymetrix
transcript
ID
Gene assignment
Gene
a b b r e v ia t io n
3662150 Metal loth ionein 1M MT1M
3903169 Peroxisomal membrane protein 4 PXMP4
2338719 Nuclear factor I/A NFIA
3730322 Man nose receptor, C type 2 MRC2
3816699 Zinc finger protein 57 ZNF57
3278057 Coiled-coil domain containing 3 CCDC3
2930243 SAM and SH3 domain containing 1 SASH1
3594986 Testis expressed 9 TEX9
2560625 Transmembrane protein 166 TMEM166
2643901 Protein phosphatase 2 PPP2R3A
2401493 Inhibitor of DNA binding 3 ID3
3050609 Cordon-bleu homolog (mouse) COBL
2902155 Psoriasis susceptibility 1 candidate 1 PSORS1C1
3899404 Ovo-like 2 (Drosophila) OVOL2
3826306 Zinc finger protein 85 ZNF85
3808854 Transcription factor 4 TCF4
3376046 Similar to hypothetical protein LOC221091
3408505 Lymphoid-restricted membrane protein LRMP
2621881 Hypoxia-inducible factor prolyl 4-hydroxylase PH-4
3890333 Transcription factor AP-2 gamma TFAP2C
2376849 Ras association (RalGDS/AF-6) domain family 5 RASSF5
3359224 Achaete-scute complex homolog 2 ASCL2
3290875 Ankyrin 3, node of Ranvier (ankyrin G) ANK3
3717034 Hypothetical protein LOC400590 LOC400590
2723605 Chromosome 4 open reading frame 19 C4orfl9
2969467 Cell division cycle 2-like 6 (CDK8-like) CDC2L6
2829947 Transforming growth factor, beta-induced TGFBI
3211938 RAS and EF-hand domain containing RASEF
3458193 Retinol dehydrogenase 16 RDH16
2605749 Period homolog 2 PER2
2995320 Hypothetical protein DKFZp586ll420 DKFZp586ll420
3968397 WWC family member 3 WWC3
Reference
sequence
Chromosomal
location
Fold
Change
R204W
p-value
(R204W)
Fold
Change
(R279H)
p-value
(R279H)
Fold
Change
(R304W )
p-value
(R304W )
NM_176870 16ql3 2,27 0,00839 2,21 0,02581 2,61 0,00405
NM_007238 20q ll.22 2,01 0,03473 2,33 0,04031 2,51 0,01169
NM_005595 Ip31.3-p31.2 1,90 0,00095 3,00 0,00018 1,90 0,00094
NM_006039 17q23.2 2,59 0,00529 2,11 0,03841 1,97 0,02309
EF534355 19pl3.3 1,81 0,00363 2,98 0,00053 1,84 0,00317
NM_031455 10pl3 1,67 0,04127 2,82 0,00610 2,08 0,01022
NM_015278 6q24.3 2,39 0,00294 1,88 0,03329 2,29 0,00376
NM_198524 15q21.3 2,23 0,00291 2,47 0,00500 1,80 0,01191
BC063016 2pl2 2,01 0,00239 2,21 0,00416 2,24 0,00116
NM_002718 3q22.1 1,79 0,01106 2,52 0,00387 2,13 0,00326
NM_002167 Ip36.13-p36.12 1,89 0,00849 2,36 0,00644 2,14 0,00380
NM_015198 7pl2.1 2,12 0,01679 2,04 0,04875 2,23 0,01282
NM_014068 6p21.3 2,30 0,00912 2,19 0,03046 1,83 0,03345
NM_021220 20pter-qll.23 1,85 0,00628 2,46 0,00313 1,80 0,00774
NM_003429 19pl3.1-pl2 2,19 0,00090 2,12 0,00361 1,79 0,00398
NM_001083962 18q21.1 1,61 0,01637 2,95 0,00102 1,48 0,03422
NM_203422 llq l2 .3 1,58 0,02042 2,77 0,00149 1,59 0,01918
NM_006152 12pl2.1 1,38 0,04562 3,02 0,00046 1,54 0,01450
NM_177938 3p21.31 1,74 0,00061 1,95 0,00080 2,24 0,00008
NM_003222 20ql3.31 1,75 0,00891 2,64 0,00200 1,44 0,04883
NM_182663 lq32.1 1,74 0,03745 1,92 0,04732 2,03 0,01399
NM_005170 llp l5 .5 1,67 0,04747 2,03 0,03431 1,93 0,01862
NM_020987 10q21 1,76 0,00938 2,31 0,00457 1,55 0,02697
BC062632 17 q ll.2 1,66 0,04045 2,29 0,01500 1,65 0,04228
NM_001104629 4pl4 2,38 0,00001 1,55 0,00161 1,65 0,00023
NM_015076 6q21 1,48 0,00330 2,29 0,00023 1,79 0,00044
NM_000358 5q31 1,84 0,00188 1,87 0,00523 1,84 0,00183
NM_152573 9q21.32 1,84 0,01587 2,09 0,01900 1,63 0,03730
NM_003708 12ql3.3 1,90 0,00001 1,80 0,00006 1,83 0,00001
NM_022817 2q37.3 1,92 0,00617 2,02 0,01285 1,58 0,02804
NR_002186 7pl5.1 1,33 0,04313 2,17 0,00159 1,89 0,00130
NM_015691 Xp22.32 1,80 0,01856 1,91 0,03211 1,66 0,03290
204
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2849469 Ankylosis ANKH
3722355 Rho family GTPase 2 RND2
2435261 RAR-related orphan receptor C RORC
3139722 Nuclear receptor coactivator 2 NCOA2
3672368 KIAA0182 KIAA0182
3009838 Coiled-coil domain containing 146 CCDC146
3561039
Nuclear factor of kappa light polypeptide gene 
enhancer
NFKBIA
2429466 Nerve growth factor, beta polypeptide NGFB
3063501 Cytochrome P450, family 3, subfamily A CYP3A4
3248470 Chromosome 10 open reading frame 107 C10orfl07
3761420 Homeobox B7 HOXB7
2957402 Glutathione S-transferase A3 GSTA3
2614913 Chromosome 3 open reading frame 68 C3orf68
3138204 Cytochrome P450, family 7, subfamily B, polypeptide 1 CYP7B1
3733275 Potassium inwardly-rectifying channel, subfamily J KCNJ2
3387537 Mastermind-like 2 MAML2
2329266 Zinc finger protein 362 ZNF362
3894194 TBC1 domain family, member 20 TBC1D20
2439554 Absent in melanoma 2 AIM2
3743906 Tumor protein p53 TP53
2970985 TSPY-like 4 TSPYL4
3418214 Methyl-CpG binding domain protein 6 MBD6
2957499 Intestinal cell (MAK-like) kinase ICK
3264621 Transcription factor 7-like 2 TCF7L2
3726406 Acyl-CoA synthetase family member 2 ACSF2
3600960 Bardet-Biedl syndrome 4 BBS4
3571553 Chromosome 14 open reading frame 43 C14orf43
3061964 Paraoxonase 3 PON3
3926080 BTG family, member 3 BTG 3
2994835 Chimerin (chimaerin) 2 CHN2
2697902 Nicotinamide nucleotide adenylyltransferase 3 NMNAT3
Reference
sequence
Chromosomal
location
Fold
Change
R204W
p-value
(R204W)
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(R279H)
p-value
(R279H)
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Change
(R304W)
p-value
(R304W)
NM_054027 5pl5.1 1,70 0,00062 2,05 0,00044 1,62 0,00106
NM_005440 17q21 1,62 0,02384 1,73 0,03453 1,96 0,00566
NM_005060 lq21 1,70 0,01267 1,77 0,02506 1,81 0,00804
NM_006540 8ql3.3 1,73 0,00174 2,09 0,00130 1,44 0,01185
NM_014615 16q24.1 1,66 0,00731 1,79 0,01109 1,70 0,00577
NM_020879 7 q ll.2 3 1,49 0,02930 2,05 0,00673 1,60 0,01563
NM_020529 14ql3.2 1,57 0,00259 2,16 0,00054 1,40 0,01024
NM_002506 lp l3 .1 1,93 0,00557 1,63 0,04790 1,55 0,03064
NM_017460 7q22.1 1,35 0,01614 1,76 0,00265 1,98 0,00029
NM_173554 10q21.2 1,61 0,00013 1,44 0,00202 2,03 0,00001
NM_004502 17q21.3 1,59 0,00724 1,76 0,00829 1,70 0,00379
NM_000847 6pl2.1 1,70 0,00050 1,83 0,00092 1,52 0,00178
AF086095 3p24.1 1,37 0,02932 2,06 0,00218 1,57 0,00679
NM_004820 8ql2.3 1,57 0,00451 2,12 0,00114 1,29 0,04961
NM_000891 17q24.3 1,50 0,01184 1,67 0,01171 1,79 0,00214
NM_032427 llq 2 1 1,48 0,03944 1,92 0,01298 1,51 0,03127
NM_152493 lp35.1 1,35 0,02699 2,03 0,00170 1,50 0,00831
NM_144628 20pl3 1,52 0,00454 1,88 0,00182 1,47 0,00653
NM_004833 lq22 2,01 0,00001 1,30 0,00607 1,55 0,00013
NM_000546 17pl3.1 1,56 0,01891 1,78 0,01695 1,49 0,02822
NM_021648 6q22.1 1,50 0,04800 1,77 0,03242 1,53 0,03971
NM_052897 12ql3.3 1,47 0,01050 1,95 0,00236 1,38 0,02229
NM_016513 6p l2 .3-p ll.2 1,36 0,00662 2,02 0,00034 1,38 0,00528
NM_030756 10q25.2 1,40 0,01045 1,74 0,00309 1,61 0,00207
NM_025149 17q21.33 1,42 0,03093 1,84 0,00836 1,50 0,01765
AY457143 15q22.3-q23 1,47 0,01077 1,89 0,00307 1,37 0,02391
NM_194278 14q24.3 1,41 0,01912 2,01 0,00226 1,32 0,04311
NM_000940 7q21.3 1,66 0,00379 1,45 0,03728 1,61 0,00493
NM_006806 21q21.1-q21.2 1,41 0,04993 1,63 0,03220 1,66 0,01093
NM_004067 7pl5.3 1,37 0,00546 1,83 0,00070 1,48 0,00198
NM_178177 3q23 1,27 0,02154 1,45 0,00940 1,96 0,00013
Affymetrix
transcript
ID
Gene assignment
Gene
abbreviation
3192580 Chromosome 9 open reading frame 9 C9orf9
2916716 Proline-rich nuclear receptor coactivator 1 PNRC1
3726211 Pyruvate dehydrogenase kinase, isozyme 2 PDK2
3751590 Coronin 6 CORO 6
3822805 Glycoprotein, synaptic 2 GPSN2
3743763 Zinc finger and BTB domain containing 4 ZBTB4
2452069 Phosphoinositide-3-kinase, class 2, beta polypeptide PIK3C2B
3968512 Chloride channel 4 CLCN4
3268333 HtrA serine peptidase 1 HTRA1
2383356 Chaperone, ABC1 activity of bel complex homolog CABC1
3444009 C-type lectin domain family 7, member A CLEC7A
2900269 Zinc finger and SCAN domain containing 16 ZSCAN16
3598758 SMAD family member 6 SMAD6
2835021 Prenylcysteine oxidase 1 like PCYOX1L
3822122 Nuclear factor l/X NFIX
2657665 Tumor protein p63 TP63
3026599 Tripartite motif-containing 24 TRIM24
3470927 Transient receptor potential cation channel,subfamily V TRPV4
3377474 Synovial apoptosis inhibitor 1 SYVN1
3497586 Muscleblind-like 2 MBNL2
2359993 cAMP responsive element binding protein 3-like 4 CREB3L4
3651057 Chromosome 16 open reading frame 62 C16orf62
2375706 ATPase, Ca++ transporting, plasma membrane 4 ATP2B4
3741875 Zinc finger, ZZ-type with EF-hand domain 1 ZZEF1
3894637 NSFL1 (p97) cofactor (p47) NSFL1C
3008376 General transcription factor II GTF2I
3903089 N-terminal EF-hand calcium binding protein 3 NECAB3
3735346 Hypothetical protein LOC100134934 LOCI00134934
3261971 Cyclin M2 CNNM2
3837464 Glioma tumor suppressor candidate region gene 2 GLTSCR2
4018454 Angiomotin AMOT
Reference
sequence
Chromosomal
location
Fold
Change
R204W
p-value
(R204W)
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Change
(R279H)
p-value
(R279H)
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Change
(R304W)
p-value
(R304W)
BC012940 9q34 1,60 0,00142 1,66 0,00322 1,42 0,00588
NM_006813 6ql5 1,48 0,00181 1,70 0,00135 1,49 0,00177
NM_002611 17q21.33 1,45 0,00332 1,85 0,00083 1,34 0,00949
NM_032854 17 q ll.2 1,63 0,00442 1,46 0,03550 1,54 0,00783
NM_138501 19pl3.12 1,51 0,01328 1,68 0,01354 1,41 0,02701
NM_020899 17pl3.1 1,38 0,00938 1,94 0,00084 1,27 0,03158
NM_002646 lq32.1 1,47 0,02545 1,58 0,03350 1,53 0,01811
NM_001830 Xp22.3 1,54 0,00571 1,43 0,03227 1,61 0,00351
NM_002775 10q26.3 1,43 0,00978 1,55 0,01159 1,58 0,00314
NM_020247 lq42.13 1,43 0,00795 1,68 0,00445 1,43 0,00800
NM_197947 12pl3.2 1,59 0,00255 1,47 0,01761 1,46 0,00669
NM_025231 6p22.1 1,38 0,02422 1,55 0,01799 1,57 0,00587
NM_005585 15q21-q22 1,44 0,00334 1,31 0,03269 1,74 0,00037
N M_024028 5q33.1 1,46 0,01147 1,53 0,01843 1,48 0,00957
NM_002501 19pl3.13 1,31 0,00433 1,80 0,00025 1,34 0,00265
NM_003722 3q28 1,32 0,04689 1,68 0,01028 1,43 0,01822
NM_015905 7q32-q34 1,31 0,04859 1,71 0,00818 1,37 0,02861
NM_021625 12q24.11 1,29 0,01695 1,37 0,01716 1,70 0,00046
NM_032431 l lq l3 1,48 0,02271 1,49 0,04811 1,38 0,04566
NM_144778 13q32.1 1,50 0,00158 1,55 0,00345 1,29 0,01450
NM_130898 lq21 1,34 0,02753 1,53 0,01652 1,42 0,01403
AF461052 16pl2.3 1,33 0,03209 1,64 0,00938 1,30 0,04319
NM_001001396 lq32.1 1,35 0,01489 1,54 0,00861 1,30 0,02470
NM_015113 17pl3.2 1,37 0,00009 1,56 0,00005 1,25 0,00064
NM_016143 20pl3 1,30 0,01219 1,55 0,00329 1,31 0,00971
NM_032999 7 q ll.2 3 1,37 0,01534 1,38 0,03498 1,40 0,01166
NM_031232 20q ll.22 1,50 0,00001 1,23 0,00133 1,42 0,00002
BX648576 17q25.1 1,35 0,00715 1,37 0,01504 1,41 0,00363
N M_017 649 10q24.32 1,28 0,02946 1,56 0,00677 1,28 0,02819
NM_015710 19ql3 1,22 0,01873 1,58 0,00099 1,33 0,00362
NM_133265 Xq23 1,31 0,00994 1,28 0,03601 1,51 0,00130
206
Affym etrix
transcript Gene assignment J 36" 6 .
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2950515 Vacuolar protein sorting 52 homolog VPS52
3476457 Nuclear receptor co-repressor 2 NCOR2
3887094 Zinc finger, SWIM-type containing 3 ZSWIM3
3981735 Hypothetical LOC554203 LOC554203
3741997 Ankyrin repeat and FYVE domain containing 1 ANKFY1
3621140 Leucine carboxyl methyltransferase 2 LCMT2
3305081 Collagen, type XVII, alpha 1 COL17A1
3841260 CCR4-NOT transcription complex, subunit 3 CNOT3
2820893 Rieske (Fe-S) domain containing RFESD
2319560 Ubiquitination factor E4B UBE4B
3015706 Motile sperm domain containing 3 MOSPD3
3715703 Suppressor of Ty 6 homolog SUPT6H
3550343 Adenylate kinase 7 AK7
2715476 Chromosome 4 open reading frame 8 C4orf8
3644375 Tuberous sclerosis 2 TSC2
3424379 Chromosome 12 open reading frame 26 C12orf26
3739521 Rabphiiin 3A-like RPH3AL
3528172 T cell receptor alpha locus TRA@
3294361 Tetratricopeptide repeat domain 18 TTC18
3847252 Scaffold attachment factor B2 SAFB2
3329461 Zinc finger protein 408 ZNF408
2376799 Inhibitor of kappa light polypeptide gene enhancer IKBKE
3710870 Rho-type GTPase-activating protein RICH2 RICH2
3334304 DnaJ (Hsp40) homolog, subfamily C, member 4 DNAJC4
2321238 PR domain containing 2, with ZNF domain PRDM2
3346412 Chromosome 11 open reading frame 70 C llo rf70
4004044 Dystrophin DMD
3676134
SplA/ryanodine receptor domain and SOCS box
SPSB3
containing 3
3558290 Chromosome 14 open reading frame 124 C14orfl24
3254091 Mannose-binding lectin (protein A) 1, pseudogene 1 MBL1P1
3011911 Hypothetical protein FU21062 FU21062
Reference
sequence
Chromosomal
location
Fold
Change
R204W
p-value
(R204W)
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(R279H)
p-value
(R279H)
Fold
Change
(R304W)
p-value
(R304W )
NM_022553 6p2 1,24 0,02069 1,35 0,01453 1,49 0,00124
NM_006312 12q24 1,35 0,00670 1,33 0,02272 1,39 0,00441
NM_080752 20ql3.12 1,42 0,00144 1,28 0,02185 1,39 0,00193
BC071776 Xql3.2 1,26 0,02752 1,53 0,00548 1,28 0,02026
NM_016376 17pl3.3 1,37 0,00475 1,39 0,01114 1,25 0,02134
NM_014793 15ql5.3 1,34 0,00127 1,33 0,00450 1,33 0,00142
N M_000494 10q24.3 1,28 0,01440 1,48 0,00500 1,25 0,02011
NM_014516 19ql3.4 1,31 0,01600 1,45 0,01109 1,24 0,03718
NM_173362 5ql5 1,43 0,00278 1,35 0,01664 1,22 0,03571
NM_001105562 lp36 1,26 0,00053 1,39 0,00029 1,32 0,00022
NM_001040097 7q22 1,34 0,00110 1,22 0,01929 1,38 0,00067
NM_003170 17q ll.2 1,40 0,00125 1,27 0,01914 1,27 0,00623
NM_152327 14q32.2 1,22 0,00612 1,32 0,00382 1,38 0,00055
NM_003704 4pl6.3 1,22 0,03936 1,47 0,00652 1,22 0,03806
N M_000548 16pl3.3 1,33 0,00547 1,24 0,04454 1,32 0,00623
NM_032230 12q21.31 1,16 0,03366 1,37 0,00423 1,34 0,00175
BC005153 17pl3.3 1,32 0,00570 1,25 0,03971 1,29 0,00954
BC070329 14q ll.2 1,21 0,04310 1,28 0,03916 1,34 0,00698
NM_145170 10q22.2 1,25 0,02729 1,33 0,02682 1,23 0,03492
NM_014649 19pl3.3 1,30 0,00648 1,25 0,03536 1,26 0,01124
NM_024741 l l p l l . 2 1,30 0,00108 1,31 0,00334 1,20 0,00734
NM_014002 lq32.1 1,21 0,00659 1,19 0,02311 1,36 0,00059
NM_014859 17pl2 1,23 0,00736 1,37 0,00322 1,16 0,03262
NM_005528 l lq l3 1,24 0,00676 1,23 0,02138 1,21 0,01164
NM_012231 lp36.21 1,14 0,01947 1,27 0,00388 1,26 0,00127
BC054869 llq 22 .1 1,23 0,01367 1,26 0,02170 1,17 0,03719
NM_000109 Xp21.2 1,25 0,00286 1,19 0,02395 1,20 0,00658
NM_080861 16pl3.3 1,20 0,00455 1,25 0,00506 1,17 0,00814
NM_020195 14ql2 1,14 0,01936 1,22 0,00842 1,16 0,01004
NR_002724 lOq 1,09 0,00180 1,08 0,00998 1,04 0,03772
NM_001039706 7q21.13 1,04 0,00585 1,06 0,00207 1,09 0,00012
Affymetrix
transcript
ID
Gene assignment Gene
abbreviation
4026075 Gamma-aminobutyric acid (GABA) A receptor, alpha 3 GABRA3
3841198
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 3
NDUFA3
3868518 Hypothetical protein LOC554235 LOC554235
2411642 ATP/GTP binding protein-like 4 AGBL4
2798475 Pleckstrin homology domain containing, family G PLEKHG4B
2724671 Ras homolog gene family, member H RHOH
2882196 ATX1 antioxidant protein 1 homolog ATOX1
3328860 FU41423 protein FU41423
3957374 SEC14-like 4 SEC14L4
3050367 Fidgetin-like 1 FIGNL1
3934669 SMT3 suppressor of mif two 3 homolog 3 SUM03
3230141 Notch homolog 1, translocation-associated NOTCH1
2378325 SERTA domain containing 4 SERTAD4
3120443 G protein-coupled receptor 172A GPR172A
2728408 REl-silencing transcription factor REST
2360773 Metaxin 1 MTX1
4001654 G protein-coupled receptor 64 GPR64
3217395
Ankyrin repeat and sterile alpha motif domain 
containing 6
ANKS6
2318637 Vesicle-associated membrane protein 3 VA MP3
3381540 KIAA0280 KIAA0280
2406766 Mitochondrial ribosomal protein S15 MRPS15
3466206 Transmembrane and coiled-coil domain family 3 TMCC3
3883441 Sperm associated antigen 4 SPAG4
2828856 Heat shock 70kDa protein 4 HSPA4
3059464 Sema domain, immunoglobulin domain (Ig) SEMA3A
2363579
Translocase of outer mitochondrial membrane 40 
homolog
TOMM40L
2759654 Actin binding LIM protein family, member 2 ABLIM2
3189714 GTPase activating Rap/RanGAP domain-like 3 GARNL3
3203311 Aprataxin APTX
Reference
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Chromosomal
location
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(R304W)
N M_000808 Xq2 3,04 0,00001 -1,32 0,03012 1,23 0,03802
AK289489 19ql3.42 1,45 0,01218 -1,50 0,02307 1,45 0,01224
NM_001024656 19ql3.33 1,24 0,00964 -1,23 0,02959 1,23 0,01273
NM_032785 lp33 1,22 0,00690 -1,17 0,04233 1,17 0,01762
NM_052909 5pl5.33 1,19 0,02991 -1,24 0,03306 1,22 0,01715
NM_004310 4pl3 1,15 0,04483 -1,19 0,04711 1,18 0,02697
N M_004045 5q32 1,21 0,01608 -1,45 0,00231 1,32 0,00304
AK123417 l l p l l . 2 1,21 0,03800 -1,34 0,01974 1,21 0,04275
NM_174977 22ql2.2 1,12 0,02080 -1,17 0,01314 1,10 0,04059
BC027856 7pl2.2 -1,46 0,02384 1,87 0,00778 -1,40 0,03669
NM_006936 21q22.3 -1,16 0,01074 1,26 0,00468 -1,15 0,01712
NM_017617 9q34.3 -1,28 0,01009 1,41 0,00635 -1,24 0,01756
NM_019605 Iq32.1-q41 -1,10 0,02205 -1,12 0,02555 -1,11 0,01233
NM_024531 8q24.3 -1,16 0,00923 -1,26 0,00398 -1,11 0,03549
NM_005612 4ql2 -1,23 0,00096 -1,16 0,01391 -1,18 0,00312
NM_002455 lq21 -1,13 0,01619 -1,30 0,00121 -1,15 0,00947
NM_001079858 Xp22.13 -1,17 0,01506 -1,28 0,00560 -1,16 0,02039
BC012981 9q22.33 -1,20 0,01964 -1,29 0,01430 -1,16 0,04158
NM_004781 lp3 -1,17 0,02238 -1,33 0,00539 -1,23 0,00754
D87470 llq l3 .4 -1,25 0,01122 -1,22 0,04210 -1,27 0,00848
NM_031280 Ip35-p34.1 -1,24 0,01264 -1,25 0,02721 -1,29 0,00550
NM_020698 12q22 -1,25 0,01684 -1,33 0,01684 -1,21 0,03163
NM_003116 20q ll.21 -1,14 0,03296 -1,52 0,00046 -1,15 0,02602
NM_002154 5q31.1-q31.2 -1,45 0,00007 -1,23 0,00489 -1,14 0,01414
NM_006080 7q21.11 -1,22 0,04289 -1,35 0,02298 -1,24 0,03380
NM_032174 lq23.3 -1,29 0,00903 -1,34 0,01395 -1,19 0,04156
DQ413176 4pl6-pl5 -1,30 0,00261 -1,34 0,00496 -1,18 0,02158
NM_032293 9q33.3 -1,21 0,00131 -1,36 0,00041 -1,32 0,00019
NM_175073 9pl3.3 -1,26 0,00749 -1,37 0,00541 -1,27 0,00619
208
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3833620 Latent transforming growth factor beta binding protein LTBP4
2951057 Chromosome 6 open reading frame 1 C6orfl
3705641
Translocase of inner mitochondrial membrane 22 
homolog
TIMM22
2330253 ADP-ribosylhydrolase like 2 ADPRHL2
3801492 Ankyrin repeat domain 29 ANKRD29
2933331 Sorting nexin 9 SNX9
2734047 Lung cancer metastasis-associated protein MAGI
4007617 Pim-2 oncogene PIM2
2616804 SH3 and cysteine rich domain STAC
2458513 Transmembrane protein 63A TMEM63A
3068097 Dedicator of cytokinesis 4 DOCK4
3544141 Iron-sulfur cluster assembly 2 homolog ISCA2
2364155 U2AF homology motif (UHM) kinase 1 UHMK1
3298924 Muitimerin 2 MMRN2
2880679 SH3 domain and tetratricopeptide repeats 2 SH3TC2
3937967 Hypothetical protein FU26056
2835662 MSTP150 MST150
2726072 ATPase, class V, type 10D ATPIOD
3031556 GTPase, IMAP family member 2 GIMAP2
3063083 SMAD specific E3 ubiquitin protein ligase 1 SMURF1
2377094
6-phosphofructo-2-kinase/fructose-2; 6-biphosphatase
PFKFB2
2703902 Btyrylcholinesterase BCHE
3937847 Leucine-zipper-like transcription regulator 1 LZTR1
3355056 FAD-dependent oxidoreductase domain containing 1 FOXRED1
3838795 BCL2-like 12 (proline rich) BCL2L12
3226737 Cysteine conjugate-beta lyase CCBL1
2834957 Actin filament associated protein 1-like 1 AFAP1L1
3279982 Protein tyrosine phosphatase-like PTPLA
2757427
Leucine zipper-EF-hand containing transmembrane 
protein 1
LET M l
3914050 Stathmin-like 3 STMN3
R eference
sequence
N M_001042544 
NM_178508
NM_013337
NM_017825 
NM_173505 
NM_016224 
NM_032717 
NM_006875 
NM_003149 
NM_014698 
NM_014705 
NM_194279 
NM_175866 
NM_024756 
NM_024577 
AK129567 
NM_032947 
NM_020453 
NM_015660 
NM_020429
NM_006212
NM_000055 
NM_006767 
NM_017547 
NM_138639 
NM_004059 
NM_152406 
NM_014241
NM_012318
NM_015894
Chromosomal
location
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(R304W)
19ql3.2 -1,30 0,03220 -1,34 0,04973 -1,27 0,04447
6p21.31 -1,23 0,01059 -1,43 0,00216 -1,28 0,00429
17pl3.3 -1,26 0,02456 -1,39 0,01472 -1,29 0,01588
lp34.3 -1,26 0,00504 -1,50 0,00105 -1,20 0,01627
18q ll.2 -1,22 0,03377 -1,52 0,00382 -1,24 0,02306
6q25.1-q26 -1,34 0,01053 -1,30 0,03981 -1,35 0,00909
4q21.23 -1,30 0,01600 -1,47 0,00861 -1,23 0,04260
Xp ll.23 -1,49 0,00167 -1,34 0,02118 -1,23 0,03178
3p22.3 -1,27 0,03246 -1,58 0,00550 -1,25 0,03859
lq42.12 -1,31 0,04025 -1,48 0,02406 -1,36 0,02620
7q31.1 -1,30 0,01996 -1,58 0,00466 -1,29 0,02246
14q24.3 -1,34 0,00700 -1,39 0,01142 -1,44 0,00241
lq23.3 -1,47 0,00404 -1,35 0,03254 -1,36 0,01106
10q23.2 -1,24 0,03664 -1,43 0,01291 -1,55 0,00163
5q32 -1,36 0,02079 -1,56 0,01163 -1,31 0,03249
22q ll.21 -1,41 0,00059 -1,69 0,00021 -1,15 0,03299
5q33.1 -1,21 0,02540 -1,79 0,00035 -1,30 0,00618
4p l2 -1,51 0,00051 -1,49 0,00207 -1,31 0,00425
7q36.1 -1,46 0,00150 -1,53 0,00267 -1,35 0,00460
7q22.1 -1,42 0,01112 -1,63 0,00739 -1,30 0,03582
lq32.1 -1,50 0,00607 -1,50 0,01749 -1,36 0,02129
3q26.1-q26.2 -1,50 0,00126 -1,34 0,01706 -1,53 0,00094
22q ll.21 -1,28 0,02367 -1,57 0,00496 -1,53 0,00212
llq 2 -1,44 0,03811 -1,55 0,04470 -1,42 0,04306
19ql3.3 -1,40 0,00862 -1,55 0,00800 -1,47 0,00498
9q34.11 -1,52 0,01281 -1,46 0,04618 -1,51 0,01317
5q33.1 -1,54 0,00173 -1,45 0,01070 -1,52 0,00210
10pl2.33 -1,62 0,00313 -1,60 0,01033 -1,32 0,03489
4pl6.3 -1,46 0,01652 -1,70 0,01072 -1,42 0,02244
20ql3.3 -1,38 0,00887 -1,86 0,00112 -1,42 0,00558
Affymetrix
transcript
ID
Gene assignment Gene abbreviation
2620538 Leucyl-tRNA synthetase 2 LARS2
2334191 Polo-like kinase 3 PLK3
3403015 Enolase 2 EN02
4015884 armadillo repeat containing, X-linked 2 ARMCX2
3124537 Cathepsin B CTSB
3315024 ADAM metallopeptidase domain 8 ADAM8
2794792 Vascular endothelial growth factor C VEGFC
3719231 Mitochondrial rRNA methyltransferase 1 homolog MRM1
2618940 Catenin (cadherin-associated protein), beta 1 CTNNB1
2692816 Integrin, beta 5 ITGB5
3420316 High mobility group AT-hook 2 HMGA2
2901913 Tubulin, beta TUBB
3465248 Lumican LUM
2522439 Basic leucine zipper and W2 domains 1 BZW1
2655168 YEATS domain containing 2 YEATS2
3168066 Carbonic anhydrase IX CA9
2401193 Leucine zipper protein 1 LUZP1
3140920 Junctophilin 1 JPH1
3329099 Glycosyltransferase-like IB GYLTL1B
2793401 Microfibrillar-associated protein 3-like MFAP3L
3293724 Chromosome 10 open reading frame 54 C10orf54
3532793 Paired box 9 PAX9
3770505 Usher syndrome 1G USH1G
3645452 Kringle containing transmembrane protein 2 KREMEN2
3061319 Cyclin-dependent kinase 6 CDK6
2946324 Histone cluster 1, H3d HIST1H3D
3639601 RGM domain family, member A RGMA
3743551 Claudin 7 CLDN7
2891015 Tripartite motif-containing 7 TRIM7
3098977
V-yes-1 Yamaguchi sarcoma viral related oncogene 
homolog
LYN
2760869 Heparan sulfate (glucosamine) 3-O-sulfotransferase 1 HS3ST1
Reference
sequence
Chromosomal
location
Fold
Change
R204W
p-value
(R204W)
Fold
Change
(R279H)
p-value
(R279H)
Fold
Change
(R304W)
p-value
(R304W)
NM_015340 3p21.3 -1,68 0,00095 -1,31 0,04685 -1,69 0,00092
NM_004073 lp34.1 -1,28 0,00779 -1,98 0,00013 -1,44 0,00106
NM_001975 12pl3 -1,48 0,01427 -1,77 0,00764 -1,46 0,01639
NM_177949 Xq21.33-q22.2 -1,56 0,00673 -1,47 0,03102 -1,69 0,00297
NM_147780 8p23.1 -1,33 0,03046 -1,92 0,00219 -1,52 0,00594
NM_001109 10q26.3 -1,33 0,04523 -1,96 0,00332 -1,48 0,01386
NM_005429 4q34.2 -1,42 0,01708 -1,91 0,00309 -1,46 0,01266
NM_024864 17ql2 -1,56 0,00523 -1,67 0,00812 -1,59 0,00424
NM_001904 3p22.1 -1,60 0,00258 -1,86 0,00215 -1,37 0,01723
NM_002213 3q21.2 -1,59 0,01455 -1,68 0,02450 -1,59 0,01488
NM_003483 12ql5 -1,46 0,04320 -1,80 0,02020 -1,62 0,01712
NM_178014 6p21.33 -1,59 0,00197 -1,47 0,01422 -1,84 0,00048
NM_002345 12q21.3-q22 -1,55 0,01461 -1,77 0,01230 -1,59 0,01092
NM_014670 2q33 -1,63 0,00377 -1,82 0,00426 -1,50 0,00889
NM_018023 3q27.1 -1,77 0,00024 -1,32 0,02473 -1,92 0,00011
NM_001216 9pl3-pl2 -1,50 0,03962 -2,05 0,01072 -1,50 0,03935
NM_033631 lp36 -1,52 0,00446 -1,95 0,00143 -1,61 0,00246
NM_020647 8q21 -1,77 0,00959 -1,69 0,03431 -1,64 0,01774
NM_152312 l l p l l . 2 -1,43 0,00418 -2,05 0,00038 -1,63 0,00084
NM_021647 4q32.3 -1,72 0,01579 -1,75 0,03597 -1,67 0,01995
NM_022153 10q22.1 -1,94 0,00236 -1,60 0,03064 -1,61 0,01092
NM_006194 14ql2-ql3 -1,40 0,02325 -2,30 0,00100 -1,49 0,01147
NM_173477 17q25.1 -1,77 0,00318 -1,96 0,00450 -1,47 0,01919
NM_172229 16pl3.3 -1,50 0,02241 -2,25 0,00293 -1,45 0,03190
NM_001259 7q21-q22 -1,50 0,01106 -1,96 0,00306 -1,80 0,00184
BC033095 6p21.3 -1,89 0,00107 -1,48 0,02810 -1,93 0,00092
NM_020211 15q26.1 -1,58 0,02724 -2,13 0,00891 -1,64 0,02011
NM_001307 17pl3 -1,68 0,03082 -1,94 0,02980 -1,74 0,02408
NM_203296 5q35.3 -1,98 0,00220 -1,83 0,01189 -1,57 0,01510
NM_002350 8ql3 -1,56 0,03897 -2,31 0,00791 -1,58 0,03485
NM_005114 4p l6 -1,71 0,01667 -1,91 0,02032 -1,84 0,00967
Affymetrix
transcript
ID
Gene assignment Gene abbreviation
2712754 Phosphate cytidylyltransferase 1, choline, alpha PCYT1A
3554851 Cysteine-rich protein 1 CRIP1
3147985 Low density li pop rote in-re la ted protein 12 LRP12
2453881 Interferon regulatory factor 6 IRF6
3598381
Protein tyrosine phosphatase-like A domain containing 
1
PTPLAD1
3450234 Plakophilin 2 PKP2
3536434 Sterile alpha motif domain containing 4A SAMD4A
3947863 Parvin, beta PARVB
2401581 UDP-galactose-4-epimerase GALE
3445574 Guanylate cyclase 2C GUCY2C
3275922 Protein kinase C, theta PRKCQ
3091077 Dihydropyrimidinase-like 2 DPYSL2
2403446 Platelet-activating factor receptor PTAFR
2453793 Laminin, beta 3 LAMB3
3382410 Microtubule-associated protein 6 MAP6
2446047
V-abl Abelson murine leukemia viral oncogene homolog 
2
ABL2
2675150 Hyaluronoglucosaminidase 1 HYAL1
3421985 Potassium large conductance calcium-activated channel KCNMB4
2688499 Zinc finger, BED-type containing 2 ZBED2
3393622 Sodium channel, voltage-gated, type IV, beta SCN4B
3000953 Uridine phosphorylase 1 UPP1
3569257 Pleckstrin 2 PLEK2
3572209
Placental growth factor, vascular endothelial growth 
factor
PGF
2520291 Glutaminase GLS
3033209 Insulin induced gene 1 INSIG1
3435078 WD repeat domain 66 WDR66
3845263 ADAMTS-like 5 ADAMTSL5
2463567 Phospholipase D family, member 5 PLD5
3709417 Arachidonate 15-lipoxygenase, type B ALOX15B
3610110 Nuclear receptor subfamily 2, group F, member 2 NR2F2
Reference
sequence
Chromosomal
location
Fold
Change
R204W
p-value
(R204W)
Fold
Change
(R279H)
p-value
(R279H)
Fold
Change
(R304W)
p-value
(R304W )
NM_005017 3q29 -1,63 0,00129 -2,48 0,00016 -1,37 0,01040
NM_001311 14q32.33 -1,82 0,00508 -2,02 0,00705 -1,69 0,00906
NM_013437 8q22.2-q23.1 -1,94 0,00595 -1,75 0,03210 -1,87 0,00781
NM_006147 Iq32.3-q41 -1,60 0,00619 -2,32 0,00114 -1,67 0,00414
NM_016395 15q22.31 -1,84 0,00154 -2,40 0,00077 -1,37 0,02833
NM_004572 1 2 p ll -1,58 0,04017 -2,06 0,01760 -2,04 0,00679
NM_015589 14q22.2 -1,44 0,02331 -2,62 0,00078 -1,69 0,00503
NM_001003828 22ql3.2-ql3.33 -1,70 0,03223 -2,35 0,01256 -1,79 0,02256
NM_000403 Ip36-p35 -2,09 0,01129 -2,05 0,03244 -1,74 0,03554
NM_004963 12pl2.3-pl2.1 -1,91 0,01912 -2,10 0,02780 -1,86 0,02225
NM_006257 10pl5 -1,76 0,00098 -2,17 0,00064 -1,95 0,00040
NM_001386 8p22-p21 -2,06 0,00414 -2,33 0,00595 -1,50 0,04638
AK292053 Ip35-p34.3 -1,59 0,02620 -2,23 0,00700 -2,13 0,00308
NM_001017402 lq32 -1,69 0,03734 -2,60 0,00851 -1,68 0,03799
NM_207577 llq l3 .5 -1,76 0,04403 -2,43 0,01961 -1,79 0,03971
NM_007314 Iq24-q25 -1,53 0,01687 -2,92 0,00062 -1,56 0,01416
NM_007312 3p21.3-p21.2 -2,23 0,00170 -2,34 0,00406 -1,51 0,03342
NM_014505 12ql5 -1,90 0,02617 -2,25 0,02641 -1,95 0,02253
N M_024508 3ql3.13 -1,68 0,04446 -2,57 0,01078 -1,86 0,02322
NM_174934 llq 23 .3 -1,87 0,01215 -1,87 0,03127 -2,39 0,00261
NM_003364 7pl2.3 -1,82 0,00023 -2,55 0,00007 -1,78 0,00028
NM_016445 14q23.3 -1,74 0,02091 -2,35 0,00906 -2,10 0,00583
NM_002632 14q24-q31 -1,76 0,01857 -2,66 0,00466 -1,78 0,01722
NM_014905 2q32-q34 -1,74 0,04935 -2,54 0,01693 -1,92 0,02686
NM_198336 7q36 -2,43 0,00175 -2,05 0,01404 -1,76 0,01472
NM_144668 12q24.31 -1,89 0,00393 -2,26 0,00371 -2,08 0,00197
NM_213604 19pl3.3 -2,14 0,01434 -2,15 0,03512 -1,97 0,02284
NM_152666 lq43 -2,17 0,00289 -2,37 0,00535 -1,82 0,00984
NM_001141 17pl3.1 -1,49 0,03450 -2,59 0,00208 -2,38 0,00099
NM_021005 15q26 -2,39 0,00025 -2,16 0,00167 -2,02 0,00080
Affymetrix
transcript
ID
Gene assignment Gene abbreviation
2413203 Low density lipoprotein receptor-related protein 8 LRP8
4054427 Gap junction protein, beta 4 GJB4
3041816 Deafness, autosomal dominant 5 DFNA5
3352948 Sortilin-related receptor, L(DLR class) A repeats-containi SORL1
3464276 Solute carrier family 6, member 15 SLC6A15
2523045 Frizzled homolog 7 FZD7
3690154 Neuropilin (NRP) and tolloid (TLL)-like 2 NET02
3353335 Ubiquitin associated and SH3 domain containing, B UBASH3B
2344393 Protein kinase, cAMP-dependent, catalytic, beta PRKACB
4007437 Solute carrier family 38, member 5 SLC38A5
2925590 Transmembrane protein 200A TMEM200A
3976639 Porcupine homolog PORCN
2635906 Pleckstrin homology-like domain, family B, member 2 PHLDB2
2587790 G protein-coupled receptor 155 GPR155
2686023 Discoidin, CUB and LCCL domain containing 2 DCBLD2
3070183 Aminoadipate-semialdehyde synthase AASS
3726691
ATP-binding cassette, sub-family C (CFTR/MRP), 
member 3
ABCC3
3378541 Pyruvate carboxylase PC
3465274 Decor in DCN
3467315 IKK interacting protein IKIP
3414351 Amiloride-sensitive cation channel 2, neuronal ACCN2
3756896 Keratin 33B KRT33B
3473524 Nitric oxide synthase 1 NOS1
3121198 Chromosome 8 open reading frame 42 C8orf42
3549605 KIAA1622 KIAA1622
2774971 Anthrax toxin receptor 2 ANTXR2
2540157 Ornithine decarboxylase 1 ODC1
3468743 5'-nucleotidase domain containing 3 NT5DC3
3758510 Ets variant gene 4 ETV4
3464405
Peptidylglycine alpha-amidating monooxygenase 
COOH-termina
PA MCI
3864551 Plasminogen activator, urokinase receptor PLAUR
Reference
sequence
Chromosomal
location
Fold
Change
R204W
p-value
(R204W)
Fold
Change
(R279H)
p-value
(R279H)
Fold
Change
(R304W)
p-value
(R304W)
NM_004631 lp34.3 -2,08 0,00400 -2,29 0,00671 -2,23 0,00253
NM_153212 lp34.3 -1,52 0,04644 -2,64 0,00379 -2,50 0,00157
N M_004403 7pl5 -2,20 0,01731 -2,45 0,02668 -2,13 0,02038
NM_003105 Ilq23.2-q24.2 -1,53 0,03025 -2,95 0,00132 -2,31 0,00146
NM_182767 12q21.3 -2,25 0,00872 -2,21 0,02553 -2,38 0,00634
NM_003507 2q33 -2,01 0,00915 -3,29 0,00220 -1,58 0,04727
NM_018092 1 6 q ll -2,36 0,00268 -1,76 0,04290 -3,04 0,00071
NM_032873 iiq -1,49 0,02941 -3,32 0,00053 -2,40 0,00082
NM_182948 lp36.1 -2,25 0,00599 -2,58 0,00876 -2,39 0,00436
NM_033518 X p ll.23 -2,20 0,00817 -3,03 0,00505 -2,02 0,01340
BC044246 6q23.1 -2,07 0,01678 -2,07 0,04064 -3,19 0,00195
NM_022825 X p ll.23 -2,16 0,01187 -2,77 0,00972 -2,51 0,00531
NM_145753 3q -1,93 0,03428 -2,83 0,01422 -2,84 0,00495
NM_001033045 2q31.1 -2,95 0,00207 -2,60 0,01113 -2,45 0,00514
NM_080927 3ql2.1 -2,55 0,00691 -2,85 0,01183 -2,62 0,00605
NM_005763 7q31.3 -2,90 0,00494 -2,30 0,03658 -2,93 0,00470
NM_003786 17q22 -2,32 0,03146 -3,00 0,02807 -2,83 0,01380
NM_001040716 Ilq l3 .4 -q l3 .5 -2,93 0,00075 -2,85 0,00288 -2,39 0,00222
NM_001920 12q21.33 -3,09 0,00155 -2,66 0,00950 -2,45 0,00480
NM_153687 12q23.1 -2,86 0,00183 -2,54 0,00995 -2,84 0,00191
NM_020039 12ql2 -2,74 0,00444 -2,81 0,01159 -2,70 0,00472
NM_002279 17ql2-q21 -2,64 0,00099 -3,28 0,00118 -2,86 0,00065
NM_000620 12q24.2-q24.31 -3,10 0,00968 -2,99 0,02887 -2,81 0,01421
NM_175075 8p23.3 -3,22 0,00095 -1,91 0,03895 -3,89 0,00043
NM_058237 14q32.13 -2,71 0,00269 -2,85 0,00651 -3,55 0,00079
NM_058172 4q21.21 -3,32 0,00352 -2,96 0,01589 -2,91 0,00605
AK292352 2p25 -2,26 0,02094 -4,42 0,00420 -2,66 0,00965
NM_016575 12q22-q23.1 -2,52 0,01621 -3,47 0,01244 -3,54 0,00396
NM_001986 17q21.31 -3,03 0,01220 -3,35 0,02228 -3,44 0,00755
N M_005447 12q21.31 -2,77 0,01220 -4,24 0,00737 -3,03 0,00845
NM_002659 19ql3 -2,12 0,03007 -5,67 0,00211 -2,97 0,00647
Affymetrix
transcript
ID
Gene assignment Gene abbreviation
3181374 Forkhead box E l F0XE1
2496907 Interleukin 1 receptor, type II IL1R2
2571510 Interleukin 1, beta I LIB
2748605 Lecithin retinol acyltransferase LRAT
3485674 Cyclin A l CCNA1
2618620 Ectonucleoside triphosphate diphosphohydrolase 3 ENTPD3
3486956 Chromosome 13 open reading frame 15 C13orfl5
3638411 Rh family, C glycoprotein RHCG
2787459 Inositol polyphosphate-4-phosphatase, type II INPP4B
2938972 Serpin peptidase inhibitor, clade B, member 1 SERPINB1
3396593 Fasciculation and elongation protein zeta 1 FEZ1
2359483 Small proline-rich protein 4 SPRR4
2501120 Interleukin 1 family, member 9 IL1F9
4013549 Integral membrane protein 2A ITM2A
2434609 Cathepsin K CTSK
Nudix (nucleoside diphosphate linked moiety X)-type _
4008427 ' NUDT11
motif
2345816 Guanylate binding protein family, member 6 GBP6
2779302 Alcohol dehydrogenase 7 ADH7
3568603 Glutathione peroxidase 2 GPX2
3756928 Keratin 31 KRT31
Reference
sequence
Chromosomal
location
Fold
Change
R204W
p-value
(R204W)
Fold
Change
(R279H)
p-value
(R279H)
Fold
Change
(R304W)
p-value
(R304W)
NM_004473 9q22 -2,97 0,00252 -4,74 0,00136 -3,22 0,00177
NM_004633 2ql2-q22 -2,69 0,03247 -4,70 0,01415 -3,71 0,01051
NM_000576 2ql4 -3,96 0,01115 -4,17 0,02509 -3,74 0,01328
NM_004744 4q32.1 -2,83 0,02089 -6,37 0,00468 -2,74 0,02371
NM_003914 13ql2.3-ql3 -3,62 0,01219 -4,80 0,01427 -3,52 0,01345
NM_001248 3p21. -3,53 0,00307 -4,49 0,00413 -4,47 0,00130
NM_014059 13ql4.11 ■4,22 0,01758 -4,63 0,03430 -4,09 0,01921
NM_016321 15q25 -3,61 0,00001 -5,15 0,00001 -4,21 0,00000
NM_003866 4q31.21 -3,07 0,00182 -6,57 0,00041 -3,53 0,00100
NM_030666 6p25 4 ,59 0,00272 -4,98 0,00649 -3,81 0,00508
ENST00000278919 llq 2 4 .2 4 ,1 3 0,00271 -5,50 0,00347 -4,89 0,00153
NM_173080 lq21.3 -2,43 0,04329 -8,01 0,00319 -5,06 0,00342
NM_019618 2ql2-q21 -3,46 0,00194 -9,54 0,00029 -6,44 0,00022
NM_004867 Xql3.3-Xq21.2 -7,33 0,00029 -7,19 0,00107 -6,52 0,00040
NM_000396 lq21 -9,90 0,00817 -9,98 0,02173 -5,43 0,02872
NM_018159 Xp ll.2 2 -10,58 0,00006 -7,67 0,00051 -10,74 0,00006
NM_198460 lp22.2 -9,07 0,00756 -15,12 0,00851 -8,20 0,00931
NM_000673 4q23-q24 -15,66 0,00010 -16,41 0,00033 -13,87 0,00013
NM_002083 14q24.1 -25,53 0,00008 -27,97 0,00024 -12,86 0,00028
NM_002277 17ql2-q21 -32,94 0,00009 -26,44 0,00047 -29,00 0,00011
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Appendix 2
Chapter 4 . Figure 1. Limb and ectodermal phenotype in ADULT syndrome patients w ith  p.R298 mutation. Limb 
malformations in p.R298 patients can vary much. A-B. Deep median cleft and syndactyly in the limbs of the Finnish 
ADULT syndrome patient (I/1) with p.R298G mutation. C-D. Mildly affected limbs in the Italian patient (II/1) with 
p.R298Q mutation. E-F. Severely affected hands and non-affected feet of Danish ADULT patient (II/1) with p.R289Q 
mutation. G. Excessive freckling in Danish patient (I/1). H. Hypodontia and loss of permanent teeth in Danish patient 
(I/1). I. Hypoplastic nipples in Danish patient (II/1).
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Chapter 4 . Figure 3. Undifferentiated oral squamous cell carcinoma (SCC) of the Finnish ADULT syndrome 
(p.R298G) patient. The SCC oral mucosa (on the left) shows strong p63 immunoreactivity, whereas the p63 
expression in the healthy mucosa is strongest in the basal layer and gradually decreased in the suprabasal layers 
(on the right). (Magnification is 200x.)
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Chapter 6 . Figure 2. Pathogenic mutations in three RHS/AEC syndrome families. Direct sequencing of genomic 
DNA from four AEC/RHS patients revealed N-terminal mutations in the p63 gene. A . In family 1 a heterozygous 
nucleotide change c.31C>T was found in affected mother and daughter in exon 3'. The upper chromatogram 
illustrates a control sequence and the lower is from the affected mother. B. In family 3, a heterozygous deletion
c.26delA was detected in the index patient in exon 3'. The upper sequence is a control and the lower is from the 
patient. C. In family 2 a heterozygous nucleotide change c.46C>T (ANp63-isoform) was detected in exon 4 in the 
index patient. The upper chromatogram illustrates a control DNA sequence and the lower is from the patient.
D. Chromatogram of the sequenced cDNA of keratinocytes from the mother of family 1 reveals the same 
heterozygous nucleotide change detected in the genomic DNA (Fig. 2A). Mutated RNA is present in the cells 
and is not degraded by the nonsense mediated RNA decay as expected. E. The translated sequence of A N p 63a  
(AF075431) (capitals) contains two AUG sites (bold, underlined) in the two first exons (exon 3' and 4, | indicates 
the exon boundary). The mutated nucleotides: c.26A, c.31C and c.46C (indicated red and bold) are located be­
tween these two initiation sites. c.26delA mutation leads to a frameshift, which causes a PTC (indicated by *** ) 
only 5 nucleotides upstream of the second AUG site. c.31C>T changes the codon CAA into a termination codon 
TAA (this PTC is 44 nucleotides upstream from the second AUG). c.46C>T changes codon CAG into a termination 
codon TAG causing a PTC 29 nucleotides upstream of the second AUG. The second initiation codon is flanked by 
a strong Kozak sequence, where the most important nucleotides (purine at position -3 and a guanine at position 
+4) are conserved suggesting its use in translation re-initiation.
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Chapter 7 . Figure 3. Conservation of p63 binding sites and motifs in vertebrates. The percentage of p63 
binding sites (y-axis) is shown for decreasing PhastCons conservation scores (x-axis). A . The average PhastCons 
conservation score of 100-nucleotide regions centered at the summit of 11,425 p63 binding peaks (peaks 100), 
of 198 peaks located near 328 differentially regulated genes in three patients (reg_peaks 100), and of 100,000 
regions randomly chosen from the whole genome (random 100). B. The average PhastCons conservation score 
of 10nt p63 motifs from 10,675 motifs in the p63 peaks detected in the genome (peaks motifs), from 294 motifs 
near differentially regulated genes (reg_peaks motifs), and from 7,600 motifs found in random genomic regions 
(random motifs).
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Feature description P-value
Epithelium 8.34E-11
Adhesion 2,54E-09
Extracellular Matrices 1.32E-08
Basal Lamina l,38E-07
Membrane 6.28E-07
Corneal Stroma 1.64E-06
Cell, Epithelial 3,19E-06
Dentition 4,26E-06
Extracellular Space 1.14E-05
Hyalin 1.48E-05
Chapter 7 . Figure 5. Association of p63 potential target genes w ith diseases. A. Genes identified in ChIP-seq 
and expression analyses and the 198 potential direct target genes (overlap, differentially expressed genes with 
binding sites) were examined using OMIM disease base to determine their associated diseases (871, 79 and 55 
OMIM IDs, respectively) and the affected feature terms in these diseases. The similarity scores from diseases 
associated with each group of genes are indicated with dashed lines. Diseases associated with genes identified 
in expression analysis (red) and the potential direct target genes (overlap, purple) showed very similar affected 
features and are not distinguishable from each other. Diseases linked to genes identified from ChIP-seq analysis 
(blue) also showed significantly similar features. The same number of diseases associated with each group of 
genes are randomly selected from the OMIM database. The distribution of the similarity scores from these ran­
domized diseases are calculated and shown in solid lines. B. Over-represented feature descriptions in diseases 
associated with 198 potential target genes.
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Chapter 7 . Figure 6. Function analysis of p63 binding sites at SHFM1 locus on chromosome 7. A . A screenshot 
of UCSC genome browser shows the p63 binding profile from two HKC cell lines (wt1 and wt2) and several 
strong binding sites were identified near DLX5 and DLX6 on chromosome 7. Ultra-high Comparative Genomic 
Hybridization array analysis performed with DNA of a SHFM1 patient showed a chromosomal deletion of 880 kb 
on chromosome 7 (95,390,000-96,270,000, hg18, the orange arrow) which includes DSS1, SLC25A13 and part 
of DYNC1I1 but not DLX5 and DLX6. Breakpoints and 20kb averaged log2 ratios were visualized in the genome 
browser. A previously reported minimal deletion determined by markers D7S527 and D7S1796 (30) is marked 
with a green arrow. B. The p63 binding site SHFM1-BS1 was tested in transient transfection assays. Transcrip­
tion of the luciferase reporter gene was strongly activated by ANp63a through SHFM1-BS1 binding site and the 
activation was abolished by p63 EEC mutations p.R204W, p.R279H and p.R304W (left panel). Activation was 
also abolished when point mutations were introduced into the p63 binding motif in the SHFM1-BS1 binding site 
(right panel). C. SHFM1-BS1 was cloned in reporter constructs carrying the GFP or the LacZ gene to generate 
transgenic zebrafish and mice, respectively. Expression of the GFP gene in zebrafish and the LacZ gene in mice 
showed that SHFM1-BS1 can control gene expression at the apical ectodermal ridge (AER), ear and forebrain, 
The red fluorescence expressed in the muscles in the first zebrafish panel corresponds to the positive control of 
transgenesis.
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Chapter 7 . Supplementary figure 2. Comparison of the p63 motif identified in this work w ith previously 
reported motifs. A . The p63 motif was identified by de novo motif analysis where 20% of the binding sites 
were used to predict motifs, and the resulting motifs were scored for significance using the remaining 80% 
of the binding sites compared to a set of background sequences. Based on a previously developed p53scan 
algorithm (4) with this newly identified p63 Positional Weight Matrix (PWM), p63scan was developed. B-C.
The motifs from p63MH (5) and p53scan (4), respectively. D. The performance of p63scan using the de novo 
identified motif shows far superior sensitivity compared to previously reported p63MH without compromising 
specificity. Compared to p53scan, which was deduced from p53 binding sites, p63scan performs also slightly 
better on p63 binding sites. The 80% of the binding site sequences not used for motif prediction, as well as a 
set of background sequences were scanned using the different algorithms. For each individual threshold the 
fraction of binding sites with a motif (sensitivity) as well as the fraction of background sequences with a motif 
(1 -  specificity) were calculated,
Chapter 7 . Supplementary figure 6. M otif analysis of binding sites near up- or down regulated genes. The de
novo motif search on binding sites of up- or down-regulated genes revealed no major difference in p63 motifs.
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